Small molecule inhibitors for anti-nasopharyngeal cancer, methods for preparing the compounds and their uses
Small molecule compounds targeting EBNA1 effectively inhibit EBV-positive tumor cells, addressing the need for selective and pharmacokinetically favorable treatments for nasopharyngeal cancer and other EBV-related disorders.
Patent Information
- Application Number
- JP2024527105
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-16
- Filing Date
- 2022-11-16
- Publication Date
- 2024-11-21
- Estimated Expiration
- 2042-11-16
AI Technical Summary
Current treatments for nasopharyngeal cancer, particularly those targeting Epstein-Barr virus (EBV)-associated tumors, lack effective small molecule inhibitors that can selectively inhibit EBV-positive tumor cell proliferation and have favorable ADMET properties.
Development of small molecule compounds with specific structural features that inhibit EBNA1 activity, a key protein in EBV infection, for use in treating nasopharyngeal cancer and other EBV-related disorders, utilizing structure-based drug design to achieve selective inhibition and favorable pharmacokinetic properties.
The developed compounds demonstrate potent inhibitory activity against EBV-positive tumor cells, offering broad application prospects for treating nasopharyngeal cancer and other EBV-related diseases with improved absorption, distribution, metabolism, excretion, and toxicity profiles.
Smart Images

Figure 2024543351000001 
Figure 2024543351000002 
Figure 2024543351000003
Abstract
Description
[Technical field]
[0001] The present invention provides small molecule inhibitors for anti-nasopharyngeal carcinoma, methods for preparing the compounds, and their use in the treatment and / or prevention of tumor diseases such as nasopharyngeal carcinoma. [Background technology]
[0002] Nasopharyngeal cancer is a type of tumor that occurs frequently in southern China. It is a cancer derived from poorly differentiated or undifferentiated epithelial cells of the nasopharyngeal mucosa, and is a highly malignant tumor. Nasopharyngeal cancer has a clear ethnic tendency, and the majority of patients are Chinese or their descendants. The incidence rate in China is highest in Guangdong Province, followed by Guangxi Zhuang Autonomous Region, Hunan Province, Fujian Province, Jiangxi Province, etc. Nasopharyngeal cancer can occur in any age group, and the peak incidence rate has been confirmed to be between 30 and 50 years old.
[0003] Research has confirmed that the development of nasopharyngeal cancer is highly correlated with Epstein-Barr virus (EBV) infection. Epstein-Barr virus (EBV) is a human herpesvirus (Human Herpes Virus 4, HHV-4) belonging to the gamma-herpesvirinae subfamily. EBV is a B-lymphotropic virus that widely infects humans. EBV first infects oropharyngeal squamous epithelial cells, and then infects B lymphocytes in a long-term latent state. Once activated, the latent EBV is associated with many diseases, including tumors. Research has shown that EBV, in addition to causing Burkitt lymphoma, is associated with Hodgkin's disease, non-Hodgkin's lymphoma, nasopharyngeal carcinoma, NK / T-cell lymphoma, leiomyosarcoma, and malignant epithelial tumors in the stomach, breast, lung, and other sites. Therefore, EBV is classified as a group I human oncogenic virus by IARC (1997).
[0004] In the above tumor cells, when EBV infection was detected, EBNA1 (viral nuclear antigen 1) was detected in all cases. Research has revealed that EBNA1 is a protein expressed by the EBV virus and is involved in important pathological processes such as viral DNA replication, tumor induction through maintenance of viral latency and mutation, and tumor cell migration to induce immune evasion.
[0005] In recent years, research on targeting EBNA1 to develop targeted chemotherapy drugs for specific tumors has made some progress, laying the foundation for target evaluation of EBNA1 protein, structure-based drug design, evaluation of small molecule activity, etc. For example, two international patents, WO2016183534A1 and WO2015073864A1, filed by Messick TE et al. in 2015 and 2016, disclose the structure of a compound with two aromatic rings linked by an alkyne conjugate to inhibit the binding of EBNA1 to DNA, block the replication of EBV-infected cells, and exert an antitumor effect. In 2019, the team reported detailed research results that the VK series molecules can well inhibit the activity of EBNA1, and show relatively good effects both at the cellular level and in mouse nasopharyngeal carcinoma models, and the molecules of this series are currently in the phase I clinical trial stage [Sci.Transl.Med.2019,11,eaau5612.]. This finding indicates that the EBNA1 protein can be used as a new drug target for research and development of drugs to treat diseases associated with EBV infection, including tumors.
[0006] The present invention aims to develop small molecule drugs for anti-nasopharyngeal carcinoma using structure-based drug design methods. The small molecule pharmaceutical compound according to the present invention has low activity to selectively inhibit the proliferation of EBV-positive tumor cell lines at the cellular level, and at the same time has excellent drug ADMET. (Absorption, distribution, metabolism, excretion, toxicity) The growth inhibitory activity against other EBV-positive or -negative tumors also indicates the broad application prospects of the small molecules according to the present invention. Summary of the Invention [Problem to be solved by the invention]
[0007] The present invention provides compounds of general formula (I) or their enantiomers, diastereomers, tautomers, salts, crystalline forms, solvates and / or isotopically substituted derivatives thereof as anti-nasopharyngeal carcinoma inhibitors. [ka]
[0008] The present invention further provides a pharmaceutical composition comprising at least one compound according to the present invention, or an enantiomer, diastereomer, tautomer, salt, crystalline form, solvate and / or isotopically substituted derivative thereof. The present invention further provides a pharmaceutical composition comprising at least one compound according to the present invention, or an enantiomer, diastereomer, tautomer, salt, crystalline form, solvate and / or isotopically substituted derivative thereof, and at least one pharma- ceutically acceptable carrier, excipient or diluent. The present invention further provides a method for treating and / or preventing a disease or disorder caused by EBNA1 activity. The present invention further provides a use in the preparation of a medicament for treating and / or preventing a disease or disorder caused by EBNA1 activity. The present invention further provides a method for treating and / or preventing nasopharyngeal carcinoma. The present invention further provides a use in the preparation of a medicament for treating and / or preventing nasopharyngeal carcinoma. The present invention further provides a method for treating and / or preventing EBV infection in lytic and / or latent phase. The present invention further provides a use as a medicament for treating and / or preventing a disease caused by EBV infection in lytic and / or latent phase. The present invention further provides a use in the preparation of a medicament for treating and / or preventing diseases due to other non-EBV infections.The present invention further provides a process for the preparation of the compounds of general formula (I) according to the present invention. [Means for solving the problem]
[0009] The present invention relates to compounds of general formula (I) or their enantiomers, diastereomers, tautomers, salts, crystalline forms, solvates and / or isotopically substituted derivatives. [ka] During the ceremony, R 1 -H, -COOH, -C(=O)-OR 1a , -C(=O)-NHR 1b , -C(=O)-NR 1b R 1c Selected from however, R 1a , R 1b , R 1c are the same or different and are selected independently from hydrogen, optionally substituted C1-C4 linear alkyl, optionally substituted C3-C4 branched alkyl, optionally substituted C3-C4 cycloalkyl, optionally substituted halogenated C1-C4 linear alkyl, optionally substituted halogenated C3-C4 branched alkyl, optionally substituted halogenated C3-C4 cycloalkyl; Or, R 1b is selected from hydroxyl, C1-C4 alkoxy; Or, R 1b and R 1c together with the atoms to which they are attached form a cyclic group, the cyclic group being selected from optionally substituted pyrrolidinyl, optionally substituted piperidinyl, optionally substituted piperazinyl, or optionally substituted morpholinyl; Preferably, R 1 -H, -COOH, -C(=O)-OR 1a , -C(=O)-NHR 1b , -C(=O)-NR 1b R 1c Selected from R 1a , R 1b , R 1c are the same or different and are selected independently from hydrogen, optionally substituted C1-C4 linear alkyl, optionally substituted C3-C4 branched alkyl, optionally substituted halogenated C1-C4 linear alkyl, optionally substituted halogenated C3-C4 branched alkyl; Or, R 1b is selected from hydroxyl, C1-C4 alkoxy; Or, R 1b and R 1c together with the atoms to which they are attached form a cyclic group, the cyclic group being selected from optionally substituted pyrrolidinyl, optionally substituted piperidinyl; More preferably, R 1 -H, -COOH, -C(=O)-OR 1a , -C(=O)-NHR 1b , -C(=O)-NR 1b R 1c Selected from R 1a , R 1b , R 1c are the same or different and are selected independently from hydrogen, methyl, ethyl, propyl, isopropyl, butyl, Or, R 1b is selected from hydroxyl, methoxy, ethoxy, and propoxy; Or, R 1b and R 1c together with the atoms to which they are attached form a cyclic group, the cyclic group being selected from pyrrolidinyl; More preferably, R 1 -H, -COOH, -COOCH 3 , -COOCH 2 CH 3 , -CONHOH, -CONHCH 3 , -CON(CH 3 ) 2 , -CON(cC 4 H 8 ), -CONHOCH 3 Selected from R 2 teeth, selected from the group consisting of hydrogen, halogen, optionally substituted C1-C4 alkyl, optionally substituted pyrrolyl, optionally substituted indole, and optionally substituted phenyl; Preferably, R 2 is selected from hydrogen, chlorine, methyl, pyrrolyl, indole, phenyl, chlorophenyl, hydroxylphenyl, and hydroxylalkoxyphenyl; L 1 teeth, [ka] ethynyl group, however, [ka] L 1 represents the connection point to the right A ring of the compound of general formula (I), However, the asterisk * stands for L 1 represents the connection point to the left B ring of the compound of formula (I), L 2 teeth, -(CH 2 ) q -O-(CH 2 ) p -*, ·-(CH 2 ) q -NH-(CH 2 ) p -*, ·-NH-C(=O)-NH-*, ·-N(CH 3 )-C(=O)-NH-*, -CH=CH-, -(CH 2 ) n -, ·-NH-C(=O)-(CH 2 ) p -*, ·-(CH 2 ) q -C(=O)-NH-* group, Preferably, L 2 is -CH 2 -O-*, ·-O-CH 2 -*, -O-, -CH 2 -O-CH 2 -, -CH 2 -NH-*, -CH 2 -NH-CH 2 -*, -NH-CH 2 -*, -NH-C(=O)-NH-, ·-N(CH 3 )-C(=O)-NH-*, -CH=CH-, -CH 2 -, -CH 2 -CH 2 -, ·-NH-C(=O)-*, ·-NH-C(=O)-CH 2 -*, -C(=O)-NH-*, -CH2 -C(=O)-NH-*; More preferably, L 2 is -CH 2 -O-*, -O-CH 2 -*, -O-, -CH 2 -O-CH 2 -, -CH 2 -NH-*, ·-NH-C(=O)-NH-*, ·-N(CH 3 )-C(=O)-NH-*, -CH=CH-, -CH 2 -, -CH 2 -CH 2 -, ·-NH-C(=O)-*, ·-NH-C(=O)-CH 2 -*, -CH 2 -C(=O)-NH-*; However, the dot is L 2 represents the connection point to the right B ring of the compound of formula (I), However, the asterisk * stands for L 2 is the left R of the compound of formula (I) 3 represents the connection point that connects to p and q are each independently 0, 1, or 2; n is 1, 2 or 3; R 3 is selected from optionally substituted aryl, heteroaryl; Aryl is selected from phenyl; heteroaryl is selected from thiophene, pyrazolyl, imidazolyl, isothiazole, pyridine, pyrimidine, pyrazine, and quinoline; Aryl, heteroaryl are optionally substituted one or more times, similarly or differently, with hydrogen, fluorine, chlorine, cyano, C1-C4 alkyl, halogenated C1-C4 alkyl, C1-C4 alkoxy, halogenated C1-C4 alkoxy; Preferably, aryl, heteroaryl is optionally substituted one or more times, similarly or differently, with hydrogen, fluorine, cyano, methyl, methoxy, trifluoromethyl; More preferably, aryl is optionally substituted one or more times, similarly or differently, with hydrogen, cyano, trifluoromethyl; More preferably, heteroaryl is optionally substituted one or more times, similarly or differently, with hydrogen, fluorine, methyl, methoxy; More preferably, the pyridine is optionally substituted one or more times, similarly or differently, with hydrogen, fluorine, methyl, methoxy, Even more preferably, R 3 is selected from phenyl, thiophene, pyrazolyl, imidazolyl, isothiazole, pyridine, pyrimidine, pyrazine, quinoline, cyanophenyl, trifluoromethylphenyl, fluoropyridine, methylpyridine, methoxypyridine, and methylpyrazolyl; R 4 is selected from hydrogen, halogen, optionally substituted C1-C4 linear alkyl, optionally substituted C3-C4 branched alkyl, optionally substituted halogenated C1-C4 linear alkyl, optionally substituted halogenated C3-C4 branched alkyl, and hydroxyl; Preferably, R 4 is selected from hydrogen, fluorine, chlorine, methyl, hydroxyl, and is intended to be optionally substituted one or more times in the same or different manner.
[0010] The present invention further relates to pharmaceutical compositions comprising the compounds of general formula (I) above, or their enantiomers, diastereomers, tautomers, salts, crystalline forms, solvates and / or isotopically substituted derivatives.
[0011] The present invention further relates to a pharmaceutical composition comprising a compound of the above general formula (I) or an enantiomer, diastereomer, tautomer, salt, crystalline form, solvate and / or isotopically substituted derivative thereof, and a pharma- ceutically acceptable carrier, excipient, or diluent.
[0012] The present invention further relates to a method for treating and / or preventing a disease or disorder caused by EBNA1 activity, the method comprising administering to a subject an effective amount of a compound of general formula (I) as defined above, or an enantiomer, diastereomer, tautomer, salt, crystalline form, solvate and / or isotopically substituted derivative thereof, or a pharmaceutical composition thereof.
[0013] The present invention further relates to the use of the compounds of the above general formula (I) or their enantiomers, diastereomers, tautomers, salts, crystalline forms, solvates and / or isotopically substituted derivatives or pharmaceutical compositions thereof in the preparation of a medicament for treating and / or preventing a disease caused by EBNA1 activity.
[0014] The present invention further relates to a method for treating and / or preventing nasopharyngeal carcinoma, the method comprising administering to a subject an effective amount of a compound of general formula (I) as defined above, or its enantiomers, diastereomers, tautomers, salts, crystalline forms, solvates and / or isotopically substituted derivatives, or a pharmaceutical composition thereof.
[0015] The present invention further relates to the use of a compound of the above general formula (I) or its enantiomers, diastereomers, tautomers, salts, crystalline forms, solvates and / or isotopically substituted derivatives or pharmaceutical compositions thereof in the preparation of a medicament for treating and / or preventing nasopharyngeal carcinoma. Effect of the Invention
[0016] The compound of the present invention represented by the above general formula (I), or its enantiomer, diastereomer, tautomer, salt, crystal form, solvate and / or isotopically substituted derivative, or a pharmaceutical thereof The compositionThe present invention can be used for the treatment and / or prevention of a disease or disorder caused by EBNA1 activity, the disease or disorder being at least one selected from the group consisting of cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, and the like. The cancer may be, among others, nasopharyngeal carcinoma, non-Hodgkin's lymphoma, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, hepatosplenic T-cell lymphoma, B-cell lymphoma, Burkitt's lymphoma, cutaneous reticulosis, reticulosis, diffuse large B-cell lymphoma, extranodal NK / T-cell lymphoma / intravascular lymphoma, follicular lymphoma, immunoblastic lymphoma, mucosa-associated lymphoid tissue lymphoma, B-cell chronic lymphocytic leukemia, mantle cell lymphoma, mediastinal large B-cell lymphoma, lymphoplasmacytic lymphoma, lymph node marginal zone B-cell lymphoma, splenic marginal zone lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, lymphomatoid granulomatosis, angioimmunoblastic lymphadenopathy, X-linked lymphoproliferative syndrome, post-transplant lymphoproliferative disease, or Hodgkin's lymphoma. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0017] In the detailed description of the present invention, many specific details are described for the purpose of explanation, so that those skilled in the art can understand the embodiments described. However, those skilled in the art will understand that the specific details of these embodiments do not limit the scope of protection of the present invention. Furthermore, those skilled in the art can easily understand that the specific order of the relevant description and implementation method of the present invention is merely exemplary, and that the relevant order may be changed, but they shall be included in the spirit and scope of the embodiments disclosed by the present invention.
[0018] All technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art, unless otherwise defined. Even if reference is made to a term having a different definition than that provided herein, the definition provided herein shall govern.
[0019] The following terms are used throughout the specification and claims with the meaning explicitly associated therewith, unless the context clearly indicates otherwise.
[0020] As used herein, the phrase "in one embodiment" does not necessarily refer to the same embodiment, but may. Also, as used herein, the phrase "in another embodiment" does not necessarily refer to a different embodiment, but may. Thus, multiple embodiments of the invention can be readily combined without departing from the scope or spirit of the invention.
[0021] As used herein, the term "EBNA1 inhibitor" refers to an inhibitor of EBNA1 Activity of This refers to a compound that inhibits
[0022] As used herein, the term "EBV" refers to Epstein-Barr virus.
[0023] As used herein, an "effective amount," "therapeutically effective amount," or "pharmacologically effective amount" of a compound refers to an amount of the compound sufficient to provide a beneficial effect to the subject to which the compound is administered.
[0024] As used herein, the term "pharmaceutically acceptable carrier" refers to a pharma- ceutically acceptable material, composition, or carrier, such as a liquid or solid filler, stabilizer, dispersant, suspending agent, diluent, excipient, thickener, solvent, or encapsulating material, for carrying or delivering a compound usable in the present invention into the body of a subject, or for carrying or delivering a compound usable in the present invention to a subject so that the compound usable in the present invention performs its desired function.
[0025] As used herein, the term "alkyl" refers to straight chain, branched, cycloalkyl having the specified number of carbon atoms (i.e., C1-8 means 1 to 8 carbons). Examples of alkyl include methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like. Alkyl groups can be optionally substituted. Non-limiting examples of substituted alkyl groups include hydroxylmethyl, chloromethyl, trifluoromethyl, aminomethyl, 1-chloroethyl, 2-hydroxylethyl, 1,2-difluoroethyl, 3-carboxypropyl, and the like.
[0026] As used herein, the term "alkoxy" refers to the group -O-alkyl, where the alkyl group is as defined above. The alkoxy group can be optionally substituted. The term C3-C8 cycloalkoxy refers to a ring containing 3 to 8 carbon atoms and at least one oxygen atom (e.g., tetrahydrofuran, tetrahydro-2H-pyran). The C3-C8 cycloalkoxy group can be optionally substituted.
[0027] As used herein, the term "haloalkyl" refers to groups including straight-chain and branched saturated aliphatic hydrocarbon groups, having the specified number of carbon atoms, that are substituted with one or more halogens. A haloalkyl group is one in which all of the hydrogens in the alkyl group have been replaced with halogens (e.g., -CF 3 , C.F. 2 CF 3 ) full haloalkyl groups. Haloalkyl groups may be optionally substituted with one or more substituents except halogen. Examples of haloalkyl groups include, but are not limited to, fluoromethyl, dichloroethyl, trifluoromethyl, trichloromethyl, pentafluoroethyl, and pentachloroethyl groups.
[0028] As used herein, the term "halogen" refers to chlorine, bromine, fluorine, and iodine.
[0029] As used herein, the term "heteroaryl" refers to a ring group in which at least one ring member is a heteroatom selected from N, O, and S, and preferably the number of heteroatoms is 1, 2, 3, or 4. Examples include 5-10 membered oxygen-containing heteroaryl, 5-10 membered sulfur-containing heteroaryl, and 5-10 membered nitrogen-containing heteroaryl. Specific examples include, but are not limited to, thiophene, furan, pyrrolyl, pyrazolyl, imidazolyl, isothiazole, pyrazine, oxazolyl, triazolyl, thiazole, pyridine, pyrimidine, indole, quinoline, quinazoline, indazolyl, benzofuran, benzothiophene, benzoxazolyl, benzotriazolyl, benzothiazole, and the like.
[0030] As used herein, the term "optionally substituted" refers to substitution or unsubstitution of any substituent capable of substitution.
[0031] At various places in the present specification, the substituents of compounds are disclosed in groups or ranges. Specifically, the present specification includes the individual subcombinations of the members of such groups and ranges. For example, the term "C1-C8 alkyl" is specifically intended to individually disclose C1, C2, C3, C4, C5, C6, C7, C8, C1-C8, C1-C7, C1-C6, C1-C5, C1-C4, C1-C3, C1-C2, C2-C8, C2-C7, C2-C6, C2-C5, C2-C4, C2-C3, C3-C8, C3-C7, C3-C6, C3-C5, C3-C4, C4-C8, C4-C7, C4-C6, C4-C5, C5-C8, C5-C7, C5-C6 alkyl. The term "C1-C6 alkyl" is specifically intended to individually disclose C1, C2, C3, C4, C5, C6, C1-C6, C1-C5, C1-C4, C1-C3, C1-C2, C2-C6, C2-C5, C2-C4, C2-C3, C3-C6, C3-C5, C3-C4, C4-C6, C4-C5, and C5-C6 alkyl. The term "C1-C4 alkyl" is specifically intended to individually disclose C1, C2, C3, C4, C1-C4, C1-C3, C1-C2, C2-C4, C2-C3, and C3-C4 alkyl.
[0032] Throughout this specification, the term "aryl" refers to phenyl, naphthyl, and anthracene, and the term "heteroaryl" refers to thiophene, furan, pyrrolyl, pyrazolyl, imidazolyl, isothiazole, pyrazine, oxazolyl, triazolyl, thiazole, pyridine, pyrimidine, indole, quinoline, quinazoline, indazolyl, benzofuran, benzothiophene, benzoxazolyl, benzotriazolyl, and benzothiazole.
[0033] The present invention relates to compounds of general formula (I) or their enantiomers, diastereomers, tautomers, salts, crystalline forms, solvates and / or isotopically substituted derivatives: [ka] During the ceremony, R 1 -H, -COOH, -C(=O)-OR 1a , -C(=O)-NHR 1b , -C(=O)-NR 1b R 1c Selected from however, R 1a , R 1b , R 1c are the same or different and are selected independently from hydrogen, optionally substituted C1-C4 linear alkyl, optionally substituted C3-C4 branched alkyl, optionally substituted C3-C4 cycloalkyl, optionally substituted halogenated C1-C4 linear alkyl, optionally substituted halogenated C3-C4 branched alkyl, optionally substituted halogenated C3-C4 cycloalkyl; Or, R 1b is selected from hydroxyl, C1-C4 alkoxy; Or, R 1b and R 1c together with the atoms to which they are attached form a cyclic group, the cyclic group being selected from optionally substituted pyrrolidinyl, optionally substituted piperidinyl, optionally substituted piperazinyl, or optionally substituted morpholinyl; Preferably, R 1 -H, -COOH, -C(=O)-OR 1a , -C(=O)-NHR 1b , -C(=O)-NR 1b R 1c Selected from R 1a , R 1b , R 1c are the same or different and are selected independently from hydrogen, optionally substituted C1-C4 linear alkyl, optionally substituted C3-C4 branched alkyl, optionally substituted halogenated C1-C4 linear alkyl, optionally substituted halogenated C3-C4 branched alkyl; Or, R 1b is selected from hydroxyl, C1-C4 alkoxy; Or, R 1b and R 1c together with the atoms to which they are attached form a cyclic group, the cyclic group being selected from optionally substituted pyrrolidinyl, optionally substituted piperidinyl; More preferably, R 1 -H, -COOH, -C(=O)-OR 1a , -C(=O)-NHR 1b , -C(=O)-NR 1b R 1c Selected from R 1a , R 1b , R 1c are the same or different and are selected independently from hydrogen, methyl, ethyl, propyl, isopropyl, butyl, Or, R 1b is selected from hydroxyl, methoxy, ethoxy, and propoxy; Or, R 1b and R 1c together with the atoms to which they are attached form a cyclic group, the cyclic group being selected from pyrrolidinyl; More preferably, R 1 -H, -COOH, -COOCH 3 , -COOCH 2 CH 3 , -CONHOH, -CONHCH3 , -CON(CH 3 ) 2 , -CON(cC 4 H 8 ), -CONHOCH 3 Selected from R 2 teeth, selected from the group consisting of hydrogen, halogen, optionally substituted C1-C4 alkyl, optionally substituted pyrrolyl, optionally substituted indole, and optionally substituted phenyl; Preferably, R 2 is selected from hydrogen, chlorine, methyl, pyrrolyl, indole, phenyl, chlorophenyl, hydroxylphenyl, and hydroxylalkoxyphenyl; L 1 teeth, [ka] ethynyl group, however, [ka] , L 1 represents the connection point to the right A ring of the compound of general formula (I), However, the asterisk * stands for L 1 represents the connection point to the left B ring of the compound of formula (I), L 2 teeth, -(CH 2 ) q -O-(CH 2 ) p -*, ·-(CH 2 ) q -NH-(CH 2 ) p -*, ·-NH-C(=O)-NH-*, ·-N(CH 3 )-C(=O)-NH-*, -CH=CH-, -(CH 2 ) n -, ·-NH-C(=O)-(CH 2 ) p -*, ·-(CH 2 ) q-C(=O)-NH-* group, Preferably, L 2 is -CH 2 -O-*, ·-O-CH 2 -*, -O-, -CH 2 -O-CH 2 -, -CH 2 -NH-*, -CH 2 -NH-CH 2 -*, -NH-CH 2 -*, -NH-C(=O)-NH-, ·-N(CH 3 )-C(=O)-NH-*, -CH=CH-, -CH 2 -, -CH 2 -CH 2 -, ·-NH-C(=O)-*, ·-NH-C(=O)-CH 2 -*, -C(=O)-NH-*, -CH 2 -C(=O)-NH-*; More preferably, L 2 is -CH 2 -O-*, -O-CH 2 -*, -O-, -CH 2 -O-CH 2 -, -CH 2 -NH-*, ·-NH-C(=O)-NH-*, ·-N(CH 3 )-C(=O)-NH-*, -CH=CH-, -CH 2 -, -CH 2 -CH 2 -, ·-NH-C(=O)-*, ·-NH-C(=O)-CH 2 -*, -CH 2 -C(=O)-NH-*; However, the dot is L 2 represents the connection point to the right B ring of the compound of formula (I), However, the asterisk * stands for L 2 is the left R of the compound of formula (I) 3 represents the connection point that connects to p and q are each independently 0, 1, or 2; n is 1, 2 or 3; R 3is selected from optionally substituted aryl, heteroaryl; Aryl is selected from phenyl; heteroaryl is selected from thiophene, pyrazolyl, imidazolyl, isothiazole, pyridine, pyrimidine, pyrazine, and quinoline; Aryl, heteroaryl are optionally substituted one or more times, similarly or differently, with hydrogen, fluorine, chlorine, cyano, C1-C4 alkyl, halogenated C1-C4 alkyl, C1-C4 alkoxy, halogenated C1-C4 alkoxy; Preferably, aryl, heteroaryl is optionally substituted one or more times, similarly or differently, with hydrogen, fluorine, cyano, methyl, methoxy, trifluoromethyl; More preferably, aryl is optionally substituted one or more times, similarly or differently, with hydrogen, cyano, trifluoromethyl; More preferably, heteroaryl is optionally substituted one or more times, similarly or differently, with hydrogen, fluorine, methyl, methoxy; More preferably, the pyridine is optionally substituted one or more times, similarly or differently, with hydrogen, fluorine, methyl, methoxy, Even more preferably, R 3 is selected from phenyl, thiophene, pyrazolyl, imidazolyl, isothiazole, pyridine, pyrimidine, pyrazine, quinoline, cyanophenyl, trifluoromethylphenyl, fluoropyridine, methylpyridine, methoxypyridine, and methylpyrazolyl; R 4 is selected from hydrogen, halogen, optionally substituted C1-C4 linear alkyl, optionally substituted C3-C4 branched alkyl, optionally substituted halogenated C1-C4 linear alkyl, optionally substituted halogenated C3-C4 branched alkyl, and hydroxyl; Preferably, R 4 is selected from hydrogen, fluorine, chlorine, methyl, hydroxyl, and is intended to be optionally substituted one or more times in the same or different manner.
[0034] In another preferred embodiment, the present invention relates to compounds of general formula (I) above, or their enantiomers, diastereomers, tautomers, salts, crystalline forms, solvates and / or isotopically substituted derivatives, provided that L 2 Ga-(CH 2 ) q -O-(CH 2 ) p When selected from Preferably, L 2 is -CH 2 -O-*, ·-O-CH 2 -*, -O-, -CH 2 -O-CH 2 -Selected from R 3 is selected from aryl and heteroaryl; Aryl is selected from phenyl; heteroaryl is selected from thiophene, pyrazolyl, isothiazole, pyridine, pyrimidine, pyrazine, and quinoline; Aryl, heteroaryl are optionally substituted one or more times, similarly or differently, with hydrogen, C1-C4 alkyl, C1-C4 alkoxy; Preferably, aryl, heteroaryl is optionally substituted one or more times with hydrogen, methyl, methoxy, either the same or different; Preferably, R 3 is selected from phenyl, thiophene, pyrazolyl, isothiazole, pyridine, pyrimidine, pyrazine, quinoline, methylpyridine, methoxypyridine, and methylpyrazolyl; More preferably, L 2 is -CH 2 -O-*, R 3 is selected from phenyl, thiophene, pyrazolyl, isothiazole, pyridine, pyrimidine, pyrazine, quinoline, methylpyridine, methoxypyridine, methylpyrazolyl, more preferably R 3 is selected from phenyl, pyridine, methylpyridine, methoxypyridine, and even more preferably, R 3 is selected from pyridine, methylpyridine, and methoxypyridine; More preferably, L 2 is -O-CH 2 -* is selected, R 3 is selected from phenyl, thiophene, pyrazolyl, isothiazole, pyridine, pyrimidine, pyrazine, quinoline, methylpyridine, methoxypyridine, methylpyrazolyl, more preferably R 3 is selected from phenyl, pyridine, methylpyridine, methoxypyridine, and even more preferably, R 3 is selected from pyridine, methylpyridine, methoxypyridine, and even more preferably, R 3 is selected from pyridine, More preferably, L 2 is selected from -O-, R 3 is selected from phenyl, thiophene, pyrazolyl, isothiazole, pyridine, pyrimidine, pyrazine, quinoline, methylpyridine, methoxypyridine, methylpyrazolyl, more preferably R 3 is selected from phenyl, pyridine, methylpyridine, methoxypyridine, and even more preferably, R 3 is selected from pyridine, methylpyridine, methoxypyridine, and even more preferably, R 3 is selected from pyridine, More preferably, L 2 -CH 2 -O-CH 2 - is selected from R 3 is selected from phenyl, thiophene, pyrazolyl, isothiazole, pyridine, pyrimidine, pyrazine, quinoline, methylpyridine, methoxypyridine, methylpyrazolyl, more preferably R 3 is selected from phenyl, pyridine, methylpyridine, methoxypyridine, and even more preferably, R 3 is selected from pyridine, methylpyridine, methoxypyridine, and even more preferably, R 3 is selected from pyridine, Or, L 2 Ga-(CH 2 ) q -NH-(CH 2 ) p-, ·-NH-C(=O)-(CH 2 ) p -*, ·-(CH 2 ) q When selected from -C(=O)-NH-*, -CH=CH-, Preferably, L 2 is -CH 2 -NH-*, -CH 2 -NH-CH 2 -*, -NH-CH 2 -*, ·-NH-C(=O)-*, ·-NH-C(=O)-CH 2 -*, -C(=O)-NH-*, -CH 2 -C(=O)-NH-*, -CH=CH-, R 3 is selected from aryl and heteroaryl; Aryl is selected from phenyl; Heteroaryl is selected from pyridine; More preferably, L 2 is -CH 2 -NH-*, -CH 2 -NH-CH 2 -*, -NH-CH 2 -* is selected, R 3 is selected from phenyl, thiophene, pyrazolyl, isothiazole, pyridine, pyrimidine, pyrazine, quinoline, methylpyridine, methoxypyridine, methylpyrazolyl, more preferably R 3 is selected from phenyl, pyridine, methylpyridine, and methoxypyridine; More preferably, L 2 is -CH 2 -NH-*, R 3 is selected from pyridine, methylpyridine, methoxypyridine, and more preferably, L 2 is -CH 2 -NH-*, R 3 is selected from pyridine, More preferably, L 2 is ·-NH-C(=O)-*, ·-NH-C(=O)-CH 2 -* is selected, R 3is selected from phenyl, thiophene, pyrazolyl, isothiazole, pyridine, pyrimidine, pyrazine, quinoline, methylpyridine, methoxypyridine, methylpyrazolyl, more preferably R 3 is selected from phenyl, pyridine, methylpyridine, methoxypyridine, and even more preferably, R 3 is selected from pyridine, methylpyridine, methoxypyridine, and even more preferably, R 3 is selected from pyridine, More preferably, L 2 -C(=O)-NH-*, -CH 2 -C(=O)-NH-*, R 3 is selected from phenyl, thiophene, pyrazolyl, isothiazole, pyridine, pyrimidine, pyrazine, quinoline, methylpyridine, methoxypyridine, methylpyrazolyl, more preferably R 3 is selected from phenyl, pyridine, methylpyridine, methoxypyridine, and more preferably, L 2 is -CH 2 -C(=O)-NH-*, R 3 is selected from phenyl, pyridine, methylpyridine, methoxypyridine, and more preferably, L 2 is -CH 2 -C(=O)-NH-*, R 3 is selected from phenyl and pyridine; More preferably, L 2 is selected from -CH=CH-, R 3 is selected from phenyl, thiophene, pyrazolyl, isothiazole, pyridine, pyrimidine, pyrazine, quinoline, methylpyridine, methoxypyridine, methylpyrazolyl, more preferably R 3 is selected from phenyl, pyridine, methylpyridine, methoxypyridine, and even more preferably, R 3 is selected from pyridine, methylpyridine, methoxypyridine, and even more preferably, R 3 is selected from pyridine, Or, L 2 -NH-C(=O)-NH-, -N(CH3 )-C(=O)-NH-*, R 3 is selected from aryl and heteroaryl; Aryl is selected from phenyl; Heteroaryl is selected from pyridine; Aryl, heteroaryl are substituted one or more times, either the same or different, with hydrogen, fluorine, cyano, C1-C4 alkyl, halogenated C1-C4 alkyl; Preferably, aryl, heteroaryl is substituted one or more times, similarly or differently, with hydrogen, fluorine, cyano, methyl, methoxy, trifluoromethyl, preferably R 3 is selected from cyanophenyl, trifluoromethylphenyl, pyridine, fluoropyridine, methylpyridine, methoxypyridine, trifluoromethylpyridine, and trifluoromethoxypyridine; More preferably, L 2 is selected from -NH-C(=O)-NH-, R 3 is selected from cyanophenyl, trifluoromethylphenyl, pyridine, fluoropyridine, methylpyridine, methoxypyridine, trifluoromethylpyridine, trifluoromethoxypyridine, more preferably R 3 is selected from trifluoromethylphenyl, pyridine, fluoropyridine, and methylpyridine; More preferably, L 2 is -N(CH 3 )-C(=O)-NH-*, R 3 is selected from cyanophenyl, trifluoromethylphenyl, pyridine, fluoropyridine, methylpyridine, methoxypyridine, trifluoromethylpyridine, trifluoromethoxypyridine, more preferably R 3 is selected from cyanophenyl, trifluoromethylphenyl, pyridine, fluoropyridine, methylpyridine, and even more preferably, R 3 is selected from cyanophenyl, Or, L 2 Ga-(CH 2 ) nWhen selected from Preferably, L 2 is -CH 2 -, -CH 2 -CH 2 -Selected from R 3 is selected from aryl and heteroaryl; Aryl is selected from phenyl; Heteroaryl is selected from pyridine and imidazolyl; More preferably, L 2 is -CH 2 - is selected from R 3 is selected from phenyl, pyridine, imidazolyl, more preferably R 3 is selected from imidazolyl, More preferably, L 2 is -CH 2 -CH 2 - is selected from R 3 is selected from phenyl, pyridine, imidazolyl, more preferably R 3 is selected from pyridine.
[0035] In another preferred embodiment, the present invention relates to compounds of general formula (I) above, or their enantiomers, diastereomers, tautomers, salts, crystalline forms, solvates and / or isotopically substituted derivatives, provided that L 1 is selected from oxy-azetidine; R 2 is selected from hydrogen, halogen, optionally substituted C1-C4 alkyl, optionally substituted pyrrolyl, optionally substituted indole, and optionally substituted phenyl; Preferably, R 2 is selected from hydrogen, chlorine, methyl, pyrrolyl, indole, phenyl, and chlorophenyl; L 2 is -(CH 2 ) q -O-(CH 2 ) p -, -(CH 2 ) q -NH-(CH 2 )p -, -NH-C(=O)-NH-, -N(CH 3 )-C(=O)-NH-*, -CH=CH-, -(CH 2 ) n -, ·-NH-C(=O)-(CH 2 ) p -*, ·-(CH 2 ) q -C(=O)-NH-*; R 3 is selected from phenyl, thiophene, pyrazolyl, imidazolyl, isothiazole, pyridine, pyrimidine, pyrazine, quinoline, cyanophenyl, trifluoromethylphenyl, fluoropyridine, methylpyridine, methoxypyridine, and methylpyrazolyl; More preferably, R 1 -H, -COOH, -C(=O)-OR 1a , -C(=O)-NHR 1b , -C(=O)-NR 1b R 1c Selected from R 1a , R 1b , R 1c are the same or different and are selected independently from hydrogen, optionally substituted C1-C4 linear alkyl, optionally substituted C3-C4 branched alkyl, optionally substituted halogenated C1-C4 linear alkyl, optionally substituted halogenated C3-C4 branched alkyl; Or, R 1b is selected from hydroxyl, C1-C4 alkoxy; Or, R 1b and R 1c together with the atoms to which they are attached form a cyclic group, the cyclic group being selected from optionally substituted pyrrolidinyl, optionally substituted piperidinyl; More preferably, R 1 -H, -COOH, -C(=O)-OR 1a , -C(=O)-NHR 1b , -C(=O)-NR 1b R 1c Selected from R 1a , R 1b , R1c are the same or different and are selected independently from hydrogen, methyl, ethyl, propyl, isopropyl, butyl, Or, R 1b is selected from hydroxyl, methoxy, ethoxy, and propoxy; Or, R 1b and R 1c together with the atoms to which they are attached form a cyclic group, the cyclic group being selected from pyrrolidinyl; More preferably, R 1 -H, -COOH, -COOCH 3 , -COOCH 2 CH 3 , -CONHOH, -CONHCH 3 , -CON(CH 3 ) 2 , -CON(cC 4 H 8 ), -CONHOCH 3 Selected from More preferably, R 3 is selected from phenyl, cyanophenyl, and trifluoromethylphenyl, L 2 is -NH-C(=O)-NH-, -N(CH 3 )-C(=O)-NH-*, ·-(CH 2 ) q -C(=O)-NH-*, R 2 is selected from pyrrolyl and chlorophenyl; R 1 -H, -COOH, -COOCH 3 , -CONHOH, More preferably, R 3 is selected from pyridine, fluoropyridine, methylpyridine, and methoxypyridine, L 2 is -(CH 2 ) q -O-(CH 2 ) p -, -(CH 2 ) q -NH-(CH 2 ) p -, -NH-C(=O)-NH-, -N(CH 3)-C(=O)-NH-*, -CH=CH-, -(CH 2 ) n -, ·-NH-C(=O)-(CH 2 ) p -*, ·-(CH 2 ) q -C(=O)-NH-*, R 2 is selected from hydrogen, chlorine, methyl, pyrrolyl, indole, phenyl, and chlorophenyl; R 1 -H, -COOH, -COOCH 3 , -COOCH 2 CH 3 , -CONHOH, -CONHCH 3 , -CON(CH 3 ) 2 , -CON(cC 4 H 8 ), -CONHOCH 3 Selected from More preferably, L 2 -CH 2 -O-*, ·-O-CH 2 -*, -O-, -CH 2 -O-CH 2 - When selected from R 3 is selected from pyridine, methylpyridine, and methoxypyridine; R 2 is selected from pyrrolyl, phenyl, and chlorophenyl; R 1 -H, -COOH, -COOCH 3 , -COOCH 2 CH 3 , -CONHOH, -CONHCH 3 , -CON(CH 3 ) 2 , -CON(cC 4 H 8 ) are selected, More preferably, L 2 -CH 2 -NH-*, -CH 2 -NH-CH 2 -*, -NH-CH 2 -*, R 3 is selected from pyridine, methylpyridine, and methoxypyridine; R 2is selected from pyrrolyl, phenyl, and chlorophenyl; R 1 -H, -COOH, -COOCH 3 , -CONHOH, and more preferably R 3 is selected from pyridine, More preferably, L 2 -NH-C(=O)-NH-, -N(CH 3 )-C(=O)-NH-*, R 3 is selected from pyridine, fluoropyridine, and methylpyridine; R 2 is selected from hydrogen, pyrrolyl, phenyl, and chlorophenyl; R 1 -H, -COOH, -COOCH 3 , -CONHOH, -CONHCH 3 Selected from More preferably, L 2 is selected from -CH=CH-, R 3 is selected from pyridine, methylpyridine, and methoxypyridine; R 2 is selected from pyrrolyl and phenyl; R 1 -H, -COOH, -COOCH 3 , -CONHOH, and more preferably R 3 is selected from pyridine, More preferably, L 2 Ga-CH 2 -, -CH 2 -CH 2 - When selected from R 3 is selected from pyridine, methylpyridine, and methoxypyridine; R 2 is selected from pyrrolyl, R 1 -H, -COOH, -COOCH 3 More preferably, R 3 is selected from pyridine, More preferably, L 2 is ·-NH-C(=O)-*, ·-NH-C(=O)-CH 2 -*, R 3 is selected from pyridine, methylpyridine, and methoxypyridine; R 2is selected from hydrogen, chlorine, methyl, pyrrolyl, phenyl, and chlorophenyl; R 1 -H, -COOH, -COOCH 3 , -CONHOH, -CONHCH 3 , -CONHOCH 3 More preferably, R 3 is selected from pyridine, More preferably, L 2 -C(=O)-NH-*, -CH 2 -C(=O)-NH-*, R 3 is selected from pyridine, methylpyridine, and methoxypyridine; R 2 is selected from hydrogen, indole, and phenyl; R 1 -H, -COOH, -COOCH 3 , -CONHOH, -CONHCH 3 More preferably, R 3 is selected from pyridine, Or, L 1 is selected from ethynyl, R 2 is selected from optionally substituted indole, optionally substituted phenyl; L 2 is -(CH 2 ) q -O-(CH 2 ) p -, -NH-C(=O)-NH-, -N(CH 3 )-C(=O)-NH-*, ·-NH-C(=O)-(CH 2 ) p -*, ·-(CH 2 ) q -C(=O)-NH-*; Preferably, R 2 is selected from indole, phenyl, chlorophenyl, hydroxylphenyl, and hydroxylalkoxyphenyl; R 3 is selected from pyridine, methylpyridine, and methoxypyridine; More preferably, L 2 -CH 2 -O-*, ·-O-CH2 -*, -O-, -CH 2 -O-CH 2 - When selected from R 3 is selected from pyridine, R 2 is selected from indole, R 1 -H, -COOH, -COOCH 3 , -CONHOH, More preferably, L 2 -NH-C(=O)-NH-, -N(CH 3 )-C(=O)-NH-*, R 3 is selected from pyridine, fluoropyridine, and methylpyridine; R 2 is selected from indole, phenyl, hydroxylphenyl, and hydroxylalkoxyphenyl; R 1 -H, -COOH, -COOCH 3 , -CONHOH, and more preferably R 3 is selected from pyridine, More preferably, L 2 is ·-NH-C(=O)-*, ·-NH-C(=O)-CH 2 -*, R 3 is selected from pyridine, methylpyridine, and methoxypyridine; R 2 is selected from phenyl, R 1 -H, -COOH, -COOCH 3 More preferably, R 3 is selected from pyridine, More preferably, L 2 -C(=O)-NH-*, -CH 2 -C(=O)-NH-*, R 3 is selected from pyridine, methylpyridine, and methoxypyridine; R 2 is selected from indole and phenyl; R 1 -H, -COOH, -COOCH 3 , -CONHOH, and more preferably R 3 is selected from pyridine.
[0036] In another preferred embodiment, the present invention relates to a compound of general formula (I) above, or an enantiomer, diastereomer, tautomer, salt, crystalline form, solvate and / or isotopically substituted derivative thereof, which compound is Methyl 3-(3-(4-((pyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoate, 3-(3-(4-((pyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, ethyl 3-(3-(4-((pyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoate, N-hydroxyl-3-(3-(4-((pyridin-3-yloxy) N-methyl-3-(3-(4-((pyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzamide, N,N-dimethyl-3-(3-(4-((pyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzamide, (3-(3-(4-((pyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzamide -yl)-2-(1H-pyrrol-1-yl)phenyl)(pyrrolidin-1-yl)methyl ketone, 3-((4-((1-(2-(1H-pyrrol-1-yl)phenyl)azetidin-3-yl)oxy)benzyl)oxy)pyridine, 3-(3-(4-((4-methylpyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl ester, 3-(3-(4-((4-methylpyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H- pyrrol-1-yl)benzoic acid, 3-(3-(4-((5-methylpyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl, 3-(3-(4-((5-methylpyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, 3-(3-(4-(((6-methoxypyridin-3-yl)oxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl,3-(3-(4-(((6-methoxypyridin-3-yl)oxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, 3-(3-(4-((6-methylpyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl ester, 3-(3-(4-((6-methylpyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, 3-(3-(4-(((5- 3-(3-(4-(((5-methoxypyridin-3-yl)oxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, 3-(3-(4-(3-(3-cyanophenyl)-1-methylurea)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl, 3-(3-(4-(3-(3-cyanophenyl)-1-methylurea)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl -1-methylurea)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, 3-(3-(4-((pyridin-4-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl, 3-(3-(4-((pyridin-4-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, 2-(1H-pyrrol-1-yl)-3-(3-(4-((quinolin-3-yloxy)methyl)phenoxy )azetidin-1-yl)benzoic acid methyl, 2-(1H-pyrrol-1-yl)-3-(3-(4-((quinolin-3-yloxy)methyl)phenoxy)azetidin-1-yl)benzoic acid, 2-(1H-pyrrol-1-yl)-3-(3-(4-(3-(3-(trifluoromethyl)phenyl)urea)phenoxy)azetidin-1-yl)benzoic acid methyl, 2-(1H-pyrrol-1-yl)-3-(3-(4-(3-(3-(trifluoromethyl)phenyl)urea)phenoxy)azetidin-1-yl)benzoic acid,N-hydroxyl-2-(1H-pyrrol-1-yl)-3-(3-(4-(3-(3-(trifluoromethyl)phenyl)urea)phenoxy)azetidin-1-yl)benzamide, 3-(3-(4-((pyrimidin-2-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl ester, 3-(3-(4-(( Pyrimidin-2-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, 3-(3-(4-((pyridin-2-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl ester, 3-(3-(4-((pyridin-2-yloxy)methyl)phenoxy)azetidine 3-(3-(4-((pyrazin-2-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, 3-(3-(4-((pyrazin-2-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl ester, 3-(3-(4-((pyrazin-2-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, 3 -(3-(4-((pyrimidin-5-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl, 3-(3-(4-((pyrimidin-5-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, N-hydroxyl-3-(3-(4-((pyrimidin-5-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, Il3-(3-(3-methyl-4-((pyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzamide, 3-(3-(3-methyl-4-((pyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl, 3-(3-(3-methyl-4-((pyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl, 3-(3-(2-methyl-4-((pyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl 6-(3-(4-((pyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxylic acid methyl ester, 6-(3-(4-((pyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxylic acid, N-hydroxyl-6-(3-(4-((pyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxamide, 3'-chloro-6-(3-(4-((pyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxylate methyl, 3-(3-(3-chloro-4-((pyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl, 3-(3-(3-chloro-4-((pyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, 3-(3-(3-fluoro-4-((pyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl, 3-( 3-(3-fluoro-4-((pyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, 3-(3-(3-((pyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl ester, 6-((3-hydroxyl-4-(3-(pyridin-3-yl)urea)phenyl)ethynyl)-[1,1'-biphenyl]-2-carboxylate methyl ester, 3-(3-(4-((pyridin-3-ylamino)methyl)phenoxy)azetidin-1-yl N-hydroxyl-3-(3-(4-((pyridin-3-ylamino)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzamide, 3-(3-(4-(pyridin-3-ylmethoxy)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl ester, 3-(3-(4-(pyridin-3-ylamino)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl ester, 3-(3-(4-(pyridin-3-ylamino)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl ester, -3-ylmethoxy)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, N-hydroxyl-3-(3-(4-(pyridin-3-ylmethoxy)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzamide, 3-(3-(4-(pyridin-3-yloxy)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl ester, 3-(3-(4-(pyridin-3-yloxy)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid,3-(3-(4-(pyridin-4-yloxy)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl ester, 3-(3-(4-(pyridin-4-yloxy)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, 3-(3-(4-((pyridin-3-ylmethoxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl ester, 3-(3-(4-((pyridin-3-ylmethoxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl ester -yl)-2-(1H-pyrrol-1-yl)benzoic acid, N-hydroxyl-3-(3-(4-((pyridin-3-ylmethoxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzamide, (E)-3-(3-(4-(2-(pyridin-3-yl)vinyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl ester, (E)-3-(3-(4-(2-(pyridin-3-yl)vinyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl ester 3-(3-(4-(2-(pyridin-3-yl)ethyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, (E)-N-hydroxyl-3-(3-(4-(2-(pyridin-3-yl)vinyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzamide, 3-(3-(4-(2-(pyridin-3-yl)ethyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl ester, 3-(3-(4-(2-(pyridin-3-yl)ethyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, 2-(1H-pyrrol-1-yl )-3-(3-(4-((thiophen-2-yloxy)methyl)phenoxy)azetidin-1-yl)benzoic acid methyl, 2-(1H-pyrrol-1-yl)-3-(3-(4-((thiophen-2-yloxy)methyl)phenoxy)azetidin-1-yl)benzoic acid, 3-(3-(4-(nicotinamide)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl, 3-(3-(4-(nicotinamide)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid,N-(4-((1-(3-(hydroxycarbamoyl)-2-(1H-pyrrol-1-yl)phenyl)azetidin-3-yl)oxy)phenyl)nicotinamide, 3-(3-(4-(((1-methyl-1H-pyrazol-3-yl)oxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl, 3-(3-(4-(((1-methyl-1H-pyrazol-3-yl)oxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, 3 -(3-(4-((isothiazol-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl ester, 3-(3-(4-((isothiazol-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, 3-(3-(4-(3-(pyridin-3-yl)urea)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl ester, 3-(3-(4-(3-(pyridin-3-yl)urea)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl ester 3-(3-(4-(2-oxo-2-(phenylamino)ethyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, N-hydroxyl-3-(3-(4-(3-(pyridin-3-yl)urea)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzamide, 3-(3-(4-(2-oxo-2-(phenylamino)ethyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl ester, 3-(3-(4-(2-oxo-2-(phenylamino)ethyl)phenoxy)azetidin-1-yl)-2-(1H- pyrrol-1-yl)benzoic acid, (E)-6-(3-(4-(2-(pyridin-3-yl)vinyl)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-methyl carboxylate, (E)-6-(3-(4-(2-(pyridin-3-yl)vinyl)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxylic acid, (E)-N-hydroxyl-6-(3-(4-(2-(pyridin-3-yl)vinyl)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxamide,3'-chloro-6-(3-(4-(3-(3-(trifluoromethyl)phenyl)urea)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxylic acid methyl ester, 3'-chloro-6-(3-(4-(3-(3-(trifluoromethyl)phenyl)urea)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxylic acid, 3'-chloro-6-(3-(4-((pyridin-3-ylamino)methyl)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxylic acid methyl ester, 3'-chloro-6-(3-(4-((pyridin-3-ylamino)methyl)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxylic acid methyl ester (4-((pyridin-3-ylamino)methyl)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxylic acid, 3'-chloro-N-hydroxyl-6-(3-(4-((pyridin-3-ylamino)methyl)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxamide, 6-(3-(4-((pyridin-3-ylamino)methyl)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxylate methyl, 6-(3-(4-((pyridin-3-ylamino)methyl)phenoxy)azetidin-1-yl N-hydroxyl-6-(3-(4-((pyridin-3-ylamino)methyl)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxamide, 6-(3-(4-(2-oxo-2-(pyridin-3-ylamino)ethyl)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxylate methyl, 6-(3-(4-(2-oxo-2-(pyridin-3-ylamino)ethyl)phenoxy)azetidin-1-yl)-[1,1'-biphenyl] -2-carboxylic acid, N-hydroxyl-6-(3-(4-(2-oxo-2-(pyridin-3-ylamino)ethyl)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxamide, N-methyl-6-(3-(4-(2-oxo-2-(pyridin-3-ylamino)ethyl)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxamide, 3'-chloro-6-(3-(4-(3-(pyridin-3-yl)urea)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxylate methyl,3'-Chloro-6-(3-(4-(3-(pyridin-3-yl)urea)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxylic acid, 3'-chloro-N-hydroxyl-6-(3-(4-(3-(pyridin-3-yl)urea)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxamide, 6-(3-(4-(3-(pyridin-3-yl)urea)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxylate methyl, 6-(3-(4-(3-(pyridin-3-yl)urea)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxylate methyl )urea)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxylic acid, N-hydroxyl-6-(3-(4-(3-(pyridin-3-yl)urea)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxamide, N-methyl-6-(3-(4-(3-(pyridin-3-yl)urea)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxamide, 3-(3-(4-(2-oxo-2-(pyridin-3-ylamino)ethyl)phenoxy)azetidin-1-yl ) benzoate, 3-(3-(4-(2-oxo-2-(pyridin-3-ylamino)ethyl)phenoxy)azetidin-1-yl)benzoic acid, N-hydroxyl-3-(3-(4-(2-oxo-2-(pyridin-3-ylamino)ethyl)phenoxy)azetidin-1-yl)benzamide, 2-(4-((1-phenylazetidin-3-yl)oxy)phenyl)-N-(pyridin-3-yl)acetamide, 2-(1H-indol-6-yl)-3-(3-(4-(2-oxo-2-(pyridin-3-ylamino)ethyl) phenoxy)azetidin-1-yl)benzoic acid methyl ester, 2-(1H-indol-6-yl)-3-(3-(4-(2-oxo-2-(pyridin-3-ylamino)ethyl)phenoxy)azetidin-1-yl)benzoic acid, 6-(3-(4-(2-(pyridin-3-yl)acetylamido)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxylic acid methyl ester, 6-(3-(4-(2-(pyridin-3-yl)acetylamino)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxylic acid,N-hydroxyl-6-(3-(4-(2-(pyridin-3-yl)acetylamino)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxamide, N-methyl-6-(3-(4-(2-(pyridin-3-yl)acetylamino)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxamide, N-Methoxy-6-(3-(4-(2-(pyridin-3-yl)acetylamino)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxamide, N-(4-((1-([1,1'-biphenyl]-2-yl)azetidin-3-yl)oxy)phenyl)-2-(pyridin-3-yl)acetamide, 3-(3-(4-(3-(5-fluoropyridin-3-yl)urea)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl ester, 3-(3-(4-(3-(5-fluoropyridin-3-yl)urea)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl ) benzoic acid, 3-(3-(4-(3-(5-methylpyridin-3-yl)urea)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl ester, 3-(3-(4-(3-(5-methylpyridin-3-yl)urea)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, 3'-chloro-6-(3-(4-(2-(pyridin-3-yl)acetylamino)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxylate methyl ester, 3'-chloro-6-(3-(4-(2-(pyridin-3-yl)acetylamino)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxylic acid, 3-(3-(4-(2-(pyridin-3-yl)acetylamino)phenoxy)azetidin-1-yl)benzoic acid methyl ester, 3-(3-(4-(2-(pyridin-3-yl)acetylamino)phenoxy)azetidin-1-yl)benzoic acid, 3-(3-(4-(3-(pyridin-3-yl)urea)phenoxy)azetidin-1-yl)benzoic acid methyl ester, 3-(3-(4-(3-(pyridin-3-yl)urea)phenoxy)azetidin-1-yl)benzoic acid methyl ester, 3-(3-(4-(3-(pyridin-3 -yl)urea)phenoxy)azetidin-1-yl)benzoic acid, 3-(3-(4-(2-(pyridin-3-yl)acetylamino)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl ester, 3-(3-(4-(2-(pyridin-3-yl)acetylamino)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, 3-(3-(3-fluoro-4-(2-(pyridin- 3-(3-(4-(2-(pyridin-3-yl)acetylamino)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl ester, 3-(3-(3-fluoro-4-(2-(pyridin-3-yl)acetylamino)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, 2-methyl-3-(3-(4-(2-(pyridin-3-yl)acetylamino)phenoxy)azetidin-1-yl)benzoic acid methyl ester, 2 -Methyl-3-(3-(4-(2-(pyridin-3-yl)acetylamino)phenoxy)azetidin-1-yl)benzoic acid, 6-(3-(3-fluoro-4-(2-(pyridin-3-yl)acetylamino)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxylate methyl, 6-(3-(3-fluoro-4-(2-(pyridin-3-yl)acetylamino)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxylic acid, 2-chloro-3-(3-(4-(2-(pyridin-3-yl)acetylamino)phenoxy)azetidin-1-yl)benzoic acid methyl ester, 2-chloro-3-(3-(4-(2-(pyridin-3-yl)acetylamino)phenoxy)azetidin-1-yl)benzoic acid, 3-(3-(4-((1H-imidazol-1-yl)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl ester, 3-(3-(4-((1H-imidazol-1-yl)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, 3'-(2-hydroxylethodo)-6-((4-(3-(pyridin-3-yl)urea)phenyl)ethynyl)-[1,1'-biphenyl]-2-carboxylate methyl, 6-((4-(3-(pyridin-3-yl)urea)phenyl)ethynyl)-[1,1'-biphenyl]-2-carboxylate methyl, 6-((4-( 3-(pyridin-3-yl)urea)phenyl)ethynyl)-[1,1'-biphenyl]-2-carboxylic acid, N-hydroxyl-6-((4-(3-(pyridin-3-yl)urea)phenyl)ethynyl)-[1,1'-biphenyl]-2-carboxamide, 2-(1H-indol-6-yl)-3-((4-(3-(pyridin-3-yl)urea)phenyl)ethynyl)benzoic acid methyl ester, 2-(1H-indol-6-yl)-3-((4-(3-(pyridin-3-yl)urea)phenyl)ethynyl) N-hydroxyl-6-((4-(2-oxo-2-(pyridin-3-ylamino)ethyl)phenyl)ethynyl)benzoic acid, 6-((4-(2-oxo-2-(pyridin-3-ylamino)ethyl)phenyl)ethynyl)-[1,1'-biphenyl]-2-carboxylic acid methyl, 6-((4-(2-oxo-2-(pyridin-3-ylamino)ethyl)phenyl)ethynyl)-[1,1'-biphenyl]-2-carboxylic acid, N-hydroxyl-6-((4-(2-oxo-2-(pyridin-3-ylamino)ethyl)phenyl)ethynyl)-[1,1'-biphenyl]-2-carboxamide, 2-(1H-indol-6-yl)-3-((4-(2-oxo-2-(pyridin-3-ylamino)ethyl)phenyl)ethynyl)benzoic acid methyl ester, 2-(1H-indol-6-yl)-3-((4-(2-oxo-2-(pyridin-3-ylamino)ethyl)phenyl)ethynyl)benzoic acid, 6-((4-(2-(pyridin-3-yl)a 6-((4-(2-(pyridin-3-yl)acetamido group)phenyl)ethynyl)-[1,1'-biphenyl]-2-carboxylic acid methyl ester, 6-((4-(2-(pyridin-3-yl)acetamido group)phenyl)ethynyl)-[1,1'-biphenyl]-2-carboxylic acid, 3'-hydroxyl-6-((4-(3-(pyridin-3-yl)urea)phenyl)ethynyl)-[1,1'-biphenyl]-2-carboxylic acid methyl ester.
[0037] In another embodiment, the present invention further relates to a pharmaceutical composition comprising one or more compounds of the above general formula (I) according to the present invention, or their enantiomers, diastereomers, tautomers, salts, crystalline forms, solvates and / or isotopically substituted derivatives.
[0038] In another embodiment, the present invention further relates to a pharmaceutical composition comprising one or more compounds of the above general formula (I) according to the present invention, or their enantiomers, diastereomers, tautomers, salts, crystalline forms, solvates and / or isotopically substituted derivatives, and a pharma- ceutically acceptable carrier, excipient, or diluent.
[0039] In another embodiment, the present invention further relates to a method for treating and / or preventing a disease or disorder caused by EBNA1 activity, comprising administering to a subject an effective amount of a compound of the above general formula (I), or an enantiomer, diastereomer, tautomer, salt, crystal form, solvate and / or isotopically substituted derivative thereof. All of the compounds of the general formula (I) according to the present invention inhibit EBNA1 at the cellular level. Activity of It has excellent inhibitory effects against R 3 When is selected from pyridine and phenyl, it shows a better inhibitory activity.
[0040] In another embodiment, the present invention further relates to the use of one or more compounds of the above general formula (I) according to the present invention, or their enantiomers, diastereomers, tautomers, salts, crystalline forms, solvates and / or isotopically substituted derivatives, in the preparation of a medicament for treating and / or preventing a disease caused by EBNA1 activity, said use comprising administering to a subject an effective amount of at least one compound according to the present invention, or its enantiomers, diastereomers, tautomers, salts, crystalline forms, solvates and / or isotopically substituted derivatives.
[0041] In another embodiment, the present invention further relates to a method for treating and / or preventing nasopharyngeal carcinoma, the method comprising administering to a subject an effective amount of at least one pharmaceutical composition according to the present invention.
[0042] In another embodiment, the present invention further relates to the use of one or more of the above-mentioned pharmaceutical compositions according to the present invention in the preparation of a medicament for treating and / or preventing nasopharyngeal carcinoma, said use comprising administering to a subject an effective amount of at least one pharmaceutical composition according to the present invention.
[0043] In preferred embodiments, the disease or disorder is cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus, or rheumatoid arthritis.
[0044] In a more preferred embodiment, wherein the cancer is selected from the group consisting of nasopharyngeal carcinoma, non-Hodgkin's lymphoma, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, hepatosplenic T-cell lymphoma, B-cell lymphoma, Burkitt's lymphoma, cutaneous reticulosis, reticulosis, diffuse large B-cell lymphoma, extranodal NK / T-cell lymphoma / intravascular lymphoma, follicular lymphoma, immunoblastic lymphoma, mucosa-associated lymphoid tissue lymphoma, B-cell chronic lymphocytic leukemia, mantle cell lymphoma, mediastinal large B-cell lymphoma, lymphoplasmacytic lymphoma, lymph node marginal zone B-cell lymphoma, splenic marginal zone lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, lymphomatoid granulomatosis, angioimmunoblastic lymphadenopathy, X-linked lymphoproliferative syndrome, post-transplant lymphoproliferative disease, or Hodgkin lymphoma.
[0045] The examples and preparations provided by the present invention further elucidate and illustrate the compounds described in the present invention and the methods for their preparation. It should be understood that the scope of the following preparations and examples does not limit the scope of the present invention in any way.
[0046] The following synthetic procedures explain the preparation of the derivatives of general formula (I) of the present invention, and all the raw materials, reagents, catalysts, solvents, etc. used in the following synthetic procedures can be prepared by methods well known to those skilled in the art of organic chemistry or can be commercially available. All the final derivatives of the present invention can be prepared by the methods described in the procedures or by methods similar thereto, all of which are well known to those skilled in the art of organic chemistry. All the variables applicable to these procedures are defined below or by the claims.
[0047] Preparation method All reagents were purchased from chemical companies and used as received without purification unless otherwise stated, and most reactions were carried out under anhydrous conditions under nitrogen protection. For purification of reagents and solvents, refer to Purification of Laboratory Chemicals (WLFArmarego, Christina Li Lin Chai, Elsevier Inc. 2009). All solvents were redistilled before use unless otherwise stated. Tetrahydrofuran (THF) was prepared by treatment with sodium-benzophenone system, dichloromethane and N,N'-dimethylcarboxamide (DMF) were prepared by treatment with calcium hydride, and methanol was prepared by treatment with magnesium turnings followed by redistillation. Triethylamine, diisopropylethylamine (DIPEA), and pyridine were treated with calcium hydride and redistilled. The reaction was monitored by thin layer chromatography (TLC), and the thin layer silica gel plate used was GF254 (60-F250, 0.2 mm), and the color was developed by UV (wavelength 254 nm) or iodine, or by immersing in phosphomolybdic acid or ninhydrin solution and then heating. High performance column chromatography was performed using silica gel 60 (230-400 mesh ASTM), and the eluent was generally ethyl acetate and n-hexane or dichloromethane and methanol. 1 H NMR was measured using a DRX-300 or Bruker Avance-400 or Bruker Avance-500 nuclear magnetic resonance instrument, and chemical shifts were determined using residual peaks of deuterated solvents. High-resolution mass spectrometry was measured using an ABI Q-star Elite mass spectrometer or a Thermo Q Exactive Focus mass spectrometer, and the liquid phase mass spectrometer was an Agilent 6125.
[0048] General Experimental Procedure 1 [ka]
[0049] R 2 , R3 R is an aromatic ring or an aromatic heterocycle, the specific definition of which is described in the specification and claims. 4 For the definition of X, see the specification and claims. 1a ,NHR 1b ,NR 1b R 1c For specific definitions, please refer to the specification and claims. 1 , Y 2 , Y 3 , Y 4 Please see the specification and claims section for the definition.
[0050] N-Boc-3-hydroxyazetidine G1 (1.0 eq.) was prepared and dissolved in dichloromethane, protected with nitrogen gas, and cooled in an ice bath while adding triethylamine (1.5 eq.). Then methanesulfonyl chloride (1.5 eq.) was slowly added dropwise, and the mixture was allowed to warm to room temperature and react for 2 hours. The solvent was removed by rotary evaporation under reduced pressure, diluted with a large amount of ethyl acetate, and washed once with water. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain intermediate compound G2, which was a pale yellow oil. G2 was dissolved in N,N-dimethylcarboxamide without further purification, and G3 (1.2 eq.) and cesium carbonate (2.2 eq.) were added, and the mixture was heated to 100°C under nitrogen gas protection and reacted for 14 hours. The reaction solution was cooled to room temperature, diluted with a large amount of ethyl acetate, and washed twice with saturated aqueous ammonium chloride solution and once with saturated aqueous sodium bicarbonate solution. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and then separated by silica gel column chromatography to obtain compound G4.
[0051] Compound G4 (1 equivalent) was dissolved in a solvent, and sodium borohydride (3.0 equivalents) was added under nitrogen gas protection and ice bath cooling, and a small amount of methanol was added and reacted at room temperature for 2 hours. The reaction was quenched with saturated aqueous ammonium chloride solution, the organic phase was removed under reduced pressure, and extracted with a large amount of ethyl acetate. ExtractedThe organic phase was washed with saturated aqueous sodium chloride, dried over anhydrous sodium sulfate, filtered and concentrated to give compound G5. Compound G5 was dissolved in an appropriate amount of dichloromethane and treated with an excess of trifluoroacetic acid to remove the Boc protection and give the trifluoroacetate salt of compound G6.
[0052] Intermediate G6 (1.0 equivalent), 3-fluoro-2-nitrobenzoic acid methyl ester G7 (1.0 equivalent), and cesium carbonate (2.5 equivalents) were prepared and dissolved in N,N-dimethylcarboxamide, and the mixture was heated to 50°C under nitrogen gas protection and reacted for 2 hours. After cooling the reaction solution to room temperature, it was diluted with a large amount of ethyl acetate and washed with a saturated aqueous solution of ammonium chloride. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and then separated by silica gel column chromatography to obtain compound G8.
[0053] In the nitro reduction procedure, the nitro-substituted compound G8 (1.0 equivalent) waiting for reduction was dissolved in a 1:1 mixture of methanol and dichloromethane, and ammonium chloride (5.0 equivalents) was added while cooling in an ice bath, reduced zinc powder (3.0 equivalents) was added, and the mixture was stirred at room temperature for more than 2 hours, and the reaction was monitored by thin layer chromatography until completion. The reaction solution was filtered to remove solid insolubles, the filter cake was washed with ethyl acetate, the filtrate was diluted with a large amount of ethyl acetate, washed with saturated aqueous sodium bicarbonate, the aqueous phase was extracted twice more with ethyl acetate, the organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated, and then separated by silica gel column chromatography to obtain compound G9.
[0054] Compound G9 (1.0 equivalent) was dissolved in anhydrous chloroform, and an appropriate amount of dry silica gel, compound 2,5-dimethoxytetrahydrofuran (5.0 equivalent), and acetic anhydride (50.0 equivalent) were added, and the mixture was refluxed under nitrogen gas for more than 2 hours, and monitored by thin layer chromatography until the reaction was completed. The mixture was cooled to room temperature, insoluble matter was removed by filtration, the filtrate was washed with saturated aqueous sodium bicarbonate, and the aqueous phase was extracted twice more with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and then separated by silica gel column chromatography to obtain compound G10.
[0055] Compound G10 (1.0 equivalent), arylboronic acid compound (R 3 B(OH) 2 ) (3.0 equivalents), anhydrous copper acetate (0.3 equivalents) and an appropriate amount of 40-60 mesh 4A molecular sieves were mixed and dissolved in dichloromethane, triethylamine (5.0 equivalents) was added, the oxygen environment was replaced, and the mixture was stirred at room temperature for 12 hours. Insoluble matter was removed by filtration, the filtrate was washed with saturated aqueous ammonium chloride solution, and the aqueous phase was further extracted with ethyl acetate twice. The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated, and then separated by silica gel column chromatography to obtain compound G11.
[0056] In the hydrolysis procedure, compound G11 (1.0 equivalent) was dissolved in an appropriate amount of tetrahydrofuran, lithium hydroxide aqueous solution (1.0 mole per liter, 3.0 equivalents) was added, and the mixture was replaced with nitrogen gas, then stirred at room temperature for more than 4 hours and monitored by thin layer chromatography until the reaction was completed. The organic phase was removed under reduced pressure, and dilute hydrochloric acid (1.0 mole per liter) was added dropwise to the remaining aqueous phase to adjust the pH to 4, causing a large amount of white solid to precipitate in the system, which was filtered to obtain the solid. The filter cake was washed with water and then dried to obtain carboxylic acid compound G12.
[0057] Compound G12 (1.0 equivalent) was dissolved in an appropriate amount of anhydrous dichloromethane, triethylamine (3.0 equivalent), nucleophilic reagent XH (1.2 equivalent), and HATU (1.5 equivalent) were added while cooling in an ice bath, and the mixture was stirred for more than 4 hours at room temperature under the protection of nitrogen gas, and the reaction was monitored by thin layer chromatography until completion. The reaction solution was diluted with a large amount of ethyl acetate, washed with a saturated aqueous ammonium chloride solution, and the aqueous phase was extracted twice more with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and then separated by silica gel column chromatography to obtain compound G13.
[0058] Compound G9 (1.0 equivalent) was dissolved in 1,4-dioxane-water, and hydroiodic acid (20.0 equivalents or more) was added while cooling in an ice bath. After stirring for 10 minutes, an aqueous solution of sodium nitrite (1.1 equivalents) was slowly added and reacted for 1 hour. Then, an aqueous solution of potassium iodide (1.5 equivalents) was added while cooling in an ice bath, and the temperature was slowly raised to room temperature and reacted for 16 hours. A saturated sodium bicarbonate solution was added to adjust the pH to 7. The mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by silica gel column chromatography to obtain compound G14.
[0059] Compound G14 and aromatic boronic acid (R 3 B(OH) 2 ) (1.5 equivalents) in tetrahydrofuran-water, and the catalyst Pd(dppf)Cl 2 (0.1 equivalent) and K 2 CO 3 (3.0 equivalents) was added, heated to 90° C. and reacted for 16 hours. After completion of the reaction, the organic phase was removed under reduced pressure, and the residue was diluted with a large amount of ethyl acetate and washed twice with saturated saline. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and then separated by silica gel column chromatography to obtain compound G15.
[0060] Compound G16 was prepared from Compound G15 by referring to the experimental procedure for preparing Compound G11 from Compound G10.
[0061] Compound G17 was prepared from compound G16 by referring to the hydrolysis experimental procedure for preparing compound G12 from compound G11.
[0062] Compound G18 was prepared from compound G17 by referring to the experimental procedure for preparing compound G13 from compound G12.
[0063] General Experimental Procedure 2 [ka]
[0064] Compound G15 (1.0 equivalent) was dissolved in anhydrous dichloromethane, anhydrous sodium bicarbonate (5.0 equivalent) was added, and the Dess-Martin oxidant was added in portions while cooling with an ice bath, and the mixture was gradually returned to room temperature and stirred for more than 2 hours, and the reaction was monitored by thin layer chromatography until completion. A large amount of ethyl acetate was added to dilute the reaction solution, and the solution was washed with a saturated aqueous solution of sodium bicarbonate. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and then separated by silica gel column chromatography to obtain compound G19.
[0065] Compound G19 was dissolved in anhydrous methanol and the arylamine (R 3 -NH 2 ) (2.0 equivalents) was added and stirred at room temperature overnight, cooled again in an ice bath, sodium cyanoborohydride (2.0 equivalents) was added, stirred at room temperature for another 2 hours or more, and monitored by thin layer chromatography until the reaction was complete. In an ice bath, an appropriate amount of saturated aqueous ammonium chloride solution was added to quench the reaction, diluted with a large amount of ethyl acetate to extract the reaction solution, and the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and then separated by silica gel column chromatography to obtain compound G20.
[0066] Compound G19 (1.0 equivalent) was dissolved in anhydrous tetrahydrofuran, potassium tert-butoxide (1.5 equivalent) was added, the temperature was lowered to -78°C, a THF solution of an aryl Wittig reagent (1.2 equivalent) was added dropwise, and the mixture was stirred for another 2 hours while maintaining the temperature at -78°C. The reaction bottle was transferred to an ice bath, the temperature was gradually returned to 0°C, and the mixture was stirred for 2 hours. The reaction was quenched by adding a saturated aqueous ammonium chloride solution, and the reaction solution was extracted by diluting with a large amount of ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and then separated by silica gel column chromatography to obtain compound G21.
[0067] Compound G21 was dissolved in methanol, an appropriate amount of palladium carbon (0.2 equivalents) was added, and the hydrogen atmosphere was thoroughly replaced. The mixture was then stirred at room temperature for more than 2 hours and monitored by thin layer chromatography until the reaction was completed. Insoluble matter was removed by filtration, and the filtrate was concentrated and then further purified by column chromatography to obtain compound G22.
[0068] 3-Hydroxyazetidine hydrochloride (1.0 equivalent), 3-fluoro-2-nitrobenzoic acid methyl G7 (1.0 equivalent), and cesium carbonate (2.0 equivalent) were prepared and dissolved in N,N-dimethylcarboxamide, and the mixture was heated to 50°C under nitrogen gas protection and reacted for 2 hours. After cooling the reaction solution to room temperature, it was diluted with a large amount of ethyl acetate and washed three times with a saturated aqueous solution of ammonium chloride. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and then separated by silica gel column chromatography to obtain compound G24. Compound G24 (1.0 equivalent) was dissolved in dichloromethane, imidazole (2.0 equivalent) was added, and the mixture was cooled in an ice bath. Then, tert-butyldimethylchlorosilane (1.2 equivalent) was added, and the mixture was returned to room temperature and stirred for 14 hours. The reaction was quenched by adding a saturated aqueous ammonium chloride solution, and the reaction solution was extracted by diluting with a large amount of ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated. The obtained crude product was used to prepare compound G25 by referring to the nitro reduction experiment procedure for preparing compound G9 from compound G8.
[0069] With reference to the experimental procedure for preparing compound G10 from compound G9, the tert-butyldimethylsilyl ether intermediate of compound G26 was prepared from compound G25. The tert-butyldimethylsilyl ether intermediate of compound G26 (1.0 equivalent) was dissolved in dichloromethane, and a tetrahydrofuran solution of tetrabutylammonium fluoride (1.0 mole per liter, 1.5 equivalents) was added, reacted at room temperature for more than 1 hour, and monitored by thin layer chromatography until the reaction was completed. The solvent was removed under reduced pressure, the reaction solution was diluted with a large amount of ethyl acetate, washed with a saturated aqueous ammonium chloride solution, and the aqueous phase was extracted twice more with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated, and then separated by silica gel column chromatography to obtain compound G26 (R 2 is a pyrrole ring).
[0070] Compound G27 was prepared from Compound G25 by referring to the experimental procedure for preparing Compound G14 from Compound G9.
[0071] With reference to the experimental procedure for preparing compound G15 from compound G14, the tert-butyldimethylsilyl ether intermediate of compound G26 was prepared from compound G27, and the tert-butyldimethylsilyl ether protecting group of the intermediate was removed with tetrabutylammonium fluoride to obtain compound G26.
[0072] Compound G28 was prepared from compound G26 and compound G23 by referring to the experimental procedure for preparing compound G24 from compound G7.
[0073] Compound G29 was prepared from compound G28 by referring to the nitro reduction experimental procedure for preparing compound G9 from compound G8.
[0074] Under ice bath cooling, N,N'-carbonyldiimidazole (CDI) (3.0 equivalents) was added to the arylamine (R 3 -NH 2) (3.0 equivalents) in anhydrous THF, and stirred at room temperature under nitrogen gas protection for more than 2 hours. After adding compound G29 (1.0 equivalents), the reaction system was refluxed for 14 hours, cooled to room temperature, and quenched by adding saturated aqueous ammonium chloride solution. The organic phase was removed under reduced pressure, diluted with a large amount of ethyl acetate to extract the reaction solution, and the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and then separated by silica gel column chromatography to obtain compound G30.
[0075] Arylmethyl carboxylic acid (R 3 -CH 2 CO 2 H) (2.0 equivalents) was dissolved in an appropriate amount of anhydrous N,N-dimethylcarboxamide, and N,N-diisopropylethylamine (3.0 equivalents), compound G29 (1.0 equivalents), and HATU (1.5 equivalents) were added while cooling in an ice bath, and the mixture was stirred for more than 4 hours at room temperature under the protection of nitrogen gas, and the reaction was monitored by thin layer chromatography until completion. The reaction solution was diluted with a large amount of ethyl acetate, washed with a saturated aqueous ammonium chloride solution, and the aqueous phase was extracted twice more with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated, and then separated by silica gel column chromatography to obtain compound G31.
[0076] Compound G32 was prepared from compound G29 with reference to the experimental procedure for preparing compound G31 from compound G29.
[0077] 3. General Experimental Procedure [ka]
[0078] With reference to the experimental procedure for preparing compound G30 from compound G29, 3 -NH 2 Compound G34 was prepared from ) and compound G33.
[0079] With reference to the experimental procedure for preparing compound G31 from compound G29, arylmethyl carboxylic acid (R3 -CH 2 CO 2 Compound G35 was prepared from H) and compound G33.
[0080] With reference to the experimental procedure for preparing compound G31 from compound G29, 3 -NH 2 Compound G37 was prepared from G36 and compound G37.
[0081] Compound G34 (1.0 equivalent) and compound G38 (1.2 equivalent) were dissolved in anhydrous THF, triethylamine (2.0 equivalents) was added, and cuprous iodide (0.025 equivalents) and Pd(PPh 3 ) 2 Cl 2 (0.05 equivalents) were mixed in advance, then added to the reaction system and stirred at room temperature under nitrogen gas protection for 14 hours. The reaction solution was diluted with a large amount of ethyl acetate, washed with saturated ammonium chloride aqueous solution, and the aqueous phase was extracted twice more with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated, and then separated by silica gel column chromatography to obtain compound G39.
[0082] Example 1 [ka]
[0083] Compound 1 (9 mg, 50% yield) was synthesized with reference to General Experimental Procedure 1. 1 H NMR (300 MHz, CDCl 3 )δ8.37(dd,J=2.7,1.0Hz,1H),8.23(dd,J=4.1,1.9Hz,1H),7.41-7.09(m,6H),6.83-6.55(m,5H ),6.25(t,J=2.1Hz,2H),5.02(s,2H),4.93-4.78(m,1H),3.91-3.73(m,2H),3.71-3.31(m,5H). Mass spectrometry (mass to charge ratio) is C 27 H 25 N 3 NaO 4 +[M+Na] + The theoretical value is 478.1737 and the measured value is 478.1738.
[0084] Example 1a Compound 1a (3.8 mg, 80% yield) was synthesized with reference to General Experimental Procedure 1. 1 H NMR (400 MHz, CDCl 3 )δ8.41-8.30(m,1H),8.28-8.15(m,1H),7.42-7.19(m,6H),6.86-6.63(m,5H),6.37 -6.05(m,2H),5.02(s,2H),4.89-4.79(m,1H),3.85-3.75(m,2H),3.69-3.60(m,2H). Mass spectrometry (mass to charge ratio) is C 26 H 23 N 3 NaO 4 + [M+Na] + The theoretical value is 464.1581 and the measured value is 464.1582.
[0085] Example 1b Compound 1b (10.5 mg, 98% yield) was synthesized with reference to General Experimental Procedure 1. 1 H NMR (400 MHz, CDCl 3 )δ8.58-8.11(m,2H),7.44-7.05(m,5H),6.78-6.58(m,5H),6.24(t,J=2.1Hz,2H),5.02(s,2H),4.9 0-4.77(m,1H),4.06(q,J=7.1Hz,2H),3.85-3.71(m,2H),3.71-3.57(m,2H),1.09(t,J=7.1Hz,3H). Mass spectrometry (mass to charge ratio) is C 28 H 28 N 3 O 4 + [M+H] + The theoretical value is 470.2074 and the measured value is 470.2080.
[0086] Example 1c Compound 1c (6.5 mg, 96% yield) was synthesized with reference to General Experimental Procedure 1. 1 H NMR (500 MHz, CDCl 3 )δ8.44-8.13(m,2H),7.40-7.27(m,3H),7.27-7.15(m,3H),6.81-6.63(m,5H),6.43 -6.29(m,2H),5.01(s,2H),4.89-4.75(m,1H),3.88-3.75(m,2H),3.69-3.61(m,2H). Mass spectrometry (mass to charge ratio) is C 26 H 25 N 4 O 4 + [M+H] + The theoretical value is 457.1870 and the measured value is 457.1870.
[0087] Example 1d Compound 1d (6.6 mg, 64% yield) was synthesized with reference to General Experimental Procedure 1. 1 H NMR (500 MHz, CDCl 3 )δ8.47-8.08(m,2H),7.42-7.14(m,6H),6.75(t,J=2.1Hz,2H),6.72-6.66(m,2H),6.66-6.58(m,1H) ,6.31(t,J=2.1Hz,2H),5.12-5.03(m,1H),5.01(s,2H),4.89-4.76(m,1H),2.61(d,J=4.9Hz,3H).13C NMR(126MHz, CDCl 3 )δ167.44,156.83,154.93,147.05,142.30,138.27,135.76,129.49,129.03,128.93,124.17,123.94 ,123.71,121.56,119.36,115.32,114.78,110.27,77.49,77.23,76.98,69.95,66.54,59.44,26.87. Mass spectrometry (mass to charge ratio) is C 27 H 27 N 4 O 3 + [M+H] + The theoretical value is 455.2078 and the measured value is 455.2087.
[0088] Example 1e Compound 1e (13.8 mg, 33% yield) was synthesized with reference to General Experimental Procedure 1. 1 H NMR (300 MHz, CDCl 3 )δ8.54-8.03(m,2H),7.41-7.07(m,5H),6.97-6.64(m,5H),6.64-6.53(m,1H),6.21(t,J=2.0Hz,2H ),5.01(s,2H),4.89-4.76(m,1H),4.07-3.86(m,1H),3.71-3.44(m,3H),2.82(s,3H),2.63(s,3H). Mass spectrometry (mass to charge ratio) is C 28 H 29 N 4 O 3 + [M+H] + The theoretical value is 469.2234 and the measured value is 469.2229.
[0089] Example 1f Referring to General Experimental Procedure 1, compound 1f (10.4 mg, 92% yield) was synthesized. 1 H NMR (500 MHz, CDCl 3 )δ8.29(d,J=69.3Hz,2H),7.37-7.13(m,5H),6.92-6.73(m,3H),6.73-6.64(m,2H),6.64-6.51(m,1H),6.20(t,J=2.1Hz,2H) ),5.00(s,2H),4.87-4.77(m,1H),3.79(s,2H),3.64-3.53(m,2H),3.43-3.12(m,2H),3.08-2.91(m,2H),1.77-1.57(m,4H). Mass spectrometry (mass to charge ratio) is C 30 H 31 N 4 O 3 + [M+H] + The theoretical value is 495.2391 and the measured value is 495.2394.
[0090] Example 1g Referring to General Experimental Procedure 1, compound 1g (4.3 mg, 48% yield) was synthesized. 1 H NMR (400 MHz, CDCl 3 )δ8.47-8.13(m,2H),7.38-7.19(m,5H),7.19-7.08(m,1H),6.89-6.79(m,3H),6.76-6.69(m,2H),6.65-6 .55(m,1H),6.28(t,J=2.1Hz,2H),5.02(s,2H),4.91-4.81(m,1H),3.89-3.76(m,2H),3.69-3.57(m,2H). Mass spectrometry (mass to charge ratio) is C 25 H 24 N 3 O 2 + [M+H] + , the theoretical value is 398.1863 and the measured value is 398.1863.
[0091] Example 2 [ka]
[0092] Compound 2 (6 mg, 25% yield) was synthesized with reference to General Experimental Procedure 1. 1 H NMR (500 MHz, CDCl 3 )δ8.19(d,J=45.1Hz,2H),7.38-7.27(m,3H),7.15(dd,J=7.6,1.3Hz,1H),7.11(s,1H),6.77-6.63(m,5H),6.26( t,J=2.1Hz,2H),5.08(s,2H),4.88-4.80(m,1H),3.86-3.77(m,2H),3.70-3.64(m,2H),3.62(s,3H),2.26(s,3H). Mass spectrometry (mass to charge ratio) is C 28 H 28 N 3 O 4 + [M+H] + The theoretical value is 470.2074 and the measured value is 470.2076.
[0093] Example 2a Compound 2a (3 mg, 98% yield) was synthesized with reference to General Experimental Procedure 1. 1 H NMR (500 MHz, CDCl 3 )δ8.13(d,J=47.0Hz,2H),7.38-7.21(m,4H),7.15(s,1H),6.81-6.73(m,2H),6.73-6.64(m,3H) ),6.24(t,J=1.9Hz,2H),5.07(s,2H),4.89-4.78(m,1H),3.85-3.75(m,2H),3.73-3.59(m,2H). Mass spectrometry (mass to charge ratio) is C 27 H 26 N 3 O 4 + [M+H] + The theoretical value is 456.1918 and the measured value is 456.1920.
[0094] Example 3 [ka]
[0095] Compound 3 (7 mg, 28% yield) was synthesized with reference to General Experimental Procedure 1. 1 H NMR (400 MHz, CDCl 3 )δ8.14(d,J=40.5Hz,2H),7.38-7.22(m,3H),7.21-7.11(m,1H),7.08(s,1H),6.77-6.61(m,5H),6.26(t,J= 2.1Hz,2H),5.00(s,2H),4.89-4.78(m,1H),3.85-3.75(m,2H),3.70-3.63(m,2H),3.62(s,3H),2.32(s,3H). Mass spectrometry (mass to charge ratio) is C 28 H 28 N 3 O 4 + [M+H] + The theoretical value is 470.2074 and the measured value is 470.2084.
[0096] Example 3a Referring to General Experimental Procedure 1, compound 3a (4.3 mg, 44% yield) was synthesized. 1 H NMR (400 MHz, CDCl 3 )δ8.26-7.91(m,2H),7.39-7.19(m,4H),7.13(s,1H),6.84-6.62(m,5H),6.34-6.16(m,2H), 5.00(s,2H),4.88-4.78(m,1H),3.85-3.69(m,2H),3.65(dd,J=8.7,4.8Hz,2H),2.32(s,3H). Mass spectrometry (mass to charge ratio) is C 27 H 26 N 3 O 4 + [M+H] + The theoretical value is 456.1918 and the measured value is 456.1920.
[0097] Example 4 [ka]
[0098] Compound 4 (11.4 mg, 44% yield) was synthesized with reference to General Experimental Procedure 1. 1 H NMR (400 MHz, CDCl 3 )δ7.90-7.78(m,1H),7.39-7.07(m,5H),6.76-6.60(m,6H),6.26(t,J=2.1Hz,2H),4.95(s ,2H),4.89-4.78(m,1H),3.89(s,3H),3.86-3.76(m,2H),3.69-3.63(m,2H),3.62(s,3H). Mass spectrometry (mass to charge ratio) is C 28 H 28 N 3 O 5 + [M+H] + The theoretical value is 486.2023 and the measured value is 486.2028.
[0099] Example 4a Compound 4a (1.3 mg, 27% yield) was synthesized with reference to General Experimental Procedure 1. 1H NMR (500 MHz, CDCl 3 )δ8.11(s,1H),7.87-7.81(m,1H),7.37-7.18(m,5H),6.78-6.64(m,5H),6.30-6.22(m, 2H),4.95(s,2H),4.86-4.80(m,1H),3.89(s,3H),3.82-3.73(m,2H),3.69-3.61(m,2H). Mass spectrometry (mass to charge ratio) is C 27 H 26 N 3 O 5 + [M+H] + The theoretical value is 472.1867 and the measured value is 472.1869.
[0100] Example 5 [ka]
[0101] Compound 5 (16 mg, 42% yield) was synthesized with reference to General Experimental Procedure 1. 1 H NMR (300 MHz, CDCl 3 )δ8.24(d,J=2.3Hz,1H),7.40-6.97(m,6H),6.76-6.60(m,5H),6.25(t,J=2.1Hz,2H) ,4.98(s,2H),4.89-4.77(m,1H),3.86-3.73(m,2H),3.69-3.57(m,5H),2.49(s,3H). Mass spectrometry (mass to charge ratio) is C 28 H 28 N 3 O 4 + [M+H] + The theoretical value is 470.2074 and the measured value is 470.2076.
[0102] Example 5a Referring to General Experimental Procedure 1, compound 5a (8.1 mg, 83% yield) was synthesized. 1 H NMR (400 MHz, CDCl 3)δ8.33-8.09(m,1H),7.38-7.16(m,5H),7.16-6.98(m,1H),6.85-6.59(m,5H),6.34-6.11( m,2H),4.99(s,2H),4.88-4.76(m,1H),3.85-3.73(m,2H),3.73-3.56(m,2H),2.47(s,2H). Mass spectrometry (mass to charge ratio) is C 27 H 26 N 3 O 4 + [M+H] + The theoretical value is 456.1918 and the measured value is 456.1917.
[0103] Example 6 [ka]
[0104] Referring to General Experimental Procedure 1, compound 6 (17 mg, 44% yield) was synthesized. 1 H NMR (300 MHz, CDCl 3 )δ8.12-7.85(m,2H),7.37-7.22(m,3H),7.20-7.10(m,1H),6.84-6.64(m,6H),6.25(t ,J=2.1Hz,2H),5.00(s,2H),4.89-4.79(m,1H),3.88-3.74(m,5H),3.71-3.57(m,5H). Mass spectrometry (mass to charge ratio) is C 28 H 27 N 3 NaO 5 + [M+Na] + The theoretical value is 508.1843 and the measured value is 508.1845.
[0105] Example 6a Compound 6a (3.6 mg, 52% yield) was synthesized with reference to General Experimental Procedure 1. 1 H NMR (400 MHz, CDCl 3)δ7.97(s,2H),7.38-7.19(m,5H),6.88-6.64(m,5H),6.26(t,J=2.0Hz,2 H),5.00(s,2H),4.90-4.77(m,1H),3.88-3.72(m,5H),3.71-3.60(m,2H). Mass spectrometry (mass to charge ratio) is C 27 H 26 N 3 O 5 + [M+H] + The theoretical value is 472.1867 and the measured value is 472.1873.
[0106] Example 7 [ka]
[0107] Referring to General Experimental Procedure 1, compound 7 (19 mg, 68% yield) was synthesized. 1 H NMR (300 MHz, CDCl 3 )δ7.66(t,J=1.9Hz,1H),7.48(dt,J=8.1,1.8Hz,1H),7.30(t,J=8.1Hz,2H),7.24-7.15(m,3H),6.83-6.74(m,2H),6.74-6.66(m ,3H),6.31-6.21(m,3H),4.92-4.79(m,1H),3.83(dd,J=8.7,6.2Hz,2H),3.67(dd,J=8.8,4.8Hz,2H),3.61(s,3H),3.28(s,3H). High resolution mass spectrometry (mass to charge ratio) 30 H 27 N 5 O 4 Na + [M+Na] + The theoretical value is 544.1961 and the measured value is 544.1956.
[0108] Example 7a Compound 7a (2 mg, 30% yield) was synthesized with reference to General Experimental Procedure 1. 1 H NMR (300MHz, MeOH-d 4)δ7.82-7.77(m,1H),7.62-7.56(m,1H),7.40(d,J=7.7Hz,1H),7.35-7.30(m,1H),7.29(s,1H),7.29-7.21(m,2H),7.03-6.96(m, 1H),6.84(d,J=9.0Hz,2H),6.78-6.66(m,3H),6.16(s,2H),4.81-4.75(m,1H),3.88-3.79(m,2H),3.56-3.48(m,3H),3.26(s,3H). Mass spectrometry (mass to charge ratio) is C 29 H 25 N 5 O 4 Na + [M+Na] + The theoretical value is 530.1804 and the measured value is 530.1802.
[0109] Example 8 [ka]
[0110] Compound 8 (4 mg, 16% yield) was synthesized with reference to General Experimental Procedure 1. 1 H NMR (400 MHz, CDCl 3 )δ8.76-8.22(m,2H),7.36-7.22(m,4H),7.16(dd,J=7.7,1.4Hz,1H),6.90(s,1H),6.76-6.63(m,5H), 6.26(t,J=2.1Hz,2H),5.02(s,2H),4.90-4.79(m,2H),3.81(dd,J=9.1,6.2Hz,2H),3.70-3.55(m,5H). Mass spectrometry (mass to charge ratio) is C 27 H 26 N 3 O 4 + [M+H] + , the theoretical value is 456.1918 and the measured value is 456.1918.
[0111] Example 8a Compound 8a (3.2 mg, 94% yield) was synthesized with reference to General Experimental Procedure 1. 1H NMR (500 MHz, CDCl 3 )δ8.59-8.15(m,2H),7.42-7.11(m,5H),6.89(s,1H),6.79-6.55(m,5H),6.29-6. 06(m,2H),5.02(s,2H),4.87-4.75(m,1H),3.84-3.69(m,2H),3.68-3.52(m,2H). Mass spectrometry (mass to charge ratio) is C 26 H 24 N 3 O 4 + [M+H] + The theoretical value is 442.1761 and the measured value is 442.1760.
[0112] Example 9 [ka]
[0113] Compound 9 (18 mg, 27% yield) was synthesized with reference to General Experimental Procedure 1. 1 H NMR (400 MHz, CDCl 3 )δ8.80-8.64(m,1H),8.11-7.97(m,1H),7.77-7.64(m,1H),7.62-7.43(m,3H),7.39(d,J=8.6Hz,2H),7.35-7.22(m,1H),7.22-7.07( m,1H),6.81-6.61(m,5H),6.26(t,J=2.1Hz,2H),5.11(s,2H),4.90-4.80(m,1H),3.86-3.77(m,2H),3.71-3.64(m,2H),3.62(s,3H). Mass spectrometry (mass to charge ratio) is C 31 H 28 N 3 O 4 + [M+H] + The theoretical value is 506.2074 and the measured value is 506.2078.
[0114] Example 9a Referring to General Experimental Procedure 1, compound 9a (8.1 mg, 84% yield) was synthesized. 1H NMR (300 MHz, CDCl 3 )δ8.88-8.42(m,1H),8.13-7.89(m,1H),7.88-7.65(m,1H),7.65-7.45(m,3H),7.45-7.24(m,3H),7.24-7.07(m,1H),6 .87-6.53(m,5H),6.35-6.10(m,2H),5.12(s,2H),4.85(dd,J=10.6,5.7Hz,1H),3.84-3.69(m,2H),3.71-3.52(m,2H). Mass spectrometry (mass to charge ratio) is C 30 H 26 N 3 O 4 + [M+H] + The theoretical value is 492.1918 and the measured value is 492.1919.
[0115] Example 10 [ka]
[0116] Referring to General Experimental Procedure 2, compound 10 (11 mg, 44% yield) was synthesized. 1 H NMR (400 MHz, CDCl 3 )δ7.54-7.44(m,2H),7.32(d,J=5.5Hz,1H),7.23(d,J=7.7Hz,1H),7.17-7.06(m,4H),6.69(q,J=2.2Hz,2H),6.65(dd,J=8.3,1.4 Hz,1H),6.60-6.54(m,2H),6.23(t,J=2.1Hz,2H),4.70(p,J=5.3Hz,1H),3.75(dd,J=8.6,6.1Hz,2H),3.58(dd,J=8.9,4.7Hz,5H). Mass spectrometry (mass to charge ratio) is C 29 H 25 F 3 N 4 O 4 Na + [M+Na] + The theoretical value is 573.1726 and the measured value is 573.1722.
[0117] Example 10a Referring to General Experimental Procedure 2, compound 10a (4.6 mg, 72% yield) was synthesized. 1 H NMR (400MHz, MeOH-d 4 )δ7.87(d,J=2.0Hz,1H),7.57(dd,J=8.2,2.1Hz,1H),7.44(t,J=8.0Hz,1H),7.33-7.25(m,4H),7.03(dd,J=7.6,1.3Hz,1 H),6.73-6.66(m,5H),6.18(t,J=2.1Hz,2H),4.82-4.79(m,1H),3.80(dd,J=8.7,6.0Hz,2H),3.51(dd,J=8.9,4.3Hz,2H). Mass spectrometry (mass to charge ratio) is C 28 H 23 F 3 N 4 O 4 Na + [M+Na] + The theoretical value is 559.1569 and the measured value is 559.1565.
[0118] Example 10b Referring to General Experimental Procedure 2, compound 10b (2.5 mg, 14.4% yield) was synthesized. 1 H NMR (400MHz, MeOH-d 4 )δ7.98-7.79(m,1H),7.59(dd,J=8.3,2.1Hz,1H),7.46(t,J=8.0Hz,1H),7.38-7.24(m,4H),6.90- 6.62(m,6H),6.21(t,J=2.2Hz,2H),3.83(dd,J=8.7,6.1Hz,2H),3.51(td,J=10.5,9.6,4.0Hz,2H). Mass spectrometry (mass to charge ratio) is C 28 H 24 F 3 N 5 NaO 4 + [M+Na] + The theoretical value is 574.16726 and the measured value is 574.16748.
[0119] Example 11 [ka]
[0120] Referring to General Experimental Procedure 1, compound 11 (8.7 mg, 30% yield) was synthesized. 1 H NMR (300 MHz, CDCl 3 )δ8.62-8.42(m,2H),7.39(d,J=8.6Hz,2H),7.33-7.26(m,1H),7.19-7.07(m,1H),6.94(t,J=4.7Hz,1H),6.75-6.5 7(m,5H),6.31-6.14(m,2H),5.36(s,2H),4.88-4.76(m,1H),3.84-3.73(m,2H),3.67-3.57(m,5H), mass spectrometry (mass to charge ratio) is C 26 H 25 N 4 O 4 + [M+H] + The theoretical value is 457.1870 and the measured value is 457.1877.
[0121] Example 11a Referring to General Experimental Procedure 1, compound 11a (5.4 mg, 93% yield) was synthesized. 1 H NMR (300 MHz, CDCl 3 )δ8.52(d,J=4.7Hz,2H),7.39(d,J=8.6Hz,2H),7.32-7.18(m,1H),7.08-6.99(m,1H),6.94(t,J=4.8Hz,1H),6 .76-6.54(m,5H),6.23(t,J=2.1Hz,2H),5.36(s,2H),4.87-4.77(m,1H),3.82-3.68(m,2H),3.68-3.55(m,2H). Mass spectrometry (mass to charge ratio) is C 25 H 23 N 4 O 4 + [M+H] + The theoretical value is 443.1714 and the measured value is 443.1714.
[0122] Example 12 [ka]
[0123] Referring to General Experimental Procedure 1, compound 12 (5.8 mg, 83% yield) was synthesized. 1 H NMR (300 MHz, CDCl 3 )δ8.25-8.09(m,1H),7.65-7.51(m,1H),7.43-7.22(m,3H),7.21-7.07(m,1H),6.94-6.83(m,1H),6.83-6 .61(m,6H),6.25(t,J=2.1Hz,2H),5.29(s,2H),4.89-4.78(m,1H),3.87-3.73(m,2H),3.70-3.57(m,5H). Mass spectrometry (mass to charge ratio) is C 27 H 26 N 3 O 4 + [M+H] + The theoretical value is 456.1918 and the measured value is 456.1917.
[0124] Example 12a Referring to General Experimental Procedure 1, compound 12a (19.7 mg, 24% yield) was synthesized. 1 H NMR (500 MHz, CDCl 3 )δ8.23-8.09(m,1H),7.63-7.51(m,1H),7.40-7.19(m,4H),6.93-6.83(m,1H),6.77(d,J=8.4Hz,1H),6.74 -6.62(m,5H),6.21(t,J=2.1Hz,2H),5.24(s,2H),4.86-4.77(m,1H),3.82-3.72(m,2H),3.68-3.58(m,2H). Mass spectrometry (mass to charge ratio) is C 26 H 24 N 3 O 4 + [M+H] + The theoretical value is 442.1761 and the measured value is 442.1766.
[0125] Example 13 [ka]
[0126] Compound 13 (6 mg, 33% yield) was synthesized with reference to General Experimental Procedure 1. 1 H NMR (400 MHz, CDCl 3 )δ8.25(s,1H),8.20-8.06(m,2H),7.40-7.33(m,2H),7.33-7.27(m,1H),7.19-7.08(m,1H),6.76-6.63(m,5H ),6.25(t,J=2.1Hz,2H),5.31(s,2H),4.88-4.81(m,1H),3.86-3.75(m,2H),3.69-3.63(m,2H),3.62(s,3H). Mass spectrometry (mass to charge ratio) is C 26 H 25 N 4 O 4 + [M+H] + The theoretical value is 457.1870 and the measured value is 457.1872.
[0127] Example 13a Compound 13a (4 mg, 9% yield) was synthesized with reference to General Experimental Procedure 1. 1 H NMR (500 MHz, CDCl 3 )δ8.23(s,1H),8.16-8.03(m,2H),7.40-7.26(m,4H),6.75-6.64(m,5H),6.25(t,J =2.1Hz,2H),5.29(s,2H),4.86-4.78(m,1H),3.80-3.74(m,2H),3.68-3.61(m,2H). Mass spectrometry (mass to charge ratio) is C 25 H 23 N 4 O 4 + [M+H] + The theoretical value is 443.1714 and the measured value is 443.1708.
[0128] Example 14 [ka]
[0129] Compound 14 (3 mg, 17% yield) was synthesized with reference to General Experimental Procedure 1. 1 H NMR (500 MHz, CDCl 3 )δ8.86(s,1H),8.45(s,2H),7.32(t,J=8.3Hz,3H),7.16(dd,J=7.7,1.3Hz,1H),6.76-6.66(m,5H),6.2 6(t,J=2.1Hz,2H),5.08(s,2H),4.88-4.81(m,1H),3.86-3.78(m,2H),3.69-3.63(m,2H),3.62(s,3H). High resolution mass spectrometry (mass to charge ratio) 26 H 25 N 4 O 4 + [M+H] + The theoretical value is 457.1870 and the measured value is 457.1873.
[0130] Example 14a Referring to General Experimental Procedure 1, compound 14a (1.4 mg, 48% yield) was synthesized. 1 H NMR (400 MHz, CDCl 3 )δ8.84(s,1H),8.46(s,2H),7.42-7.15(m,4H),6.86-6.59(m,5H),6.24(s, 2H), 5.08 (s, 2H), 4.89-4.78 (m, 1H), 3.83-3.72 (m, 2H), 3.69-3.57 (m, 2H). High resolution mass spectrometry (mass to charge ratio) 25 H 23 N 4 O 4 + [M+H] + The theoretical value is 443.1714 and the measured value is 443.1716.
[0131] Example 14b Referring to General Experimental Procedure 1, compound 14b (1.7 mg, 20% yield) was synthesized. 1 H NMR (300 MHz, CDCl 3)δ8.85(s,1H),8.45(s,2H),7.45-7.28(m,4H),6.87-6.58(m,5H),6.41(t,J=1. 9Hz, 2H), 5.08 (s, 2H), 4.93-4.78 (m, 1H), 3.89-3.75 (m, 2H), 3.75-3.59 (m, 2H). Mass spectrometry (mass to charge ratio) is C 25 H 23 N 5 NaO 4 + [M+Na] + The theoretical value is 480.16423 and the measured value is 480.16483.
[0132] Example 15 [ka]
[0133] Compound 15 (5 mg, 10.5% yield) was synthesized with reference to General Experimental Procedure 1. 1 H NMR (500 MHz, CDCl 3 )δ8.49-8.15(m,2H),7.31-7.24(m,4H),7.15(dd,J=7.7,1.3Hz,1H),6.71(t,J=2.1Hz,2H),6.68(dd,J=8.2,1.3Hz,1H),6.61(d,J=2.4Hz,1H),6. 51(dd,J=8.3,2.6Hz,1H),6.25(t,J=2.1Hz,2H),5.00(s,2H),4.88-4.78 (m,1H),3.85-3.75(m,2H),3.67-3.63(m,2H),3.61(s,3H),2.33(s,3H). Mass spectrometry (mass to charge ratio) is C 28 H 28 N 3 O 4 + [M+H] + The theoretical value is 470.20743 and the measured value is 470.20764.
[0134] Example 15a Referring to General Experimental Procedure 1, compound 15a (2 mg, yield 34.36%) was synthesized. 1H NMR (500 MHz, CDCl 3 )δ8.37(s,1H),8.24(s,1H),7.34-7.24(m,5H),6.75(t,J=2.1Hz,2H),6.71(dd,J=8.0,1.4Hz,1H),6.61(d,J=2.4Hz,1H),6.50( dd,J=8.3,2.5Hz,1H),6.27(t,J=2.0Hz,2H),5.00(s,2H),4.88-4.78(m,1H),3.86-3.74(m,2H),3.68-3.57(m,2H),2.33(s,3H). Mass spectrometry (mass to charge ratio) is C 27 H 26 N 3 O 4 + [M+H] + The theoretical value is 456.19178 and the measured value is 456.19189.
[0135] Example 16 [ka]
[0136] Referring to General Experimental Procedure 1, compound 16 (5 mg, yield 6.43%) was synthesized. 1 H NMR (500 MHz, CDCl 3 )δ8.38(s,1H),8.24(s,1H),7.32-7.28(m,1H),7.28-7.21(m,2H),7.21-7 .19(m,1H),7.17-7.13(m,2H),6.71(t,J=2.1Hz,2H),6.69(dd,J=8.2,1.3H z,1H),6.44(d,J=8.3Hz,1H),6.26(t,J=2.1Hz,2H),4.99(s,2H),4.89-4. 79(m,1H),3.85-3.77(m,2H),3.68-3.64(m,2H),3.62(s,3H),2.19(s,3H). Mass spectrometry (mass to charge ratio) is C 28 H 28 N 3 O 4 + [M+H] + The theoretical value is 470.20743 and the measured value is 470.2076.
[0137] Example 16a Referring to General Experimental Procedure 1, compound 16a (4 mg, yield 58.90%) was synthesized. 1 H NMR (500 MHz, CDCl 3 )δ8.34(s,1H),8.21(s,1H),7.32-7.27(m,2H),7.25-7.21(m,2H),7.20-7.18(m,1H),7.17-7.12(m,1H),6.76-6.71(m,2H),6.69(d,J=7 .8Hz,1H),6.43(d,J=8.3Hz,1H),6.27-6.22(m,2H),4.98(s,2H),4.87-4.80(m,1H),3.81-3.74(m,2H),3.67-3.63(m,2H),2.19(s,3H). Mass spectrometry (mass to charge ratio) is C 27 H 26 N 3 O 4 + [M+H] + The theoretical value is 456.19178 and the measured value is 456.19193.
[0138] Example 17 [ka]
[0139] Referring to General Experimental Procedure 1, compound 17 (31 mg, 35.2% yield) was synthesized. 1 H NMR (300 MHz, CDCl 3 )δ8.37(s,1H),8.25(s,1H),7.46-7.13(m,11H),6.74-6.59(m,3H),5.02(s, 2H), 4.74(ddd,J=6.2,4.8,1.4Hz,1H),3.77-3.63(m,2H),3.57-3.42(m,5H). Mass spectrometry (mass to charge ratio) is C 29 H 27 N 2 O 4 + [M+H] +The theoretical value is 467.19653 and the measured value is 467.19669.
[0140] Example 17a Referring to General Experimental Procedure 1, compound 17a (25 mg, 85% yield) was synthesized. 1 H NMR (500MHz, MeOH-d 4 )δ8.31-8.15(m,1H),8.15-8.00(m,1H),7.52-7.39(m,1H),7.39-7.17(m,9H),7.17-7.00(m, 1H),6.78-6.61(m,3H),5.05(s,2H),4.79-4.68(m,1H),3.78-3.63(m,2H),3.41-3.32(m,2H). Mass spectrometry (mass to charge ratio) is C 28 H 25 N 2 O 4 + [M+H] + The theoretical value is 453.2 and the measured value is 453.2.
[0141] Example 17b Referring to General Experimental Procedure 1, compound 17b (6.7 mg, 79% yield) was synthesized. 1 H NMR (500MHz, MeOH-d 4 )δ8.28-8.16(m,1H),8.12-8.05(m,1H),7.49-7.39(m,1H),7.38-7.23(m,9H),6.85(d,J=7.4Hz,1H), 6.74-6.63(m,3H),5.05(s,2H),4.78-4.72(m,1H),4.58(s,1H),3.78-3.64(m,2H),3.41-3.35(m,2H). Mass spectrometry (mass to charge ratio) is C 28 H 26 N 3 O 4 + [M+H] + The theoretical value is 468.2 and the measured value is 468.2.
[0142] Example 18 [ka]
[0143] Referring to General Experimental Procedure 1, compound 18 (15 mg, 19.0% yield) was synthesized. 1 H NMR (400 MHz, CDCl 3 )δ8.39(s,1H),8.25(d,J=4.5Hz,1H),7.44-7.12(m,11H),6.76-6.65(m,3H),5.04 (s,2H),4.79(p,J=5.4Hz,1H),3.81(s,1H),3.71(s,2H),3.57(s,3H),3.50(s,1H). Mass spectrometry (mass to charge ratio) is C 29 H 26 ClN 2 O 4 + [M+H] + The theoretical value is 501.15756 and the measured value is 501.15768.
[0144] Example 19 [ka]
[0145] Compound 19 (5 mg, 4.21% yield) was synthesized with reference to General Experimental Procedure 1. 1 H NMR (500 MHz, CDCl 3 )δ8.39(s,1H),8.26(s,1H),7.39(d,J=8.5Hz,1H),7.32-7.28(m,1H),7.26-7.22(m,2 H),7.16(dd,J=7.6,1.2Hz,1H),6.78(d,J=2.5Hz,1H),6.71(t,J=2.1Hz,2H),6.68(dd, J=8.2,1.2Hz,1H),6.62(dd,J=8.5,2.5Hz,1H),6.26(t,J=2.1Hz,2H),5.12(s,2H),4. 85-4.77(m,1H),3.81(dd,J=8.9,6.3Hz,2H),3.64(dd,J=9.1,4.8Hz,2H),3.62(s,3H). Mass spectrometry (mass to charge ratio) is C 27 H 25 ClN3 O 4 + [M+H] + The theoretical value is 490.15281 and the measured value is 490.15295.
[0146] Example 19a Referring to General Experimental Procedure 1, compound 19a (3 mg, yield 44.12%) was synthesized. 1 H NMR (300 MHz, CDCl 3 )δ8.35(s,1H),8.23(s,1H),7.39(d,J=8.5Hz,1H),7.33-7.20(m,4H),6.80-6.58(m,5 H),6.25(s,2H),5.11(s,2H),4.88-4.74(m,1H),3.83-3.72(m,2H),3.65-3.58(m,2H). Mass spectrometry (mass to charge ratio) is C 26 H 23 ClN 3 O 4 + [M+H] + , the theoretical value is 476.13716 and the measured value is 476.13736.
[0147] Example 20 [ka]
[0148] Compound 20 (5 mg, 4.92% yield) was synthesized with reference to General Experimental Procedure 1. 1 H NMR (400 MHz, CDCl 3 )δ8.43(s,1H),8.30(s,1H),7.39-7.28(m,4H),7.18(dd,J=7.6,1.1Hz,1H),6.74-6.67(m,3H),6.56-6.45(m,2H),6.28 (t,J=2.0Hz,2H),5.09(s,2H),4.88-4.80(m,1H),3.83(dd,J=8.9,6.3Hz,2H),3.67(dd,J=9.0,4.8Hz,2H),3.64(s,3H). Mass spectrometry (mass to charge ratio) is C 27 H 25 FN3 O 4 + [M+H] + The theoretical value is 474.18236 and the measured value is 474.18250.
[0149] Example 20a Referring to General Experimental Procedure 1, compound 20a (1.5 mg, 30.92% yield) was synthesized. 1 H NMR (500 MHz, CDCl 3 )δ8.65-7.97(m,2H),7.37-7.27(m,4H),7.23-7.13(m,1H),6.72(s,2H),6.66-6.59(m,1H),6.51-6. 41(m,2H),6.25-6.13(m,2H),5.06(s,2H),4.83-4.73(m,1H),3.79-3.72(m,2H),3.65-3.57(m,2H). Mass spectrometry (mass to charge ratio) is C 26 H 23 FN 3 O 4 + [M+H] + , the theoretical value is 460.16671 and the measured value is 460.16672.
[0150] Example 21 [ka]
[0151] Compound 21 (3 mg, 9.59% yield) was synthesized with reference to General Experimental Procedure 1. 1 H NMR (500 MHz, CDCl 3)δ 8.52 - 8.33 (m, 1H), 8.33 - 8.18 (m, 1H), 7.32 - 7.27 (m, 2H), 7.26 - 7.22 (m, 2H), 7.15 (dd, J = 7.7, 1.3 Hz, 1H), 7.01 (d, J = 7.6 Hz, 1H), 6.79 - 6.77 (m, 1H), 6.70 (t, J = 2.1 Hz, 2H), 6.68 (dd, J = 8.2, 1.3 Hz, 1H), 6.64 (dd, J = 8.1, 2.3 Hz, 1H), 6.25 (t, J = 2.1 Hz, 2H), 5.06 (s, 2H), 4.88 - 4.81 (m, 1H), 3.80 (dd, J = 9.1, 6.2 Hz, 2H), 3.65 (dd, J = 9.1, 4.8 Hz, 2H), 3.61 (s, 3H). Mass spectrometry (mass-to-charge ratio) is C 27 H 26 N 3 O 4 + [M + H] + , the theoretical value is 456.19178, and the measured value is 456.19480.
[0152] Example 22
Chemical Structure
[0153] Referring to General Experimental Procedure 3, compound 22 (30 milligrams, yield 43.05%) was synthesized. 1 H NMR (500 MHz, DMSO) δ 10.31 (s, 1H), 9.55 (s, 1H), 8.55 (s, 1H), 8.41 (s, 1H), 8.18 (d, J = 4.3 Hz, 1H), 8.03 (d, J = 8.4 Hz, 1H), 7.92 (d, J = 7.5 Hz, 1H), 7.78 (d, J = 7.8 Hz, 1H), 7.72 (d, J = 7.8 Hz, 1H), 7.51 (t, J = 7.8 Hz, 1H), 7.45 (dt, J = 14.2, 6.9 Hz, 3H), 7.30 (d, J = 6.7 Hz, 3H), 6.66 (d, J = 1.6 Hz, 1H), 6.62 (d, J = 8.4 Hz, 1H), 3.51 (s, 3H) ppm. Mass spectrometry (mass-to-charge ratio) is C 28 H 21 O 4 N 3 + [M + H]+ The theoretical value is 464.2 and the measured value is 464.2.
[0154] Example 23 [ka]
[0155] Referring to General Experimental Procedure 1, compound 23 (39 mg, 31% yield) was synthesized. 1 H NMR (400MHz, MeOH-d 4 )δ7.93-7.85(m,1H),7.76-7.67(m,1H),7.36-7.23(m,3H),7.13-6.94(m,3H),6.82-6.66(m,5H ),6.20(t,J=2.1Hz,2H),4.87-4.79(m,1H),4.26(s,2H),3.89-3.80(m,2H),3.58-3.46(m,5H). Mass spectrometry (mass to charge ratio) is C 27 H 27 N 4 O 3 + [M+H] + The theoretical value is 455.20777 and the measured value is 455.20776.
[0156] Example 23a Referring to General Experimental Procedure 1, compound 23a (4.4 mg, 80% yield) was synthesized. 1 H NMR (400MHz, MeOH-d 4 )δ8.01-7.62(m,2H),7.31-6.91(m,5H),6.89-6.63(m,5H),6.54(dd,J=8.2,1.2Hz,1H),6. 12(t,J=2.1Hz,2H),4.84-4.73(m,1H),4.25(s,2H),3.81-3.65(m,2H),3.51-3.35(m,2H). Mass spectrometry (mass to charge ratio) is C 26 H 25 N 4 O 3 + [M+H] + The theoretical value is 441.19212 and the measured value is 441.19196.
[0157] Example 23b Referring to General Experimental Procedure 1, compound 23b (3 mg, 27% yield) was synthesized. 1 H NMR (400 MHz, CDCl 3 )δ8.12-7.85(m,2H),7.43-7.30(m,2H),7.27-7.17(m,2H),7.12-7.00(m,1H),6.93-6.80(m,1H),6.80 -6.57(m,5H),6.44-6.31(m,2H),4.88-4.77(m,1H),4.27(s,2H),3.85-3.74(m,2H),3.70-3.61(m,2H). Mass spectrometry (mass to charge ratio) is C 26 H 26 N 5 O 3 + [M+H] + The theoretical value is 456.20302 and the measured value is 456.20313.
[0158] Example 24 [ka]
[0159] Referring to General Experimental Procedure 1, compound 24 (40 mg, yield 39.85%) was synthesized. 1 H NMR (500 MHz, CDCl 3 )δ8.66(d,J=1.8Hz,1H),8.58(dd,J=4.8,1.3Hz,1H),7.78-7.72(m,1H),7.3 4-7.27(m,2H),7.15(dd,J=7.6,1.1Hz,1H),6.89-6.84(m,2H),6.70(t,J=2. 1Hz,2H),6.69-6.66(m,1H),6.65-6.62(m,2H),6.25(t,J=2.1Hz,2H),5.02( s, 2H), 4.80-4.74 (m, 1H), 3.81-3.74 (m, 2H), 3.66-3.62 (m, 2H), 3.61 (s, 3H). Mass spectrometry (mass to charge ratio) is C 27 H 26 N 3 O4 + [M+H] + The theoretical value is 456.19178 and the measured value is 456.19189.
[0160] Example 24a Referring to General Experimental Procedure 1, compound 24a (6 mg, yield 51.59%) was synthesized. 1 H NMR (500 MHz, CDCl 3 )δ8.62(s,1H),8.59-8.49(m,1H),7.81(d,J=7.8Hz,1H),7.35(dd,J=7. 7,5.0Hz,1H),7.33-7.27(m,1H),7.26-7.20(m,1H),6.88-6.81(m,2H), 6.74(s,2H),6.68(d,J=7.1Hz,1H),6.66-6.60(m,2H),6.26-6.20(m,2H ),5.01(s,2H),4.79-4.73(m,1H),3.81-3.71(m,2H),3.66-3.59(m,2H). Mass spectrometry (mass to charge ratio) is C 26 H 24 N 3 O 4 + [M+H] + The theoretical value is 442.17613 and the measured value is 442.17578.
[0161] Example 24b Referring to General Experimental Procedure 1, compound 24b (10 mg, yield 53.83%) was synthesized. 1 H NMR (500MHz, MeOH-d 4 / CDCl 3)δ8.58(d,J=1.2Hz,1H),8.47(dd,J=4.8,1.2Hz,1H),7.94-7.85(m,1H),7.43(dd ,J=7.8,5.0Hz,1H),7.29(t,J=7.9Hz,1H),6.94-6.87(m,2H),6.86-6.82(m,1H), 6.75(t,J=2.1Hz,2H),6.69(dd,J=8.2,0.9Hz,1H),6.67-6.62(m,2H),6.19(t,J= 2.1Hz, 2H), 5.06 (s, 2H), 4.79-4.75 (m, 1H), 3.82-3.74 (m, 2H), 3.60-3.50 (m, 2H). Mass spectrometry (mass to charge ratio) is C 26 H 25 N 4 O 4 + [M+H] + The theoretical value is 457.18703 and the measured value is 457.18719.
[0162] Example 25 [ka]
[0163] Compound 25 (8 mg, 52% yield) was synthesized with reference to General Experimental Procedure 1. 1 H NMR (400 MHz, CDCl 3 )δ8.39-8.36(m,1H),8.36-8.33(m,1H),7.32(t,J=7.9Hz,1H),7.27-7.21(m,2H),7.18(dd,J=7.7,1.3Hz,1H),7.00-6.96(m,2H), 6.77-6.68(m,5H),6.28(t,J=2.1Hz,2H),4.88-4.80(m,1H),3.82(dd,J=9.0,6.3Hz,2H),3.68(dd,J=9.1,4.8Hz,2H),3.64(s,3H). Mass spectrometry (mass to charge ratio) is C 26 H 24 N 3 O 4 + [M+H] + The theoretical value is 442.17613 and the measured value is 442.17535.
[0164] Example 25a Referring to General Experimental Procedure 1, compound 25a (6 mg, yield 51.64%) was synthesized. 1 H NMR (400 MHz, CDCl 3 )δ8.31-8.28(m,1H),8.28-8.24(m,1H),7.32-7.28(m,1H),7.27-7.23(m,2H),7.22-7.16(m,1H),6.98-6.91(m,2H),6. 74(t,J=2.0Hz,2H),6.71-6.65(m,3H),6.23(t,J=2.0Hz,2H),4.84-4.75(m,1H),3.81-3.72(m,2H),3.66-3.61(m,2H). Mass spectrometry (mass to charge ratio) is C 25 H 22 N 3 O 4 + [M+H] + The theoretical value is 428.16048 and the measured value is 428.1606.
[0165] Example 26 [ka]
[0166] Compound 26 (7 mg, 48% yield) was synthesized with reference to General Experimental Procedure 1. 1 H NMR (400 MHz, CDCl 3 )δ8.50-8.45(m,2H),7.33(t,J=7.9Hz,1H),7.20-7.17(m,1H),7.03-7.00(m,2H),6.84-6.80(m,2H),6.77 -6.71(m,5H),6.28(t,J=2.1Hz,2H),4.89-4.81(m,1H),3.87-3.81(m,2H),3.72-3.67(m,2H),3.64(s,3H). Mass spectrometry (mass to charge ratio) is C 26 H 24 N 3 O 4 + [M+H] +The theoretical value is 442.17613 and the measured value is 442.17609.
[0167] Example 26a Referring to General Experimental Procedure 1, compound 26a (7 mg, yield 72.30%) was synthesized. 1 H NMR (400MHz, MeOH-d 4 -CDCl 3 )δ8.33(d,J=6.2Hz,2H),7.37-7.34(m,1H),7.28(t,J=7.9Hz,1H),7.16(d,J=7.6Hz,1H),7.00-6.95(m,2H),6.83-6.79(m, 2H),6.74-6.71(m,3H),6.69-6.65(m,1H),6.20(t,J=1.9Hz,2H),4.87-4.75(m,1H),3.81-3.71(m,2H),3.65-3.58(m,2H). Mass spectrometry (mass to charge ratio) is C 25 H 22 N 3 O 4 + [M+H] + The theoretical value is 428.16048 and the measured value is 428.16049.
[0168] Example 27 [ka]
[0169] Referring to General Experimental Procedure 1, compound 27 (11.4 mg, 18.3% yield) was synthesized. 1 H NMR (400 MHz, CDCl 3 )δ8.71-8.37(m,2H),7.73(d,J=7.8Hz,1H),7.40-7.22(m,4H),7.16(d,J=7.6Hz,1H),6.77-6.60(m,5H),6.26(t,J =2.2Hz,2H),4.84(q,J=5.5Hz,1H),4.55(s,2H),4.50(s,2H),3.81(dd,J=8.6,6.2Hz,2H),3.64(d,J=17.0Hz,5H). Mass spectrometry (mass to charge ratio) is C 28 H28 N 3 O 4 + [M+H] + The theoretical value is 470.20743 and the measured value is 470.20859.
[0170] Example 27a Referring to General Experimental Procedure 1, compound 27a (10.3 mg, 17.11% yield) was synthesized. 1 H NMR (400 MHz, CDCl 3 )δ8.64-8.44(m,2H),7.78(d,J=8.0Hz,1H),7.41-7.19(m,4H),6.76(t,J=2.2Hz,2H),6.72-6.64(m,3H),6.25(t,J=2 .2Hz,2H),4.84(p,J=5.5Hz,1H),4.54(s,2H),4.50(s,2H),3.79(dd,J=8.6,6.2Hz,2H),3.65(dd,J=8.7,4.9Hz,2H). Mass spectrometry (mass to charge ratio) is C 27 H 26 N 3 O 4 + [M+H] + The theoretical value is 456.19178 and the measured value is 456.19113.
[0171] Example 27b Referring to General Experimental Procedure 1, compound 27b (28 mg, 64.72% yield) was synthesized. 1 H NMR (300 MHz, CDCl 3 )δ8.64-8.33(m,2H),7.71(d,J=7.6Hz,1H),7.27(t,J=9.7Hz,4H),6.82-6.54(m,5H),6.33(s,2H),5.30(s ,2H),4.90-4.72(m,1H),4.53(s,2H),4.49(s,2H),3.78(q,J=7.2,6.7Hz,2H),3.64(dd,J=8.5,4.6Hz,2H). Mass spectrometry (mass to charge ratio) is C 27 H 26 N 4 NaO 4 + [M+Na]+ , the theoretical value is 493.18463 and the measured value is 493.18463.
[0172] Example 28 [ka]
[0173] Referring to General Experimental Procedure 2, compound 28 (12 mg, 56.78% yield) was synthesized. 1 H NMR (500 MHz, CDCl 3 )δ8.72(d,J=2.2Hz,1H),8.49(dd,J=4.8,1.6Hz,1H),7.82(dt,J=8.0,1.8Hz,1H) ,7.48-7.43(m,2H),7.35-7.29(m,2H),7.18(dd,J=7.7,1.4Hz,1H),7.12(d,J=16. 4Hz,1H),6.95(d,J=16.4Hz,1H),6.75-6.70(m,5H),6.28(t,J=2.1Hz,2H),4.93-4 .85(m,1H),3.84(dd,J=9.2,6.2Hz,2H),3.69(dd,J=9.2,4.8Hz,2H),3.64(s,3H). Mass spectrometry (mass to charge ratio) is C 28 H 26 N 3 O 3 + [M+H] + The theoretical value is 452.19687 and the measured value is 452.19684.
[0174] Example 28a Referring to General Experimental Procedure 2, compound 28a (5 mg, yield 57.34%) was synthesized. 1 H NMR (300 MHz, CDCl 3)δ8.61(s,1H),8.42(d,J=4.1Hz,1H),7.87-7.78(m,1H),7.44(d,J=8.7Hz,2H),7.35-7.27(m,2H),7.26-7.20(m,1H),7.11(d,J=16.4Hz,1H) ),6.91(d,J=16.4Hz,1H),6.79-6.74(m,2H),6.73-6.64(m,3H),6.32- 6.21(m,2H),4.90-4.81(m,1H),3.86-3.73(m,2H),3.71-3.60(m,2H). Mass spectrometry (mass to charge ratio) is C 27 H 24 N 3 O 3 + [M+H] + The theoretical value is 438.18122 and the measured value is 438.18134.
[0175] Example 28b Referring to General Experimental Procedure 2, compound 28b (7 mg, 57.34% yield) was synthesized. 1 H NMR (500MHz, MeOH-d 4 / CDCl 3 )δ8.63(d,J=1.6Hz,1H),8.36(dd,J=4.8,1.1Hz,1H),8.03(dt,J=8.0,1.7Hz,1H),7.5 3-7.47(m,2H),7.41(dd,J=8.0,4.9Hz,1H),7.34-7.29(m,1H),7.24(d,J=16.4Hz,1H) ,7.04(d,J=16.4Hz,1H),6.85(dd,J=7.5,1.2Hz,1H),6.77-6.70(m,5H),6.20(t,J=2. 1Hz,2H),4.91-4.88(m,1H),3.84(dd,J=8.9,6.2Hz,2H),3.54(dd,J=9.0,4.3Hz,2H). Mass spectrometry (mass to charge ratio) is C 27 H 25 N 4 O 3 + [M+H] + The theoretical value is 453.19212 and the measured value is 453.19217.
[0176] Example 29 [ka]
[0177] Compound 29 (2.5 mg, 49.78% yield) was synthesized with reference to General Experimental Procedure 2. 1 H NMR (500 MHz, CDCl 3 )δ8.47-8.42(m,1H),8.42-8.37(m,1H),7.45-7.40(m,1H),7.29(t,J=7.9Hz,1H),7.20(dd ,J=7.7,4.8Hz,1H),7.15(dd,J=7.6,1.2Hz,1H),7.04-6.98(m,2H),6.71(t,J=2.1Hz,2H), 6.68(dd,J=8.2,1.2Hz,1H),6.60(d,J=8.6Hz,2H),6.25(t,J=2.1Hz,2H),4.84-4.76(m,1H ),3.79(dd,J=8.9,6.3Hz,2H),3.65(dd,J=9.0,4.9Hz,2H),3.61(s,3H),2.91-2.81(m,4H). Mass spectrometry (mass to charge ratio) is C 28 H 28 N 3 O 3 + [M+H] + The theoretical value is 454.21252 and the measured value is 454.21262.
[0178] Example 29a Refer to General Experimental Procedure 2 to determine the compound 29a (5.5 mg, 56.76% yield) was synthesized. 1 H NMR (500MHz, MeOH-d 4)δ8.30(d,J=4.0Hz,1H),8.26(s,1H),7.46-7.36(m,1H),7.32-7.26(m,1H),7.21-7.15(m,1H),7.15-7.10(m,1H),6.98-6.90(m,2H), 6.69-6.58(m,3H),6.57-6.49(m,2H),6.19-6.12(m,2H),4.77-4.69(m,1H),3.72-3.68(m,2H),3.58-3.54(m,2H),2.87-2.74(m,4H). Mass spectrometry (mass to charge ratio) is C 27 H 26 N 3 O 3 + [M+H] + The theoretical value is 440.19687 and the measured value is 440.19690.
[0179] Example 30 [ka]
[0180] Referring to General Experimental Procedure 1, compound 30 (7 mg, 6.37% yield) was synthesized. 1 H NMR (500 MHz, CDCl 3 )δ7.33-7.27(m,3H),7.15(dd,J=7.7,1.3Hz,1H),6.72-6.67(m,6H),6.56(dd,J=5.8,1.5Hz,1H),6. 27-6.24(m,3H),4.98(s,2H),4.88-4.81(m,1H),3.82-3.79(m,2H),3.67-3.63(m,2H),3.62(s,3H). Mass spectrometry (mass to charge ratio) is C 26 H 25 N 2 O 4 S + [M+H] + The theoretical value is 461.15295 and the measured value is 461.15305.
[0181] Example 30a: Referring to General Experimental Procedure 1, compound 30a (6 mg, yield 61.89%) was synthesized.1 H NMR (400 MHz, CDCl 3 )δ7.36-7.29(m,3H),7.23-7.17(m,1H),6.74-6.66(m,6H),6.60-6.55(m,1H),6.29-6.26( m,1H),6.22(s,2H),5.00(s,2H),4.89-4.80(m,1H),3.82-3.73(m,2H),3.69-3.60(m,2H). Mass spectrometry (mass to charge ratio) is C 25 H 23 N 2 O 4 S + [M+H] + The theoretical value is 447.13730 and the measured value is 447.13751.
[0182] Example 31 [ka]
[0183] Referring to General Experimental Procedure 2, compound 31 (103 mg, 79.90% yield) was synthesized. 1 H NMR (400 MHz, CDCl 3 )δ9.07(s,1H),8.75(d,J=4.8Hz,1H),8.19(d,J=7.9Hz,1H),8.09(s,1H),7.51(d,J=8.4Hz,2H),7.42(dd,J=8.0,4.9Hz,1H),7.29(dd,J=14.2,6. 2Hz,1H),7.15(d,J=7.6Hz,1H),6.70(d,J=8.8Hz,5H),6.25(t,J=2.2Hz, 2H), 4.83(p,J=5.5Hz,1H),3.81(t,J=7.4Hz,2H),3.64(d,J=17.3Hz,5H). Mass spectrometry (mass to charge ratio) is C 27 H 24 N 4 NaO 4 + [M+Na] + The theoretical value is 491.16898 and the measured value is 491.16910.
[0184] Example 31a Referring to General Experimental Procedure 2, compound 31a (81 mg, yield 92.78%) was synthesized. 1 H NMR (400MHz, DMSO-d 6 )δ10.35(s,1H),9.08(s,1H),8.74(d,J=4.8Hz,1H),8.27(d,J=8.0Hz,1H),7.64(d,J=8.4Hz,2H),7.55(d,J=6.9Hz,1H),7. 27(d,J=7.9Hz,1H),6.93(d,J=7.4Hz,1H),6.85-6.60(m,5H),6.11(s,2H),4.89(s,1H),3.78(t,J=7.4Hz,2H),3.42(s,2H). Mass spectrometry (mass to charge ratio) is C 26 H 23 N 4 O 4 + [M+H] + The theoretical value is 455.17138 and the measured value is 455.17120.
[0185] Example 31b Referring to General Experimental Procedure 2, compound 31b (3.4 mg, 17.69% yield) was synthesized. 1 H NMR (400MHz, MeOH-d 4 )δ9.07(d,J=2.2Hz,1H),8.72(dd,J=5.0,1.6Hz,1H),7.59(dd,J=8.0,5.5Hz,3H),7.40-7.25(m,1H),6.85(dd,J=7 .5,1.3Hz,1H),6.81-6.68(m,5H),6.22(t,J=2.1Hz,2H),3.85(dd,J=8.8,6.1Hz,2H),3.54(dd,J=8.9,4.4Hz,2H). Mass spectrometry (mass to charge ratio) is C 26 H 23 N 5 NaO 4 + [M+Na] + The theoretical value is 492.16423 and the measured value is 492.16479.
[0186] Example 32 [ka]
[0187] Referring to General Experimental Procedure 1, compound 32 (11 mg, 23.99% yield) was synthesized. 1 H NMR (400 MHz, CDCl 3 )δ7.39-7.35(m,2H),7.34-7.29(m,1H),7.19-7.13(m,2H),6.75-6.66(m,5H),6.27(t,J=2.1Hz,2H),5.65(d,J=2.3Hz, 1H),5.11(s,2H),4.90-4.82(m,1H),3.82(dd,J=9.1,6.2Hz,2H),3.78(s,3H),3.67(dd,J=9.2,4.9Hz,2H),3.64(s,3H). Mass spectrometry (mass to charge ratio) is C 26 H 27 N 4 O 4 + [M+H] + The theoretical value is 459.20268 and the measured value is 459.20270.
[0188] Example 32a Referring to General Experimental Procedure 1, compound 32a (6 mg, yield 61.89%) was synthesized. 1 H NMR (500 MHz, CDCl 3 )δ7.35-7.27(m,3H),7.26-7.21(m,1H),7.12(d,J=2.2Hz,1H),6.73-6.65(m,5H),6.22(t,J=2.0Hz,2H), 5.62(d,J=2.3Hz,1H),5.07(s,2H),4.87-4.78(m,1H),3.80-3.75(m,2H),3.74(s,3H),3.65-3.61(m,2H). Mass spectrometry (mass to charge ratio) is C 25 H 25 N 4 O 4 + [M+H] + The theoretical value is 445.18703 and the measured value is 445.18728.
[0189] Example 33 [ka]
[0190] Referring to General Experimental Procedure 1, compound 33 (23 mg, yield 27.14%) was synthesized. 1 H NMR (500 MHz, CDCl 3 )δ8.44(d,J=4.7Hz,1H),7.38-7.34(m,2H),7.29(t,J=7.9Hz,1H),7.15(dd,J=7.6,1.3Hz,1H),6.72-6.67(m,5H),6.61(d ,J=4.7Hz,1H),6.25(t,J=2.1Hz,2H),5.33(s,2H),4.87-4.81(m,1H),3.83-3.78(m,2H),3.67-3.64(m,2H),3.61(s,3H). Mass spectrometry (mass to charge ratio) is C 25 H 24 N 3 O 4 S + [M+H] + The theoretical value is 462.14820 and the measured value is 462.14835.
[0191] Example 33a Referring to General Experimental Procedure 1, compound 33a (10 mg, yield 68.76%) was synthesized. 1 H NMR (500 MHz, CDCl 3 / MeOH-d 4 )δ8.46-8.37(m,1H),7.35-7.29(m,2H),7.25-7.19(m,1H),7.16-7.05(m,1H),6.74-6.63(m,4H),6.63 -6.52(m,2H),6.23-6.12(m,2H),5.26(s,2H),4.83-4.73(m,1H),3.77-3.67(m,2H),3.62-3.54(m,2H). Mass spectrometry (mass to charge ratio) is C 24 H 22 N 3 O 4 S + [M+H] +The theoretical value is 448.13255 and the measured value is 448.13272.
[0192] Example 34 [ka]
[0193] Referring to General Experimental Procedure 2, compound 34 (40 mg, 75.16% yield) was synthesized. 1 H NMR (400 MHz, CDCl 3 )δ8.39(s,1H),8.30(d,J=4.8Hz,1H),8.06(d,J=8.4Hz,1H),7.27(s,14H),7.17(dd,J=7.7,1.4Hz,1H),6.88( s,1H),6.77-6.64(m,8H),6.26(t,J=2.1Hz,2H),4.82(t,J=5.5Hz,1H),3.86-3.78(m,2H),3.68-3.59(m,6H). Mass spectrometry (mass to charge ratio) is C 27 H 26 N 5 O 4 + [M+H] + The theoretical value is 484.19793 and the measured value is 484.19885.
[0194] Example 34a Referring to General Experimental Procedure 2, compound 34a (25 mg, 85.82% yield) was synthesized. 1 H NMR (500MHz, MeOH-d 4 )δ10.15(d,J=2.6Hz,1H),9.72(dd,J=4.8,1.5Hz,1H),9.55(ddd,J=8.4,2.7,1.4Hz,1H),8.96-8.89(m,1H),8.88-8.78(m,3H),8.52(dd,J=7.6 ,1.3Hz,1H),8.30(t,J=2.1Hz,2H),8.28-8.20(m,3H),7.71(t,J=2.1Hz ,2H),6.39-6.27(m,1H),5.42-5.26(m,2H),5.05(dd,J=8.9,4.4Hz,2H). Mass spectrometry (mass to charge ratio) is C26 H 24 N 5 O 4 + [M+H] + The theoretical value is 470.18228 and the measured value is 470.18253.
[0195] Example 34b Referring to General Experimental Procedure 2, compound 34b (20 mg, 76% yield) was synthesized. 1 H NMR (400MHz, MeOH-d 4 )δ8.60(d,J=2.4Hz,1H),8.16(dd,J=4.8,1.3Hz,1H),8.00(d,J=8.4Hz,1H),7.48-7.22(m,4H),6.87(d,J=7.5Hz,1H),6.77(t,J= 2.1Hz,2H),6.76-6.59(m,3H),6.18(t,J=2.2Hz,2H),4.84-4.78(m,1H),3.80(dd,J=8.7,6.1Hz,2H),3.50(dd,J=8.9,4.4Hz,2H). Mass spectrometry (mass to charge ratio) is C 26 H 25 N 6 O 4 + [M+H] + The theoretical value is 485.2 and the measured value is 485.2.
[0196] Example 35 [ka]
[0197] Compound 35 (25 mg, 18% yield) was synthesized with reference to General Experimental Procedure 2. 1 H NMR (400 MHz, CDCl 3 )δ7.42(d,J=7.8Hz,2H),7.35-7.03(m,7H),6.77-6.60(m,5H),6.26(t,J=2.1 Hz, 2H), 4.90-4.79 (m, 1H), 3.87-3.75 (m, 2H), 3.71-3.64 (m, 4H), 3.62 (s, 3H). Mass spectrometry (mass to charge ratio) is C 29 H28 N 3 O 4 + [M+H] + The theoretical value is 482.20 and the measured value is 482.20.
[0198] Example 35a Referring to General Experimental Procedure 2, compound 35a (3.5 mg, 25% yield) was synthesized. 1 H NMR (400 MHz, CDCl 3 )δ7.41(d,J=7.9Hz,2H),7.35-7.04(m,7H),6.81-6.61(m,5H),6.30-6.17(m,2H),4.87-4.78(m,1H),3.84-3.74(m,2H),3.70-3.60(m,4H). Mass spectrometry (mass to charge ratio) is C 28 H 26 N 3 O 4 + [M+H] + The theoretical value is 468.19 and the measured value is 468.20.
[0199] Example 36 [ka]
[0200] Referring to General Experimental Procedure 2, compound 36 (28 mg, 66% yield) was synthesized. 1 H NMR (500 MHz, CDCl 3 )δ8.84-8.28(m,2H),7.79(d,J=8.0Hz,1H),7.44-7.23(m,9H),7.22-7.16(m,1H),7.07(d,J=16.4Hz,1 H),6.91(d,J=16.4Hz,1H),6.72-6.60(m,3H),4.80-4.69(m,1H),3.75-3.67(m,2H),3.55-3.46(m,5H). Mass spectrometry (mass to charge ratio) is C 30 H 27 N 2 O 3 + [M+H] +The theoretical value is 463.20 and the measured value is 463.20.
[0201] Example 36a Referring to General Experimental Procedure 2, compound 36a (24 mg, 90% yield) was synthesized. 1 H NMR (400MHz, MeOH-d 4 )δ8.89-8.40(m,2H),8.40-8.28(m,1H),7.74-7.61(m,1H),7.58-7.48(m,2H),7.46-7.25(m,7H),7. 12(t,J=12.2Hz,2H),6.75(t,J=9.1Hz,3H),4.82-4.76(m,1H),3.81-3.71(m,2H),3.45-3.36(m,2H). Mass spectrometry (mass to charge ratio) is C 29 H 25 N 2 O 3 + [M+H] + The theoretical value is 449.18597 and the measured value is 449.20.
[0202] Example 36b Referring to General Experimental Procedure 2, compound 36b (10 mg, 59% yield) was synthesized. 1 H NMR (400MHz, MeOH-d 4 )δ8.62(s,1H),8.36(d,J=4.0Hz,1H),8.02(d,J=7.9Hz,1H),7.48(d,J=8.5Hz,2H),7.43-7.17(m,8H),7.03(d,J =16.4Hz,1H),6.87(d,J=7.3Hz,1H),6.76-6.64(m,3H),4.83-4.73(m,1H),3.79-3.68(m,2H),3.43-3.36(m,2H). Mass spectrometry (mass to charge ratio) is C 29 H 26 N 3 O 3 + [M+H] + The theoretical value is 464.19687 and the measured value is 464.20.
[0203] Example 37 [ka]
[0204] Compound 37 (27 mg, 56% yield) was synthesized with reference to General Experimental Procedure 2. 1 H NMR (400 MHz, CDCl 3 )δ7.56(d,J=10.6Hz,2H),7.37(t,J=7.8Hz,1H),7.34-7.27(m,5H),7.23(dd,J=7.7,1.2Hz,1H),7.21-7.15(m, 3H),6.84(s,1H),6.70-6.62(m,3H),6.58(s,1H),4.73(t,J=5.6Hz,1H),3.79-3.66(m,2H),3.58-3.46(m,5H). Mass spectrometry (mass to charge ratio) is C 31 H 24 ClF 3 N 3 O 4 - [MH] - The theoretical value is 594.1 and the measured value is 594.2.
[0205] Example 37a Referring to General Experimental Procedure 2, compound 37a (2.3 mg, 34% yield) was synthesized. 1 H NMR (500MHz, MeOH-d 4 )δ7.88(d,J=2.2Hz,1H),7.58(dd,J=8.1,2.0Hz,1H),7.45(t,J=7.9Hz,1H),7.35-7.24(m,8H),7.12(d,J=7.5Hz, 1H),6.74(d,J=8.6Hz,1H),6.72-6.67(m,2H),4.80-4.76(m,1H),3.83-3.70(m,2H),3.42(dd,J=14.5,8.8Hz,2H). Mass spectrometry (mass to charge ratio) is C 30 H 22 ClF 3 N 3 O 4 - [MH] - The theoretical value is 580.1 and the measured value is 580.2.
[0206] Example 38 [ka]
[0207] Referring to General Experimental Procedure 2, compound 38 (23 mg, 55% yield) was synthesized. 1 H NMR (400 MHz, CDCl 3 )δ8.14-7.89(m,2H),7.37-7.14(m,8H),7.12-7.03(m,1H),6.90-6.82(m,1H),6.71 -6.61(m,3H),4.81-4.70(m,1H),4.25(s,2H),3.83-3.63(m,2H),3.62-3.45(m,5H). Mass spectrometry (mass to charge ratio) is C 29 H 27 ClN 3 O 3 + [M+H] + The theoretical value is 500.2 and the measured value is 500.2.
[0208] Example 38a Compound 38a (16 mg, 96% yield) was synthesized with reference to General Experimental Procedure 2. 1 H NMR (400MHz, MeOH-d 4 )δ7.95-7.87(m,1H),7.87-7.79(m,1H),7.49-7.12(m,10H),6.81-6.66(m, 3H), 4.83-4.75(m, 1H), 4.31(s, 2H), 3.84-3.69(m, 2H), 3.46-3.35(m, 2H). Mass spectrometry (mass to charge ratio) is C 28 H 25 ClN 3 O 3 + [M+H] + The theoretical value is 486.2 and the measured value is 486.1.
[0209] Example 38b Referring to General Experimental Procedure 2, compound 38b (7.3 mg, 85% yield) was synthesized. 1H NMR (400MHz, MeOH-d 4 )δ7.96-7.79(m,1H),7.79-7.61(m,1H),7.43-7.18(m,7H),7.14-7.02(m,1H),7.02-6.91(m,1H),6.91 -6.82(m,1H),6.76-6.61(m,3H),4.82-4.70(m,1H),4.25(s,2H),3.88-3.65(m,2H),3.48-3.27(m,2H). Mass spectrometry (mass to charge ratio) is C 28 H 26 ClN 4 O 3 + [M+H] + The theoretical value is 501.2 and the measured value is 501.1.
[0210] Example 39 [ka]
[0211] Compound 39 (23 mg, 63% yield) was synthesized with reference to General Experimental Procedure 2. 1 H NMR (400 MHz, CDCl 3 )δ8.08-8.01(m,1H),8.01-7.92(m,1H),7.41-7.15(m,11H),7.10-7.02(m,1H),6.90-6.81(m, 1H),6.71-6.58(m,2H),4.77-4.68(m,1H),4.25(s,2H),3.73-3.66(m,2H),3.55-3.42(m,5H). Mass spectrometry (mass to charge ratio) is C 29 H 28 N 3 O 3 + [M+H] + The theoretical value is 466.2 and the measured value is 466.2.
[0212] Example 39a Referring to General Experimental Procedure 2, compound 39a (1.6 mg, 32% yield) was synthesized. 1 H NMR (400MHz, MeOH-d 4)δ7.92-7.81(m,1H),7.79-7.68(m,1H),7.38-7.14(m,9H),7.12-7.01(m,2H),6.73 -6.60(m,3H),4.76-4.66(m,1H),4.25(s,2H),3.73-3.66(m,2H),3.38-3.33(m,2H). Mass spectrometry (mass to charge ratio) is C 28 H 26 N 3 O 3 + [M+H] + The theoretical value is 452.2 and the measured value is 452.2.
[0213] Example 39b Referring to General Experimental Procedure 2, compound 39b (2.2 mg, 37% yield) was synthesized. 1 H NMR (400MHz, MeOH-d 4 )δ7.92-7.82(m,1H),7.77-7.66(m,1H),7.41-7.18(m,8H),7.16-7.09(m,1H),7.03-6.95(m,1H),6.89 -6.82(m,1H),6.74-6.60(m,3H),4.77-4.70(m,1H),4.25(s,2H),3.76-3.67(m,2H),3.40-3.34(m,2H). Mass spectrometry (mass to charge ratio) is C 28 H 27 N 4 O 3 + [M+H] + The theoretical value is 467.2 and the measured value is 467.2.
[0214] Example 40 [ka]
[0215] Referring to General Experimental Procedure 2, compound 40 was synthesized (65 mg, 59% yield). 1 H NMR (400 MHz, CDCl 3)δ8.46-8.37(m,1H),8.37-8.29(m,1H),8.17-8.06(m,1H),7.44-7.06(m,10H ),6.75-6.62(m,3H),4.80-4.68(m,1H),3.77-3.61(m,4H),3.55-3.45(m,5H). Mass spectrometry (mass to charge ratio) is C 30 H 28 N 3 O 4 + [M+H] + The theoretical value is 494.2 and the measured value is 494.2.
[0216] Example 40a Referring to General Experimental Procedure 2, compound 40a (5 mg, 51% yield) was synthesized. 1 H NMR (500MHz, MeOH-d 4 )δ8.76-8.63(m,1H),8.32-8.15(m,1H),8.14-8.02(m,1H),7.44-7.18(m,9H),7.15-7.07(m, 1H),6.76-6.62(m,3H),4.77-4.70(m,1H),3.76-3.65(m,2H),3.62(s,2H),3.39-3.33(m,2H). Mass spectrometry (mass to charge ratio) is C 29 H 26 N 3 O 4 + [M+H] + The theoretical value is 480.2 and the measured value is 480.2.
[0217] Example 40b Referring to General Experimental Procedure 2, compound 40b (3.2 mg, 46% yield) was synthesized. 1 H NMR (500MHz, MeOH-d 4 )δ8.75-8.63(m,1H),8.27-8.17(m,1H),8.13-8.03(m,1H),7.43-7.15(m,9H),6.88-6.79(m, 1H),6.72-6.59(m,3H),4.79-4.69(m,1H),3.75-3.66(m,2H),3.59(s,2H),3.40-3.31(m,2H). Mass spectrometry (mass to charge ratio) is C29 H 27 N 4 O 4 + [M+H] + The theoretical value is 495.2 and the measured value is 495.2.
[0218] Example 40c Refer to General Experimental Procedure 2. Compound 40c (7.3 mg, 44% yield) Synthetic . 1 H NMR (400 MHz, CDCl 3 )δ8.49-8.41(m,1H),8.30(d,J=4.0Hz,1H),8.16(d,J=8.3Hz,1H),7.93-7.84(m,1H),7.42-7.21(m,6H),7.16-7.08(m,2H),7.08-7.01(m ,1H),6.71-6.55(m,3H),5.17-5.06(m,1H),4.79-4.67(m,1H),3.76-3.67(m,2H),3.62(s,2H),3.51-3.44(m,2H),2.57(d,J=4.9Hz,3H). Mass spectrometry (mass to charge ratio) is C 30 H 29 N 4 O 3 + [M+H] + The theoretical value is 493.2 and the measured value is 493.1.
[0219] Example 41 [ka]
[0220] Referring to General Experimental Procedure 2, compound 41 (50 milligrams, 48.31% yield) was synthesized. 1 H NMR (400 MHz, CDCl 3)δ8.38(d,J=2.4Hz,1H),8.28(dd,J=4.8,1.3Hz,1H),8.15-8.04(m,1H),7.36-7.30(m,4H),7.27-7.19(m,4H),6.89-6.81(m,1H) ,6.73-6.62(m,3H),4.78-4.71(m,1H),3.83-3.75(m,1H),3.74-3.65(m,1H),3.59(s,3H),3.58-3.53(m,1H),3.52-3.44(m,1H). Mass spectrometry (mass to charge ratio) is C 29 H 26 ClN 4 O 4 + [M+H] + The theoretical value is 529.16371 and the measured value is 529.16412.
[0221] Example 41a Referring to General Experimental Procedure 2, compound 41a (3 mg, yield 30.82%) was synthesized. 1 H NMR (400MHz, MeOH-d 4 )δ8.64-8.58(m,1H),8.19(d,J=3.6Hz,1H),8.04-7.98(m,1H),7.40-7.30(m,7H),7.29-7.24(m,1H),7.17- 7.13(m,1H),6.79-6.75(m,1H),6.74-6.69(m,2H),4.82-4.79(m,1H),3.83-3.72(m,2H),3.48-3.41(m,2H). Mass spectrometry (mass to charge ratio) is C 28 H 24 ClN 4 O 4 + [M+H] + The theoretical value is 515.14806 and the measured value is 515.14850.
[0222] Example 41b Referring to General Experimental Procedure 2, compound 41b (11 mg, 42.49% yield) was synthesized. 1 H NMR (500MHz, MeOH-d 4)δ8.58(d,J=2.4Hz,1H),8.16(dd,J=4.8,1.1Hz,1H),8.02-7.95(m,1H),7.40-7.26(m,8H),6.89-6.84 (m,1H),6.76-6.71(m,1H),6.71-6.66(m,2H),4.82-4.76(m,1H),3.86-3.71(m,2H),3.49-3.36(m,2H). Mass spectrometry (mass to charge ratio) is C 28 H 25 ClN 5 O 4 + [M+H] + The theoretical value is 530.15896 and the measured value is 530.15936.
[0223] Example 42 [ka]
[0224] Referring to General Experimental Procedure 2, compound 42 (50 mg, 47.32% yield) was synthesized. 1 H NMR (500MHz, MeOH-d 4 )δ8.85-8.76(m,1H),8.42-8.33(m,1H),8.25-8.16(m,1H),7.66-7.41(m,9H),7.35-7.23(m,1H),7.03 -6.93(m,1H),6.92-6.84(m,2H),5.00-4.91(m,1H),3.99-3.91(m,2H),3.68(s,3H),3.64-3.57(m,2H). Mass spectrometry (mass to charge ratio) is C 29 H 27 N 4 O 4 + [M+H] + The theoretical value is 495.20268 and the measured value is 495.20291.
[0225] Example 42a Referring to General Experimental Procedure 2, compound 42a (4.2 mg, 36.02% yield) was synthesized. 1 H NMR (500MHz, MeOH-d4 )δ8.59(d,J=2.2Hz,1H),8.17(dd,J=4.8,1.4Hz,1H),8.01-7.97(m,1H),7.38-7.31(m,4H),7.31-7.26(m,5H),7.11( dd,J=7.6,1.0Hz,1H),6.75-6.71(m,1H),6.69-6.64(m,2H),4.76-4.71(m,1H),3.73-3.69(m,2H),3.39-3.36(m,2H). Mass spectrometry (mass to charge ratio) is C 28 H 25 N 4 O 4 + [M+H] + The theoretical value is 481.18703 and the measured value is 481.18729.
[0226] Example 42b Referring to General Experimental Procedure 2, compound 42b (7.5 mg, 35.09% yield) was synthesized. 1 H NMR (400MHz, MeOH-d 4 )δ8.61(d,J=2.0Hz,1H),8.22-8.16(m,1H),8.04-7.96(m,1H),7.41-7.34(m,6H),7.33-7.28(m,3H),6.88(dd,J =7.5,0.9Hz,1H),6.75-6.71(m,1H),6.71-6.66(m,2H),4.81-4.73(m,1H),3.79-3.71(m,2H),3.42-3.38(m,2H). Mass spectrometry (mass to charge ratio) is C 28 H 26 N 5 O 4 + [M+H] + The theoretical value is 496.19793 and the measured value is 496.19809.
[0227] Example 42c Referring to General Experimental Procedure 2, compound 42c (20 mg, 64.91% yield) was synthesized. 1 H NMR (500 MHz, CDCl 3)δ8.54(s,1H),8.44(d,J=2.4Hz,1H),8.19(dd,J=4.7,1.1Hz,1H),8.15-8.09( m,1H),7.72(s,1H),7.36-7.18(m,7H),7.02(dd,J=7.5,0.9Hz,1H),6.78-6.72 (m,2H),6.61(dd,J=8.3,0.8Hz,1H),6.46-6.39(m,2H),5.42(q,J=4.8Hz,1H), 4.67-4.60(m,1H),3.66-3.59(m,2H),3.38-3.32(m,2H),2.59(d,J=4.9Hz,3H). Mass spectrometry (mass to charge ratio) is C 29 H 28 N 5 O 3 + [M+H] + The theoretical value is 494.21867 and the measured value is 494.21881.
[0228] Example 43 [ka]
[0229] Compound 43 (60 mg, 56% yield) was synthesized with reference to General Experimental Procedure 2. 1 H NMR (500 MHz, CDCl 3 )δ8.49-8.39(m,1H),8.36-8.29(m,1H),8.18-7.98(m,1H),7.49-7.40(m,1H),7.39-7.20(m,6H),7.17-7.11(m,1H),6.8 4(d,J=8.6Hz,2H),6.70-6.62(m,1H),5.15-5.05(m,1H),4.44-4.32(m,2H),3.99-3.91(m,2H),3.90(s,3H),3.72(s,2H). Mass spectrometry (mass to charge ratio) is C 24 H 24 N 3 O 4 + [M+H] + The theoretical value is 418.2 and the measured value is 418.1.
[0230] Example 43a Referring to General Experimental Procedure 2, compound 43a (30 mg, 68% yield) was synthesized. 1 H NMR (400MHz, MeOH-d 4 )δ8.78-8.67(m,1H),8.30-8.20(m,1H),8.16-8.07(m,1H),7.45-7.22(m,5H),7.17-7.08(m,1H),6.91 -6.80(m,2H),6.79-6.69(m,1H),5.19-5.07(m,1H),4.40-4.31(m,2H),3.90-3.79(m,2H),3.67(s,2H). Mass spectrometry (mass to charge ratio) is C 23 H 22 N 3 O 4 + [M+H] + The theoretical value is 404.2 and the measured value is 404.1.
[0231] Example 43b Referring to General Experimental Procedure 2, compound 43b (2.3 mg, 27% yield) was synthesized. 1 H NMR (500MHz, MeOH-d 4 )δ8.77-8.66(m,1H),8.28-8.19(m,1H),8.15-8.04(m,1H),7.43-7.19(m,4H),7.11-7.02(m,1H),6.89-6.79( m,3H),6.71-6.61(m,1H),5.17-5.10(m,1H),4.57(s,1H),4.40-4.29(m,2H),3.90-3.77(m,2H),3.66(s,2H). Mass spectrometry (mass to charge ratio) is C 23 H 23 N 4 O 4 + [M+H] + The theoretical value is 419.2 and the measured value is 419.1.
[0232] Example 43c Referring to General Experimental Procedure 2, compound 43c (10.5 mg, 6.8% yield) was synthesized. 1 H NMR (400MHz, MeOH-d4 )δ8.73(s,1H),8.24(d,J=4.2Hz,1H),8.15-8.06(m,1H),7.41-7.32(m,1H),7.29(d,J=8.7Hz,2H),7.22-7.13(m,2H),6.88 -6.78(m,2H),6.77-6.68(m,1H),6.54-6.45(m,2H),5.12-5.03(m,1H),4.33-4.21(m,2H),3.81-3.72(m,2H),3.65(s,2H). Mass spectrometry (mass to charge ratio) is C 22 H 22 N 3 O 2 + [M+H] + The theoretical value is 360.2 and the measured value is 360.0.
[0233] Example 44 [ka]
[0234] Referring to General Experimental Procedure 2, compound 44 (15 mg, 36% yield) was synthesized. 1 H NMR (500 MHz, CDCl 3 )δ8.64-8.53(m,1H),8.41-8.33(m,1H),8.33-8.22(m,1H),8.14-8.03(m,1H),7.70-7.56(m,2H),7.32-6.99(m,8H),6.70 -6.62(m,1H),6.62-6.56(m,2H),6.56-6.48(m,1H),4.71-4.59(m,1H),3.75-3.61(m,2H),3.59(s,2H),3.55-3.39(m,5H). Mass spectrometry (mass to charge ratio) is C 32 H 29 N 4 O 4 + [M+H] + The theoretical value is 533.2 and the measured value is 533.2.
[0235] Example 44a Referring to General Experimental Procedure 2, compound 44a (3 mg, 25% yield) was synthesized. 1 H NMR (400MHz, MeOH-d 4 )δ8.73-8.64(m,1H),8.27-8.20(m,1H),8.12-8.04(m,1H),7.55-7.46(m,1H),7.42-7.30(m,2H),7.27-7.13(m,4H),7.06 -6.96(m,2H),6.73-6.52(m,3H),6.48-6.38(m,1H),4.73-4.66(m,1H),3.76-3.62(m,2H),3.60(s,2H),3.39-3.34(m,2H). Mass spectrometry (mass to charge ratio) is C 31 H 27 N 4 O 4 + [M+H] + The theoretical value is 519.2 and the measured value is 519.2.
[0236] Example 45 [ka]
[0237] Refer to General Experimental Procedure 2 to obtain compound 45 ( 26.30 Milligrams, 75.86% yield were synthesized. 1 H NMR (500 MHz, CDCl 3 )δ8.60-8.54(m,2H),7.75-7.69(m,1H),7.38-7.26(m,9H),7.20(dd,J=7.6,1.0Hz,1H),7.07-7.03(br,1H), 6.68-6.64(m,1H),6.61-6.55(m,2H),4.73-4.64(m,1H),3.70-3.64(m,4H),3.51(s,3H),3.49-3.45(m,2H). Mass spectrometry (mass to charge ratio) is C 30 H 28 N 3 O 4 + [M+H] + The theoretical value is 494.20743 and the measured value is 494.20764.
[0238] Example 45a Referring to General Experimental Procedure 2, compound 45a (30 mg, 77.19% yield) was synthesized. 1 H NMR (500MHz, MeOH-d 4 )δ8.51(d,J=1.6Hz,1H),8.44(dd,J=4.9,1.3Hz,1H),7.84(dt,J=7.9,1.9Hz,1H),7.46-7.37(m,3H),7.37-7.25(m,6H),7.11( dd,J=7.6,1.0Hz,1H),6.73(dd,J=8.2,1.0Hz,1H),6.68-6.60(m,2H),4.74-4.70(m,1H),3.73-3.67(m,4H),3.38-3.34(m,2H). Mass spectrometry (mass to charge ratio) is C 29 H 26 N 3 O 4 + [M+H] + The theoretical value is 480.19178 and the measured value is 480.19202.
[0239] Example 45b Referring to General Experimental Procedure 2, compound 45b (8.1 mg, 47.39% yield) was synthesized. 1 H NMR (400MHz, MeOH-d 4 )δ8.57-8.49(m,1H),8.49-8.41(m,1H),7.89-7.83(m,1H),7.46-7.27(m,9H),6.91-6.85(m,1H) ,6.75-6.70(m,1H),6.70-6.63(m,2H),4.79-4.72(m,1H),3.79-3.70(m,4H),3.41-3.37(m,2H). Mass spectrometry (mass to charge ratio) is C 29 H 27 N 4 O 4 + [M+H] + The theoretical value is 495.20268 and the measured value is 495.20288.
[0240] Example 45c Referring to General Experimental Procedure 2, compound 45c (10.3 mg, 50% yield) was synthesized. 1 H NMR (400MHz, MeOH-d 4 )δ8.51(s,1H),8.44(d,J=4.1Hz,1H),7.88-7.81(m,1H),7.79-7.71(m,1H),7.46-7.22(m,9H),6.85(dd,J=7.5 ,1.0Hz,1H),6.71-6.61(m,3H),4.77-4.69(m,1H),3.78-3.67(m,4H),3.41-3.33(m,2H),2.52(d,J=3.9Hz,3H). Mass spectrometry (mass to charge ratio) is C 30 H 29 N 4 O 3 + [M+H] + The theoretical value is 493.2 and the measured value is 493.0.
[0241] Example 45d Referring to General Experimental Procedure 2, compound 45d (7.3 mg, 34% yield) was synthesized. 1 H NMR (400MHz, MeOH-d 4 )δ8.51(d,J=1.7Hz,1H),8.44(dd,J=4.9,1.4Hz,1H),7.84(dt,J=7.9,1.8Hz,1H),7.47-7.23(m,9H),6.85(dd,J=7.5,0.9Hz, 1H),6.74-6.68(m,1H),6.68-6.62(m,2H),4.78-4.70(m,1H),3.79-3.73(m,2H),3.71(s,2H),3.42-3.37(m,2H),3.28(s,3H). Mass spectrometry (mass to charge ratio) is C 30 H 29 N 4 O 4 + [M+H] + The theoretical value is 509.2 and the measured value is 509.2.
[0242] Example 45e Referring to General Experimental Procedure 2, compound 45e (9.2 mg, 50% yield) was synthesized. 1H NMR (400 MHz, CDCl 3 )δ8.63-8.46(m,2H),7.73(d,J=7.8Hz,1H),7.49-7.20(m,10H),7.19-7.09(m,1H),6.94-6.85( m,1H),6.66-6.54(m,3H),4.81-4.71(m,1H),3.92-3.79(m,2H),3.67(s,2H),3.57-3.46(m,2H). Mass spectrometry (mass to charge ratio) is C 28 H 26 N 3 O 2 + [M+H] + The theoretical value is 436.2 and the measured value is 436.1.
[0243] Example 46 [ka]
[0244] Referring to General Experimental Procedure 2, compound 46 (41 mg, 59% yield) was synthesized. 1 H NMR (400MHz, DMSO-d 6 )δ9.07(s,1H),8.72(s,1H),8.37(s,1H),8.15(d,J=2.6Hz,1H),7.94(dt,J= 11.7,2.3Hz,1H),7.37-7.29(m,3H),7.01(dd,J=7.6,1.1Hz,1H),6.80(dd,J =8.3,1.0Hz,1H),6.74-6.69(m,4H),6.14(t,J=2.1Hz,2H),4.93-4.79(m,1H ),3.81(dd,J=8.7,6.3Hz,2H),3.48(s,3H),3.45(dd,J=9.0,4.1Hz,2H)ppm. Mass spectrometry (mass to charge ratio) is C 27 H 24 FN 5 O 4 + [M+H] + The theoretical value is 502.2 and the measured value is 502.1.
[0245] Example 46a: Referring to General Experimental Procedure 2, compound 46a (11 mg, 79% yield) was synthesized. 1 H NMR (500MHz, DMSO-d 6 )δ10.06(s,1H),9.58(s,1H),8.39(s,1H),8.11(s,1H),7.92(d,J=11.8H z,1H),7.33(d,J=8.9Hz,2H),7.22(t,J=7.6Hz,1H),6.92(d,J=7.5Hz,1H ),6.72(t,J=1.9Hz,2H),6.67(d,J=8.9Hz,2H),6.59(d,J=6.5Hz,1H),6.05(s,2H),4.83(s,1H),3.71(t,J=7.1Hz,2H),3.37(d,J=6.8Hz,2H)ppm. Mass spectrometry (mass to charge ratio) is C 26 H 22 FN 5 O 4 + [M+H] + The theoretical value is 488.17286 and the measured value is 488.17319.
[0246] Example 47 [ka]
[0247] Referring to General Experimental Procedure 2, compound 47 (54 mg, 78% yield) was synthesized. 1 H NMR (400MHz, DMSO-d 6 )δ8.71(s,1H),8.61(s,1H),8.36(s,1H),8.00(s,1H),7.75(s,1H),7.34(dd,J=15 .3,8.5Hz,3H),7.01(dd,J=7.6,1.2Hz,1H),6.80(dd,J=8.3,1.2Hz,1H),6.73(t,J =2.1Hz,2H),6.69(d,J=9.0Hz,2H),6.14(t,J=2.1Hz,2H),4.93-4.79(m,1H),3.81 (dd,J=8.8,6.3Hz,2H),3.48(s,3H),3.45(dd,J=8.9,4.2Hz,2H),2.26(s,3H)ppm. Mass spectrometry (mass to charge ratio) is C28 H 27 N 5 O 4 + [M+H] + The theoretical value is 498.2 and the measured value is 498.1.
[0248] Example 47a Referring to General Experimental Procedure 2, compound 47a (11 mg, 75% yield) was synthesized. 1 H NMR (500MHz, DMSO-d 6 )δ9.56(s,1H),9.40(s,1H),8.41(s,1H),7.98(s,1H),7.72(s,1H),7.32(d ,J=9.0Hz,2H),7.21(t,J=7.7Hz,1H),6.90(d,J=7.6Hz,1H),6.72(t,J=2.0H z,2H),6.67(d,J=9.0Hz,2H),6.57(d,J=7.7Hz,1H),6.06(s,2H),4.83(d,J =4.6Hz,1H),3.69(t,J=7.3Hz,2H),3.38(d,J=11.6Hz,2H),2.25(s,3H)ppm. Mass spectrometry (mass to charge ratio) is C 27 H 25 N 5 O 4 + [M+H] + The theoretical value is 484.19793 and the measured value is 484.19809.
[0249] Example 48 [ka]
[0250] Compound 48 (1.3 mg, 2% yield) was synthesized with reference to General Experimental Procedure 2. 1 H NMR (400 MHz, CDCl 3)δ8.66-8.44(m,2H),7.78-7.68(m,1H),7.40-7.06(m,9H),6.73-6.55(m,3H),4.79-4.67(m,1H),3.83-3.60(m,4H),3.51(d,J=47.9Hz,5H). Mass spectrometry (mass to charge ratio) is C 30 H 27 ClN 3 O 4 + [M+H] + The theoretical value is 528.2 and the measured value is 528.1.
[0251] Example 48a Referring to General Experimental Procedure 2, compound 48a (2 mg, 20% yield) was synthesized. 1 H NMR (400MHz, MeOH-d 4 )δ8.57-8.48(m,1H),8.48-8.40(m,1H),7.85(d,J=7.8Hz,1H),7.47-7.26(m,7H),7.26-7.19(m,1H),7.19- 7.11(m,1H),6.80-6.72(m,1H),6.72-6.65(m,2H),4.81-4.74(m,1H),3.85-3.68(m,4H),3.47-3.34(m,2H). Mass spectrometry (mass to charge ratio) is C 29 H 25 ClN 3 O 4 + [M+H] + The theoretical value is 514.2 and the measured value is 514.1.
[0252] Example 49 [ka]
[0253] Compound 49 (6.6 mg, 13% yield) was synthesized with reference to General Experimental Procedure 2. 1 H NMR (400 MHz, CDCl 3)δ8.64-8.44(m,2H),7.81-7.70(m,1H),7.53-7.19(m,6H),7.17-7.06(m,1H),6.81-6.70(m, 2H), 6.68-6.61 (m, 1H), 5.09-5.00 (m, 1H), 4.38-4.28 (m, 2H), 3.97-3.84 (m, 5H), 3.70 (s, 2H). Mass spectrometry (mass to charge ratio) is C 24 H 24 N 3 O 4 + [M+H] + The theoretical value is 418.2 and the measured value is 418.1.
[0254] Example 49a Referring to General Experimental Procedure 2, compound 49a (3.2 mg, 66% yield) was synthesized. 1 H NMR (500MHz, MeOH-d 4 )δ8.53(s,1H),8.45(d,J=3.9Hz,1H),7.86(d,J=7.9Hz,1H),7.52-7.35(m,4H),7.28(t,J=7.9Hz,1H),7.13(s,1 H),6.88-6.79(m,2H),6.78-6.69(m,1H),5.15-5.07(m,1H),4.39-4.28(m,2H),3.87-3.80(m,2H),3.73(s,2H). Mass spectrometry (mass to charge ratio) is C 23 H 22 N 3 O 4 + [M+H] + The theoretical value is 404.2 and the measured value is 404.1.
[0255] Example 50 [ka]
[0256] Referring to General Experimental Procedure 2, compound 50 (80 milligrams, 57.04% yield) was synthesized. 1 H NMR (500MHz, MeOH-d 4)δ8.61(d,J=2.6Hz,1H),8.18(dd,J=4.8,1.4Hz,1H),8.01(ddd,J=8.4,2.6,1.4Hz,1H),7.43-7.35(m,4H),7.30(t,J=7.9Hz,1H),7.13(dd,J= 2.5,1.6Hz,1H),6.91-6.81(m,2H),6.76(ddd,J=8.1,2.6,1.1Hz,1H),5.13(ddd,J=6.1,4.1,1.9Hz,1H),4.40-4.29(m,2H),3.92-3.78(m,6H). Mass spectrometry (mass to charge ratio) is C 23 H 23 N 4 O 4 + [M+H] + The theoretical value is 419.17138 and the measured value is 419.17139.
[0257] Example 50a Referring to General Experimental Procedure 2, compound 50a (17 mg, 70.36% yield) was synthesized. 1 H NMR (400MHz, DMSO-d 6 )δ9.62(s,1H),9.45(s,1H),8.65(s,1H),8.25-8.05(m,1H),8.01-7.86(m,1H),7.43(d,J=8.5Hz,2H),7.34-7.22(m,3H),7.04(s, 1H),6.85(d,J=8.6Hz,2H),6.69(d,J=7.0Hz,1H),5.12(h,J=4.3Hz,1H),4.34(dd,J=8.4,6.1Hz,2H),3.80(dd,J=8.4,4.0Hz,2H). Mass spectrometry (mass to charge ratio) is C 22 H 21 N 4 O 4 + [M+H] + , the theoretical value is 405.15573 and the measured value is 405.15573.
[0258] Example 51 [ka]
[0259] Referring to General Experimental Procedure 2, compound 51 (55 mg, 75.31% yield) was synthesized. 1 H NMR (500 MHz, CDCl 3 )δ8.61-8.54(m,2H),7.76-7.69(m,1H),7.35-7.30(m,3H),7.29-7.27(m,1H),7.14(dd,J=7.6,1.1Hz,1H),7.01(br,1H),6.69(t,J=2.1Hz,2 H),6.67(d,J=7.3Hz,1H),6.63(d,J=9.0Hz,2H),6.24(t,J=2.1Hz,2H),4.82-4.75(m,1H),3.80-3.74(m,2H),3.70(s,2H),3.65-3.57(m,5H). Mass spectrometry (mass to charge ratio) is C 28 H 27 N 4 O 4 + [M+H] + The theoretical value is 483.20268 and the measured value is 483.20282.
[0260] Example 51a Referring to General Experimental Procedure 2, compound 51a (15 mg, yield 61.80%) was synthesized. 1 H NMR (400MHz, MeOH-d 4 )δ8.54(d,J=1.6Hz,1H),8.46(dd,J=4.9,1.3Hz,1H),7.90-7.84(m,1H),7.48-7.41(m,3H),7.33(t,J=7.9Hz,1H),7.09(dd,J=7.6,1.1Hz,1H) ,6.77(dd,J=8.2,1.1Hz,1H),6.74-6.66(m,4H),6.20(t,J=2.1Hz,2H) ,4.82-4.79(m,1H),3.86-3.78(m,2H),3.74(s,2H),3.57-3.51(m,2H). Mass spectrometry (mass to charge ratio) is C 27 H 25 N 4 O 4 + [M+H] +The theoretical value is 469.18703 and the measured value is 469.18716.
[0261] Example 52 [ka]
[0262] Referring to General Experimental Procedure 2, compound 52 (65 mg, 82.55% yield) was synthesized. 1 H NMR (400 MHz, CDCl 3 )δ8.61(M,2H),8.03(t,J=9.0Hz,1H),7.81-7.69(m,1H),7.39-7.29(m,2H),7.20(br,1H),7.19-7.15(m,1H),6.75-6.66(m,3H),6 .52-6.47(m,1H),6.46-6.42(m,1H),6.26(t,J=2.0Hz,2H),4.83-4.75(m,1H),3.83-3.77(m,2H),3.76(s,2H),3.66-3.59(m,5H). Mass spectrometry (mass to charge ratio) is C 28 H 26 FN 4 O 4 + [M+H] + The theoretical value is 501.19326 and the measured value is 501.19354.
[0263] Example 52a Referring to General Experimental Procedure 2, compound 52a (20 mg, 51.44% yield) was synthesized. 1 H NMR (400MHz, MeOH-d 4)δ8.56(s,1H),8.47(d,J=4.3Hz,1H),7.94-7.84(m,1H),7.63-7.53(m,1H),7.46(d d,J=7.8,4.9Hz,1H),7.33(t,J=7.9Hz,1H),7.08(dd,J=7.6,1.3Hz,1H),6.77(dd,J= 8.2,1.2Hz,1H),6.72(t,J=2.1Hz,2H),6.63(dd,J=12.0,2.7Hz,1H),6.58-6.52(m, 1H), 6.20 (t, J=2.1Hz, 2H), 5.09-5.01 (m, 1H), 3.88-3.79 (m, 4H), 3.55-3.49 (m, 2H). Mass spectrometry (mass to charge ratio) is C 27 H 24 FN 4 O 4 + [M+H] + , the theoretical value is 487.17761 and the measured value is 487.17767.
[0264] Example 53 [ka]
[0265] Referring to General Experimental Procedure 2, compound 53 (90 mg, 65.15% yield) was synthesized. 1 H NMR (500 MHz, CDCl 3 )δ8.61-8.53(m,2H),7.78-7.67(m,1H),7.40-7.35(m,2H),7.35-7.29(m,2H),7.15(t,J=7.9Hz,1H),7.09(br,1H),6.78 -6.74(m,2H),6.70(d,J=7.5Hz,1H),5.05-4.93(m,1H),4.37-4.29(m,2H),3.92-3.85(m,5H),3.71(s,2H),2.34(s,3H). Mass spectrometry (mass to charge ratio) is C 25 H 26 N 3 O 4 + [M+H] + The theoretical value is 432.19178 and the measured value is 432.19177.
[0266] Example 53a Referring to General Experimental Procedure 2, compound 53a (12 mg, 72.96% yield) was synthesized. 1 H NMR (400MHz, MeOH-d 4 )δ8.55(d,J=1.3Hz,1H),8.50-8.42(m,1H),7.92-7.86(m,1H),7.52-7.42(m,3H),7.31-7.26(m,1H),7.17(t,J=7.9Hz,1H) ,6.90-6.84(m,2H),6.83-6.77(m,1H),5.08-5.05(m,1H),4.43-4.35(m,2H),3.89-3.82(m,2H),3.76(s,2H),2.36(s,3H). Mass spectrometry (mass to charge ratio) is C 24 H 22 N 3 O 4 - [MH] - The theoretical value is 416.16158 and the measured value is 416.16177.
[0267] Example 54 [ka]
[0268] Referring to General Experimental Procedure 2, compound 54 (45 mg, 73.64% yield) was synthesized. 1 H NMR (500 MHz, CDCl 3 )δ8.62-8.54(m,2H),7.99(t,J=9.0Hz,1H),7.75-7.68(m,1H),7.38-7.26(m,7H),7.21(d,J=6.7Hz,1H),7.13(br,1H),6.70-6.62(m,1 H),6.43(dd,J=12.2,2.7Hz,1H),6.40-6.34(m,1H),4.69-4.64(m,1H),3.73(s,2H),3.70-3.63(m,2H),3.51(s,3H),3.47-3.42(m,2H). Mass spectrometry (mass to charge ratio) is C 30 H 27 FN3 O 4 + [M+H] + The theoretical value is 512.19801 and the measured value is 512.19824.
[0269] Example 54a Referring to General Experimental Procedure 2, compound 54a (6 mg, 41.13% yield) was synthesized. 1 H NMR (500MHz, MeOH-d 4 )δ8.52(d,J=1.8Hz,1H),8.44(dd,J=4.9,1.3Hz,1H),7.87-7.83(m,1H),7. 53(t,J=8.9Hz,1H),7.45-7.40(m,1H),7.37-7.26(m,6H),7.14-7.08(m,1H ),6.77-6.71(m,1H),6.57(dd,J=12.1,2.7Hz,1H),6.53-6.46(m,1H),4.76 -4.75(m,1H),3.77(s,2H),3.72(dd,J=8.9,6.2Hz,2H),3.38-3.35(m,2H). Mass spectrometry (mass to charge ratio) is C 29 H 25 FN 3 O 4 + [M+H] + The theoretical value is 498.18236 and the measured value is 498.18250.
[0270] Example 55 [ka]
[0271] Referring to General Experimental Procedure 2, compound 55 (80 milligrams, 73.64% yield) was synthesized. 1 H NMR (500 MHz, CDCl 3)δ8.57(d,J=2.7Hz,2H),7.77-7.71(m,1H),7.41-7.36(m,2H),7.34-7.29(m,2H),7.20-7.11(m,2H),6.76-6.72(m, 2H),6.66(dd,J=7.7,1.9Hz,1H),5.00-4.95(m,1H),4.57-4.49(m,2H),4.05-4.01(m,2H),3.91(s,3H),3.70(s,2H). Mass spectrometry (mass to charge ratio) is C 24 H 23 ClN 3 O 4 + [M+H] + The theoretical value is 452.13716 and the measured value is 452.13699.
[0272] Example 55a Referring to General Experimental Procedure 2, compound 55a (11 mg, 70.95% yield) was synthesized. 1 H NMR (500MHz, MeOH-d 4 )δ8.54(d,J=1.7Hz,1H),8.46(dd,J=4.9,1.3Hz,1H),7.91-7.86(m,1H),7.50-7.43(m,3H),7.22(t,J=7.9Hz,1H),7.11(dd,J=7.6 ,1.4Hz,1H),6.87-6.81(m,2H),6.78(dd,J=8.2,1.3Hz,1H),5.06-5.03(m,1H),4.56-4.52(m,2H),4.02-3.96(m,2H),3.74(s,2H). Mass spectrometry (mass to charge ratio) is C 23 H 21 ClN 3 O 4 + [M+H] + The theoretical value is 438.1 and the measured value is 438.0.
[0273] Example 56 [ka]
[0274] Referring to General Experimental Procedure 2, compound 56 (12 mg, 26.49% yield) was synthesized. 1 H NMR (500 MHz, CDCl 3 )δ7.59(s,1H),7.29(t,J=7.9Hz,1H),7.19-6.94(m,5H),6.70(t,J=2.1Hz,2H),6.69-6.65(m,3H),6.24(t,J=2. 1Hz,2H),5.03(s,2H),4.85-4.77(m,1H),3.79(dd,J=9.1,6.2Hz,2H),3.64(dd,J=9.1,4.8Hz,2H),3.61(s,3H). Mass spectrometry (mass to charge ratio) is C 25 H 25 N 4 O 3 + [M+H] + The theoretical value is 429.2 and the measured value is 429.2.
[0275] Example 56a Referring to General Experimental Procedure 2, compound 56a (2 mg, yield 20.68%) was synthesized. 1 H NMR (500MHz, MeOH-d 4 )δ7.96(s,1H),7.27(t,J=7.9Hz,1H),7.23-7.19(m,2H),7.19-7.16(m,1H),7.10-7.06(m,1H),7.00-6.95(m,1H),6.76-6.71(m ,4H),6.69-6.66(m,1H),6.15(t,J=2.0Hz,2H),5.17(s,2H),4.87-4.85(m,1H),3.82-3.76(m,2H),3.49(dd,J=8.9,4.4Hz,2H). Mass spectrometry (mass to charge ratio) is C 24 H 23 N 4 O 3 + [M+H] + The theoretical value is 415.2 and the measured value is 415.2.
[0276] Example 57 [ka]
[0277] Referring to General Experimental Procedure 3, compound 57 (120 mg, 71.0% yield) was synthesized. 1 H NMR(400MHz,MeOD)δ8.60(s,1H),8.24-8.15(m,1H),8.00(d,J=9.3Hz,1H),7.72(dd,J=7.8,3.5Hz,2H),7.46(t,J=7.8Hz,1H),7.42-7.31(m,4 H),7.11(d,J=8.7Hz,2H),7.03(dd,J=8.3,1.9Hz,1H),6.96(s,1H),6.88(d,J=7.6Hz,1H),4.12-4.02(m,2H),3.92-3.83(m,2H),3.58(s,3H). Mass spectrometry (mass to charge ratio) is C 30 H 26 N 3 O 5 + [M+H] + The theoretical value is 508.19 and the measured value is 508.20.
[0278] Example 58 [ka]
[0279] Referring to General Experimental Procedure 3, compound 58 (50 milligrams, 52.80% yield) was synthesized. 1 H NMR (500MHz, MeOH-d 4 )δ8.60(d,J=2.4Hz,1H),8.19(dd,J=4.8,1.2Hz,1H),8.01(ddd,J=8.4,2.6,1.4Hz,1H),7.73(d,J=7 .8Hz,2H),7.48-7.41(m,4H),7.39-7.35(m,3H),7.34-7.30(m,2H),7.09-7.04(m,2H),3.55(s,3H). Mass spectrometry (mass to charge ratio) is C 28 H 22 N 3 O 3 + [M+H] +The theoretical value is 448.16557 and the measured value is 448.16568.
[0280] Example 58a Referring to General Experimental Procedure 3, compound 58a (1.4 mg, 14.45% yield) was synthesized. 1 H NMR (400MHz, MeOH-d 4 )δ8.62-8.56(m,1H),8.22-8.16(m,1H),8.05-7.99(m,1H),7.75-7.62(m,3H),7.43-7.36(m,8H),7.10-7.06(m,2H). Mass spectrometry (mass to charge ratio) is C 27 H 18 N 3 O 3 - [MH] - The theoretical value is 432.13537 and the measured value is 432.13550.
[0281] Example 58b Referring to General Experimental Procedure 3, compound 58b (3.7 mg, 43.94% yield) was synthesized. 1 H NMR (500MHz, MeOH-d 4 )δ8.61(s,1H),8.19(d,J=4.5Hz,1H),8.01(d,J=8.9Hz,1H),7.70-7.65(m,1H),7.47-7.36(m,10H),7.12-7.05(m,2H). Mass spectrometry (mass to charge ratio) is C 27 H 19 N 4 O 3 - [MH] - The theoretical value is 447.14626 and the measured value is 447.14661.
[0282] Example 59 [ka]
[0283] Referring to General Experimental Procedure 3, compound 59 (40 milligrams, 41.15% yield) was synthesized.1 H NMR (500MHz, MeOH-d 4 )δ8.58(d,J=2.4Hz,1H),8.18(dd,J=4.8,1.4Hz,1H),7.99(ddd,J=8.4,2.6,1.4Hz,1H),7.71(dd,J=7.7,1.3Hz,1H),7.65(dd,J=7.8,1.3Hz,1H), 7.60(dd,J=8.1,0.5Hz,1H),7.44-7.39(m,2H),7.38-7.33(m,1H),7.32- 7.27(m,3H),7.01-6.95(m,3H),6.52(dd,J=3.1,0.9Hz,1H),3.49(s,3H). Mass spectrometry (mass to charge ratio) is C 30 H 23 N 4 O 3 + [M+H] + , the theoretical value is 487.17647 and the measured value is 487.17667.
[0284] Example 59a Referring to General Experimental Procedure 3, compound 59a (5.5 mg, 80.90% yield) was synthesized. 1 H NMR (400MHz, MeOH-d 4 )δ8.63-8.58(m,1H),8.21-8.17(m,1H),8.05-7.99(m,1H),7.67-7.59(m,3H) ,7.53-7.49(m,1H),7.42-7.28(m,6H),7.01-6.98(m,2H),6.53-6.50(m,1H). Mass spectrometry (mass to charge ratio) is C 29 H 21 N 4 O 3 + [M+H] + The theoretical value is 473.16082 and the measured value is 473.16101.
[0285] Example 60 [ka]
[0286] Referring to General Experimental Procedure 3, compound 60 (55 mg, 48.51% yield) was synthesized. 1 H NMR (500MHz, MeOH-d 4 )δ8.71(d,J=2.3Hz,1H),8.25(dd,J=4.8,1.3Hz,1H),8.10(ddd,J=8.4,2.5,1.5Hz,1H),7.77-7.72(m,2H ),7.48-7.36(m,5H),7.33-7.29(m,2H),7.28-7.24(m,2H),7.13-7.08(m,2H),3.69(s,2H),3.54(s,3H). Mass spectrometry (mass to charge ratio) is C 29 H 23 N 2 O 3 + [M+H] + The theoretical value is 447.17032 and the measured value is 447.17050.
[0287] Example 60a Referring to General Experimental Procedure 3, compound 60a (7.1 mg, 81.45% yield) was synthesized. 1 H NMR (400MHz, MeOH-d 4 )δ8.74(d,J=2.3Hz,1H),8.30-8.24(m,1H),8.16-8.09(m,1H),7.78(dd,J=7.7,1.0Hz,1H),7.7 3(dd,J=7.7,1.1Hz,1H),7.49-7.36(m,7H),7.32-7.24(m,2H),7.16-7.09(m,2H),3.72(s,2H). Mass spectrometry (mass to charge ratio) is C 28 H 21 N 2 O 3 + [M+H] + The theoretical value is 433.15467 and the measured value is 433.15485.
[0288] Example 60b Referring to General Experimental Procedure 3, compound 60b (4 mg, 15.84% yield) was synthesized. 1 H NMR (400MHz, MeOH-d 4)δ8.74(d,J=1.7Hz,1H),8.30-8.25(m,1H),8.15-8.09(m,1H),7.75-7.68(m,1H) ),7.50-7.38(m,8H),7.29(d,J=8.1Hz,2H),7.15(d,J=8.1Hz,2H),3.72(s,2H). Mass spectrometry (mass to charge ratio) is C 28 H 20 N 3 O 3 - [MH] - The theoretical value is 446.15102 and the measured value is 446.15088.
[0289] Example 61 [ka]
[0290] Referring to General Experimental Procedure 3, compound 61 (65 mg, yield 61.43%) was synthesized. 1 H NMR (500MHz, MeOH-d 4 )δ8.74-8.64(m,1H),8.29-8.21(m,1H),8.13-8.04(m,1H),7.75-7.70(m,1H ),7.67(dd,J=7.8,1.3Hz,1H),7.61-7.57(m,1H),7.45-7.41(m,2H),7.40-7. 34(m,1H),7.29(d,J=3.1Hz,1H),7.21-7.16(m,2H),7.04-7.00(m,2H),6.97( dd,J=8.1,1.5Hz,1H),6.50(dd,J=3.1,0.9Hz,1H),3.66(s,2H),3.49(s,3H). Mass spectrometry (mass to charge ratio) is C 31 H 24 N 3 O 3 + [M+H] + The theoretical value is 486.18122 and the measured value is 486.18149.
[0291] Example 61a Referring to General Experimental Procedure 3, compound 61a (15 mg, 38.62% yield) was synthesized. 1 H NMR (500MHz, MeOH-d 4 )δ8.69(d,J=2.2Hz,1H),8.24(dd,J=4.8,1.4Hz,1H),8.11-8.04(m,1H),7.72-7.66(m,2H),7.58(d,J=8.1Hz,1H),7.47-7.44(m,1H),7.43- 7.35(m,2H),7.28-7.24(m,1H),7.21-7.16(m,2H),7.05(dd,J=8.1,1.5Hz,1H),7.03-6.98(m,2H),6.49(dd,J=3.1,0.8Hz,1H),3.66(s,2H). Mass spectrometry (mass to charge ratio) is C 30 H 20 N 3 O 3 - [MH] - The theoretical value is 470.15102 and the measured value is 470.15100.
[0292] Example 62 [ka]
[0293] Referring to General Experimental Procedure 3, compound 62 (60 mg, 52.92% yield) was synthesized. 1 H NMR (500 MHz, CDCl 3 )δ8.59-8.56(m,1H),8.54(s,1H),7.79(dd,J=7.8,1.3Hz,1H),7.74-7.68 (m,2H),7.44-7.29(m,10H),7.10-7.03(m,2H),3.70(s,2H),3.58(s,3H). Mass spectrometry (mass to charge ratio) is C 29 H 23 N 2 O 3 + [M+H] + The theoretical value is 447.17032 and the measured value is 447.17038.
[0294] Example 62a Referring to General Experimental Procedure 3, compound 62a (45 mg, 84.47% yield) was synthesized. 1 H NMR (500MHz, DMSO-d 6 )δ10.37(s,1H),8.49(d,J=1.4Hz,1H),8.44(dd,J=4.7,1.3Hz,1H),7.76-7.66(m,3H),7.59-7.28(m,9H),7.12-7.04(m,2H),3.69(s,2H). Mass spectrometry (mass to charge ratio) is C 28 H 21 N 2 O 3 + [M+H] + The theoretical value is 433.15467 and the measured value is 433.15475.
[0295] Example 63 [ka]
[0296] Referring to General Experimental Procedure 3, compound 63 (68 mg, 71.38% yield) was synthesized. 1 H NMR(400MHz,DMSO)δ9.49(s,1H),9.06(s,1H),8.97(s,1H),8.45(d,J=152.9Hz,1H),7.92(d, J=8.4Hz,1H),7.75(dd,J=7.7,1.1Hz,1H),7.68(dd,J=7.8,1.1Hz,1H),7.49(t,J=7.8Hz,1H) ,7.44(d,J=8.7Hz,2H),7.34(dt,J=16.0,7.2Hz,1H),7.23(t,J=7.8Hz,1H),7.15(d,J=8.6Hz ,2H),6.80(dd,J=8.1,2.0Hz,1H),6.77-6.71(m,1H),6.68(d,J=7.6Hz,1H),3.53(s,3H)ppm. Mass spectrometry (mass to charge ratio) is C 28 H 21 O 4 N 3 + [M+H] + The theoretical value is 464.2 and the measured value is 464.2.
[0297] Example 64 Measurement of C666-1 cell activity In order to evaluate the inhibitory effect of the small molecule compound of the present invention on EBNA1 at the cellular level, a cytotoxicity experiment was carried out. The small molecule compound of the present invention can selectively kill EB virus-positive cell lines (C666-1 cells), and its killing ability is obviously superior to that of EB virus-negative cell lines (HONE1 cells and HK1 cells).
[0298] As explained in the Background of the Invention section, nasopharyngeal carcinoma is a disease that is highly correlated with latent EBV infection. In the latent state, EBV expresses only a limited number of proteins to maintain genome replication, and among them, EBNA1 protein is an essential functional protein. Research has shown that inhibiting EBNA1 results in: Nasopharyngeal cancer cells It has been confirmed that the small molecule compound of the present invention can reduce the proliferation of or kill the corresponding nasopharyngeal carcinoma cells. Therefore, the EB virus-positive nasopharyngeal carcinoma tumor cells (C666-1 cells) can be selected for the experiment to verify the effect of the small molecule compound of the present invention.
[0299] At the time of testing, 100 microliters of the different cell lines were inoculated into a clear 96-well plate, with C666-1 at 5 × 10 cells per well. 3Cells were inoculated into wells. After the cells were cultured for 24 hours at 37°C in a 5% carbon dioxide incubator, 10 microliters of compounds with concentrations ranging from 1 mmol / L to 7.8 mmol / L were added to each well (8 spots, 2-fold dilutions, final concentrations 100-0.78 mmol / L) and treated for 72 hours at 37°C in a carbon dioxide incubator. Cell activity was assessed using the redox indicator resazurin. After adding 10 microliters of 600 mmol / L resazurin to each well and incubating at 37°C for 3 hours, a Tecan microplate reader was used to detect the fluorescent signal excited at a wavelength of 560 nanometers and emitted at a wavelength of 590 nanometers. The inhibition curves were fitted using software to determine the half effective concentration (EC 50 ) was calculated. EC 50 The selectivity of compound activity was evaluated by comparing the results.
[0300] [Table 1] TIFF2024543351000172.tif179129TIFF2024543351000173.tif180129TIFF2024543351000174.tif184131TIFF2024543351000175.tif179130TIFF202 4543351000176.tif181130TIFF2024543351000177.tif165130TIFF2024543351000178.tif165131TIFF2024543351000179.tif177129TIFF2024543351 000180.tif172131TIFF2024543351000181.tif163130TIFF2024543351000182.tif171128TIFF2024543351000183.tif176131TIFF2024543351000184. tif180130TIFF2024543351000185.tif172132TIFF2024543351000186.tif174128TIFF2024543351000187.tif177130TIFF2024543351000188.tif89130
[0301] The data in the above table demonstrate that the compounds according to the present invention can effectively inhibit the proliferation activity of C666-1 cells, and in a dose-dependent manner.
[0302] Although the present technology has been described with reference to specific exemplary embodiments, it should be understood that the invention should not be unduly limited to such specific embodiments. Indeed, those skilled in the art will recognize that other embodiments and variations of the invention can be designed without departing from the true spirit and scope of the invention. It is intended that the appended claims be construed to include all such embodiments and equivalent variations.
Claims
1. A compound of general formula (I) or an enantiomer, diastereomer, tautomer, salt, crystal form, solvate and / or isotopically substituted derivative thereof. 【Chemistry 1】 During the ceremony, R 1 is -H, -COOH, -C(=O)-OR 1a , -C(=O)-NHR 1b , -C(=O)-NR 1b R 1c Selected from however, R 1a , R 1b , R 1c are the same or different and are selected independently from hydrogen, optionally substituted C1-C4 linear alkyl, optionally substituted C3-C4 branched alkyl, optionally substituted C3-C4 cycloalkyl, optionally substituted halogenated C1-C4 linear alkyl, optionally substituted halogenated C3-C4 branched alkyl, optionally substituted halogenated C3-C4 cycloalkyl; Or, R 1b is selected from hydroxyl, C1-C4 alkoxy; Or, R 1b and R 1c together with the atoms to which they are attached form a cyclic group, said cyclic group being selected from optionally substituted pyrrolidinyl, optionally substituted piperidinyl, optionally substituted piperazinyl, or optionally substituted morpholinyl; R 2 teeth, selected from the group consisting of hydrogen, halogen, optionally substituted C1-C4 alkyl, optionally substituted pyrrolyl, optionally substituted indole, and optionally substituted phenyl; L 1 teeth, 【Chemistry 2】 ethynyl group, however, 【Chemistry 3】 L 1 represents a connection point to the right A ring of the compound of formula (I), However, the asterisk * stands for L 1 represents the connection point to the left B ring of the compound of formula (I), L 2 teeth, ・-(CH 2 ) q -O-(CH 2 ) p -*, -(CH 2 ) q -NH-(CH 2 ) p -*,・-NH-C(=O)-NH-*,・-N(CH 3 )-C(=O)-NH-*, -CH=CH-, -(CH 2 ) n -, -NH-C(=O)-(CH 2 ) p -*, -(CH 2 ) q -C(=O)-NH-* group, Preferably, L 2 is -CH 2 -O-*, ・-O-CH 2 -*, -O-, -CH 2 -O-CH 2 -, -CH 2 -NH-*, -CH 2 -NH-CH 2 -*,・-NH-CH 2 -*, -NH-C(=O)-NH-, -N(CH 3 )-C(=O)-NH-*, -CH=CH-, -CH 2 --, --CH 2 -CH 2 -, .-NH-C(=O)-*, .-NH-C(=O)-CH 2 -*, ・-C(=O)-NH-*, ・-CH 2 -C(=O)-NH-*; However, the dot is L 2 represents the connection point to the right B ring of the compound of formula (I), However, the asterisk * stands for L 2 is the left R of the compound of formula (I) 3 represents the connection point that connects to p and q are each independently 0, 1, or 2; n is 1, 2 or 3; R 3 is selected from optionally substituted aryl, heteroaryl; The aryl is selected from phenyl; the heteroaryl is selected from thiophene, pyrazolyl, imidazolyl, isothiazole, pyridine, pyrimidine, pyrazine, and quinoline; The aryl, heteroaryl are optionally substituted one or more times, similarly or differently, with hydrogen, fluorine, chlorine, cyano, C1-C4 alkyl, halogenated C1-C4 alkyl, C1-C4 alkoxy, halogenated C1-C4 alkoxy; R 4 is selected from hydrogen, halogen, optionally substituted C1-C4 straight chain alkyl, optionally substituted C3-C4 branched alkyl, optionally substituted halogenated C1-C4 straight chain alkyl, optionally substituted halogenated C3-C4 branched alkyl, and hydroxyl.
2. L 2 - (CH 2 ) q -O-(CH 2 ) p When selected from - R 3 is selected from aryl and heteroaryl; The aryl is selected from phenyl; the heteroaryl is selected from thiophene, pyrazolyl, isothiazole, pyridine, pyrimidine, pyrazine, and quinoline; The aryl, heteroaryl are optionally substituted one or more times with hydrogen, C1-C4 alkyl, C1-C4 alkoxy, either the same or different; Or, L 2 - (CH 2 ) q -NH-(CH 2 ) p -, -NH-C(=O)-(CH 2 ) p -*, -(CH 2 ) q When selected from -C(=O)-NH-*, -CH=CH-, R 3 is selected from aryl and heteroaryl; The aryl is selected from phenyl; said heteroaryl being selected from pyridine; Or, L 2 is -NH-C(=O)-NH-, -N(CH 3 )-C(=O)-NH-*, R 3 is selected from aryl and heteroaryl; The aryl is selected from phenyl; said heteroaryl being selected from pyridine; The aryl and heteroaryl are substituted one or more times, either the same or different, with hydrogen, fluorine, cyano, C1-C4 alkyl, or halogenated C1-C4 alkyl; Or, L 2 - (CH 2 ) n When selected from - R 3 is selected from aryl and heteroaryl; The aryl is selected from phenyl; The heteroaryl is selected from pyridine and imidazolyl; 2. A compound according to claim 1, or an enantiomer, diastereomer, tautomer, salt, crystalline form, solvate and / or isotopically substituted derivative thereof.
3. L 1 is selected from oxy-azetidine; R 2 is selected from hydrogen, halogen, optionally substituted C1-C4 alkyl, optionally substituted pyrrolyl, optionally substituted indole, and optionally substituted phenyl; L 2 is selected from -(CH 2 ), -O-(CH q ), -(CH 2 ), -NH-(CH p ), -NH-C(=O)-NH-, -N(CH 2 ), -CH=CH-, -(CH q ), -NH-C(=O)-(CH 2 ), -(CH p ), -C(=O)-NH- 3 ), 2 ), n ), -NH-C(=O)-(CH 2 ), p ), -(CH 2 ), q ), -C(=O)-NH- R 3 is selected from phenyl, thiophene, pyrazolyl, imidazolyl, isothiazole, pyridine, pyrimidine, pyrazine, quinoline, cyanophenyl, trifluoromethylphenyl, fluoropyridine, methylpyridine, methoxypyridine, methylpyrazolyl; 2. A compound according to claim 1, or an enantiomer, diastereomer, tautomer, salt, crystalline form, solvate and / or isotopically substituted derivative thereof.
4. L 1 is selected from ethynyl, R 2 is selected from optionally substituted indole, optionally substituted phenyl; L 2 is -(CH 2 ) q -O-(CH 2 ) p -, -NH-C(=O)-NH-, -N(CH 3 )-C(=O)-NH-*, .-NH-C(=O)-(CH 2 ) p -*, -(CH 2 ) q -C(=O)-NH-*; R 3 is selected from pyridine, methylpyridine, and methoxypyridine; 2. A compound according to claim 1, or an enantiomer, diastereomer, tautomer, salt, crystalline form, solvate and / or isotopically substituted derivative thereof.
5. 3-(3-(4-((pyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl, 3-(3-(4-((pyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid ethyl, N-hydroxyl-3-(3-(4-((pyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoate N-methyl-3-(3-(4-((pyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzamide, N,N-dimethyl-3-(3-(4-((pyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzamide, (3-(3-(4-((pyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzamide 3-((4-((1-(2-(1H-pyrrol-1-yl)phenyl)azetidin-3-yl)oxy)benzyl)oxy)pyridine, 3-(3-(4-((4-methylpyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl ester, 3-(3-(4-((4-methylpyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)phenyl)(pyrrolidin-1-yl)methyl ketone, 3-((4-((1-(2-(1H-pyrrol-1-yl)phenyl)azetidin-3-yl)oxy)benzyl)oxy)pyridine, 3-(3-(4-((4-methylpyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl ester, pyrrol-1-yl)benzoic acid, 3-(3-(4-((5-methylpyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl, 3-(3-(4-((5-methylpyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, 3-(3-(4-(((6-methoxypyridin-3-yl)oxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl,3-(3-(4-(((6-methoxypyridin-3-yl)oxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, 3-(3-(4-((6-methylpyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl, 3-(3-(4-((6-methylpyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, 3-(3-(4-((5- methoxypyridin-3-yl)oxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl, 3-(3-(4-(((5-methoxypyridin-3-yl)oxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, 3-(3-(4-(3-(3-cyanophenyl)-1-methylurea)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl, 3-(3-(4-(3-(3-cyanophenyl)-1-methylurea)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl 3-(3-(4-((pyridin-4-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl ester, 3-(3-(4-((pyridin-4-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl ester, 3-(3-(4-((pyridin-4-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, 2-(1H-pyrrol-1-yl)-3-(3-(4-((quinolin-3-yloxy)methyl)phenoxy )azetidin-1-yl)benzoic acid methyl, 2-(1H-pyrrol-1-yl)-3-(3-(4-((quinolin-3-yloxy)methyl)phenoxy)azetidin-1-yl)benzoic acid, 2-(1H-pyrrol-1-yl)-3-(3-(4-(3-(3-(trifluoromethyl)phenyl)urea)phenoxy)azetidin-1-yl)benzoic acid methyl, 2-(1H-pyrrol-1-yl)-3-(3-(4-(3-(3-(trifluoromethyl)phenyl)urea)phenoxy)azetidin-1-yl)benzoic acid,N-hydroxyl-2-(1H-pyrrol-1-yl)-3-(3-(4-(3-(3-(trifluoromethyl)phenyl)urea)phenoxy)azetidin-1-yl)benzamide, 3-(3-(4-((pyrimidin-2-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl, 3-(3-(4-((pyrimidin-2-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, 3-(3-(4-((pyridin-2-yloxy)methyl)phenoxy)azetidin-1-yl 3-(3-(4-((pyridine-2-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, 3-(3-(4-((pyrazin-2-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, 3-(3-(4-((pyrazin-2-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, 3-(3-(4-((pyrazin-2-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, Methyl ((pyrimidin-5-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoate, 3-(3-(4-((pyrimidin-5-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, N-hydroxyl-3-(3-(4-((pyrimidin-5-oxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzamide, 3-(3-(3-methyl-4-((pyridin-3-yloxy)methyl)phenoxy)azetidine methyl 3-(3-(3-methyl-4-((pyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoate, methyl 3-(3-(2-methyl-4-((pyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoate, methyl 3-(3-(2-methyl-4-((pyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoate, 3-(3-(2-methyl-4-((pyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid,6-(3-(4-((pyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxylic acid methyl, 6-(3-(4-((pyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxylic acid, N-hydroxyl-6-(3-(4-((pyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl) -[1,1'-biphenyl]-2-carboxamide, 3'-chloro-6-(3-(4-((pyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxylate methyl, 3-(3-(3-chloro-4-((pyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoate methyl, 3-(3-(3-chloro-4-((pyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)- 3-(3-(3-fluoro-4-((pyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, 3-(3-(3-fluoro-4-((pyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl, 3-(3-(3-fluoro-4-((pyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, 3-(3-(3-fluoro-4-((pyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, Methyl ((pyridin-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoate, methyl 6-((3-hydroxyl-4-(3-(pyridin-3-yl)urea)phenyl)ethynyl)-[1,1'-biphenyl]-2-carboxylate, methyl 3-(3-(4-((pyridin-3-ylamino)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoate, methyl 3-(3- (4-((pyridin-3-ylamino)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, N-hydroxyl-3-(3-(4-((pyridin-3-ylamino)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzamide, methyl 3-(3-(4-(pyridin-3-ylmethoxy)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoate,3-(3-(4-(pyridin-3-ylmethoxy)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, N-hydroxyl-3-(3-(4-(pyridin-3-ylmethoxy)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzamide, 3-(3-(4-(pyridin-3-yloxy)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl ester, 3-(3-(4-(pyridin-3-yloxy)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, 3-(3-(4-(pyridin-4-yloxy)phenoxy)azetidin-1-yl)-2- Methyl (1H-pyrrol-1-yl)benzoate, 3-(3-(4-(pyridin-4-yloxy)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, 3-(3-(4-((pyridin-3-ylmethoxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoate, 3-(3-(4-((pyridin-3-ylmethoxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, N-hydroxyl-3-(3-(4-((pyridin-3-ylmethoxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid (E)-N-hydroxyl-3-(3-(4-(2-(pyridin-3-yl)vinyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzamide, (E)-3-(3-(4-(2-(pyridin-3-yl)vinyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl, (E)-3-(3-(4-(2-(pyridin-3-yl)vinyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, (E)-N-hydroxyl-3-(3-(4-(2-(pyridin-3-yl)vinyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl) 3-(3-(4-(2-(pyridin-3-yl)ethyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzamide, 3-(3-(4-(2-(pyridin-3-yl)ethyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl, 3-(3-(4-(2-(pyridin-3-yl)ethyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, 2-(1H-pyrrol-1-yl)-3-(3-(4-((thiophen-2-yloxy)methyl)phenoxy)azetidin-1-yl)benzoic acid methyl,2-(1H-pyrrol-1-yl)-3-(3-(4-((thiophen-2-yloxy)methyl)phenoxy)azetidin-1-yl)benzoic acid, 3-(3-(4-(nicotinamide)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl, 3-(3-(4-(nicotinamide)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, N-(4-((1-(3-(hydroxycarbamoyl)-2-(1H-pyrrol-1-yl)phenyl)azetidin-3-yl)oxy)phenyl)nicotinamide, 3-(3-(4-(((1-methyl-1H-pyrrol-1-yl) methyl 3-(3-(4-((1-methyl-1H-pyrazol-3-yl)oxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoate, methyl 3-(3-(4-((1-methyl-1H-pyrazol-3-yl)oxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, methyl 3-(3-(4-((isothiazol-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoate, methyl 3-(3-(4-((isothiazol-3-yloxy)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoate, 3-(3-(4-(3-(pyridin-3-yl)urea)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl, 3-(3-(4-(3-(pyridin-3-yl)urea)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, N-hydroxyl-3-(3-(4-(3-(pyridin-3-yl)urea)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzamide, 3-( 3-(4-(2-oxo-2-(phenylamino)ethyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl, 3-(3-(4-(2-oxo-2-(phenylamino)ethyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, (E)-6-(3-(4-(2-(pyridin-3-yl)vinyl)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxylate methyl,(E)-6-(3-(4-(2-(pyridin-3-yl)vinyl)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxylic acid, (E)-N-hydroxyl-6-(3-(4-(2-(pyridin-3-yl)vinyl)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxamide, 3'-chloro-6-(3-(4-(3-(3-(trifluoromethyl)phenyl)urea)phenoxy)azetidine- 1-yl)-[1,1'-biphenyl]-2-carboxylate methyl, 3'-chloro-6-(3-(4-(3-(3-(trifluoromethyl)phenyl)urea)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxylic acid, 3'-chloro-6-(3-(4-((pyridin-3-ylamino)methyl)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxylate methyl, 3'-chloro-6-(3-(4-(( pyridin-3-ylamino)methyl)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxylic acid, 3'-chloro-N-hydroxyl-6-(3-(4-((pyridin-3-ylamino)methyl)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxamide, 6-(3-(4-((pyridin-3-ylamino)methyl)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxamide Methyl 6-(3-(4-((pyridin-3-ylamino)methyl)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxylic acid, N-hydroxyl-6-(3-(4-((pyridin-3-ylamino)methyl)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxamide, 6-(3-(4-(2-oxo-2-(pyridin-3-ylamino)ethyl)phenoxy)azetidin-1-yl) - [1,1'-biphenyl] -2-carboxylate methyl, 6-(3-(4-(2-oxo-2-(pyridin-3-ylamino)ethyl)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxylic acid, N-hydroxyl-6-(3-(4-(2-oxo-2-(pyridin-3-ylamino)ethyl)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxamide,N-methyl-6-(3-(4-(2-oxo-2-(pyridin-3-ylamino)ethyl)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxamide, 3'-chloro-6-(3-(4-(3-(pyridin-3-yl)urea)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxylate methyl, 3'-chloro-6-(3-(4-(3-(pyridin-3-yl)urea)phenoxy)azetidin-1-yl)- [1,1'-biphenyl]-2-carboxylic acid, 3'-chloro-N-hydroxyl-6-(3-(4-(3-(pyridin-3-yl)urea)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxamide, 6-(3-(4-(3-(pyridin-3-yl)urea)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxylate methyl, 6-(3-(4-(3-(pyridin-3-yl)urea)phenoxy)azetidin- 1-yl)-[1,1'-biphenyl]-2-carboxylic acid, N-hydroxyl-6-(3-(4-(3-(pyridin-3-yl)urea)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxamide, N-methyl-6-(3-(4-(3-(pyridin-3-yl)urea)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxamide, 3-(3-(4-(2-oxo-2-(pyridin-3-ylamino)ethane methyl 3-(3-(4-(2-oxo-2-(pyridin-3-ylamino)ethyl)phenoxy)azetidin-1-yl)benzoate, methyl 3-(3-(4-(2-oxo-2-(pyridin-3-ylamino)ethyl)phenoxy)azetidin-1-yl)benzoic acid, N-hydroxyl-3-(3-(4-(2-oxo-2-(pyridin-3-ylamino)ethyl)phenoxy)azetidin-1-yl)benzamide, 2-(4-((1-phenylazetidin-3-yl)oxy)phenyl)-N-(pyridin-3-yl)acetamide, 2-(1H-indol-6-yl)-3-(3-(4-(2-oxo-2-(pyridin-3-ylamino)ethyl)phenoxy)azetidin-1-yl)benzoic acid methyl, 2-(1H-indol-6-yl)-3-(3-(4-(2-oxo-2-(pyridin-3-ylamino)ethyl)phenoxy)azetidin-1-yl)benzoic acid,6-(3-(4-(2-(pyridin-3-yl)acetylamido)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxylic acid methyl, 6-(3-(4-(2-(pyridin-3-yl)acetylamino)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxylic acid, N-hydroxyl-6-(3-(4-(2-(pyridin-3-yl)acetylamido)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxamide, N-methyl-6-(3-(4-(2-(pyridin-3-yl)acetylamino)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxamide, N-methoxy-6-(3-(4-(2-(pyridin- N-(4-((1-([1,1'-biphenyl]-2-yl)azetidin-3-yl)oxy)phenyl)-2-(pyridin-3-yl)acetamide, 3-(3-(4-(3-(5-fluoropyridin-3-yl)urea)phenoxy)azetidin-1-yl)-2-(1H-pyrrole 3-(3-(4-(3-(5-fluoropyridin-3-yl)urea)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, 3-(3-(4-(3-(5-methylpyridin-3-yl)urea)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl ester ... 3'-chloro-6-(3-(4-(2-(pyridin-3-yl)acetylamino)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxylate methyl ester, 3'-chloro-6-(3-(4-(2-(pyridin-3-yl)acetylamino)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxylate methyl ester,1'-biphenyl]-2-carboxylic acid, 3-(3-(4-(2-(pyridin-3-yl)acetylamino)phenoxy)azetidin-1-yl)benzoic acid methyl ester, 3-(3-(4-(2-(pyridin-3-yl)acetylamino)phenoxy)azetidin-1-yl)benzoic acid, 3-(3-(4-(3-(pyridin-3-yl)urea)phenoxy)azetidin-1-yl)benzoic acid methyl ester, 3-(3-(4-(3-(pyridin-3-yl)urea)phenoxy)azetidin-1-yl)benzoic acid, 3-(3-(4-(2-(pyridin-3-yl)acetylamino)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl ester, 3-(3-(4-(2-(pyridin-3-yl)acetylamino)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, 3-(3-(3-fluoro-4-(2-(pyridin-3-yl)acetylamino)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl ester, 3-(3-(3-fluoro-4-(2-(pyridin-3-yl)acetylamino)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl ester, -(1H-pyrrol-1-yl)benzoic acid, 2-methyl-3-(3-(4-(2-(pyridin-3-yl)acetylamino)phenoxy)azetidin-1-yl)benzoic acid methyl ester, 2-methyl-3-(3-(4-(2-(pyridin-3-yl)acetylamino)phenoxy)azetidin-1-yl)benzoic acid, 6-(3-(3-fluoro-4-(2-(pyridin-3-yl)acetylamino)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxylate methyl ester, 6-(3-(3-fluoro-4-(2-(pyridin-3-yl)acetylamino)phenoxy)azetidin-1-yl)-[1,1'-biphenyl]-2-carboxylate methyl ester,1'-biphenyl]-2-carboxylic acid, 2-chloro-3-(3-(4-(2-(pyridin-3-yl)acetylamino)phenoxy)azetidin-1-yl)benzoic acid methyl, 2-chloro-3-(3-(4-(2-(pyridin-3-yl)acetylamino)phenoxy)azetidin-1-yl)benzoic acid, 3-(3-(4-((1H-imidazol-1-yl)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid methyl, 3-(3-(4-((1H-imidazol-1-yl)methyl)phenoxy)azetidin-1-yl)-2-(1H-pyrrol-1-yl)benzoic acid, 3'-(2-hydroxylethox)-6-((4-(3-(pyridin-3-yl)urea)phenyl)ethynyl)-[1,1'-biphenyl]-2-carboxylate methyl, 6-((4-(3-(pyridin-3-yl)urea)phenyl)ethynyl)-[1,1'-biphenyl]-2-carboxylate methyl, 6-((4-( 3-(pyridin-3-yl)urea)phenyl)ethynyl)-[1,1'-biphenyl]-2-carboxylic acid, N-hydroxyl-6-((4-(3-(pyridin-3-yl)urea)phenyl)ethynyl)-[1,1'-biphenyl]-2-carboxamide, 2-(1H-indol-6-yl)-3-((4-(3-(pyridin-3-yl)urea)phenyl)ethynyl)benzoic acid methyl ester, 2-(1H-indol-6-yl)-3-((4-(3-(pyridin-3-yl)urea)phenyl)ethynyl) 6-((4-(2-oxo-2-(pyridin-3-ylamino)ethyl)phenyl)ethynyl)-[1,1'-biphenyl]-2-carboxylic acid, N-hydroxyl-6-((4-(2-oxo-2-(pyridin-3-ylamino)ethyl)phenyl)ethynyl)-[1,1'-biphenyl]-2-carboxylic acid, N-hydroxyl-6-((4-(2-oxo-2-(pyridin-3-ylamino)ethyl)phenyl)ethynyl)-[1,1'-biphenyl]-2-carboxamide, 2-(1H-indol-6-yl)-3-((4-(2-oxo-2-(pyridin-3-ylamino)ethyl)phenyl)ethynyl)benzoic acid methyl, 2-(1H-indol-6-yl)-3-((4-(2-oxo-2-(pyridin-3-ylamino)ethyl)phenyl)ethynyl)benzoic acid, 6-((4-(2-(pyridin-3-yl)a 6-((4-(2-(pyridin-3-yl)acetamido group)phenyl)ethynyl)-[1,1'-biphenyl]-2-carboxylic acid methyl ester, 6-((4-(2-(pyridin-3-yl)acetamido group)phenyl)ethynyl)-[1,1'-biphenyl]-2-carboxylic acid, 3'-hydroxyl-6-((4-(3-(pyridin-3-yl)urea)phenyl)ethynyl)-[1,1'-biphenyl]-2-carboxylic acid methyl ester, 2. A compound according to claim 1, or an enantiomer, diastereomer, tautomer, salt, crystalline form, solvate and / or isotopically substituted derivative thereof.
6. A pharmaceutical composition comprising a compound of general formula (I) according to any one of claims 1 to 5, or an enantiomer, diastereomer, tautomer, salt, crystalline form, solvate and / or isotopically substituted derivative thereof, and / or a pharma- ceutically acceptable carrier, excipient, or diluent.
7. A method for treating and / or preventing a disease or disorder caused by EBNA1 activity, comprising administering to a subject an effective amount of at least one compound according to any one of claims 1 to 5, or an enantiomer, diastereomer, tautomer, salt, crystalline form, solvate and / or isotopically substituted derivative thereof, or administering to a subject an effective amount of at least one pharmaceutical composition according to claim 6.
8. A method for treating and / or preventing nasopharyngeal carcinoma comprising administering to a subject an effective amount of at least one compound according to any one of claims 1 to 5, or an enantiomer, diastereomer, tautomer, salt, crystalline form, solvate and / or isotopically substituted derivative thereof, or administering to a subject an effective amount of at least one pharmaceutical composition according to claim 6.
9. The method of claim 7, wherein the disease or disorder caused by EBNA1 activity is cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus, or rheumatoid arthritis.
10. 10. The method of claim 9, wherein the cancer is nasopharyngeal carcinoma, non-Hodgkin's lymphoma, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, hepatosplenic T-cell lymphoma, B-cell lymphoma, Burkitt's lymphoma, cutaneous reticulosis, reticulosis, diffuse large B-cell lymphoma, extranodal NK / T-cell lymphoma / intravascular lymphoma, follicular lymphoma, immunoblastic lymphoma, mucosa-associated lymphoid tissue lymphoma, B-cell chronic lymphocytic leukemia, mantle cell lymphoma, mediastinal large B-cell lymphoma, lymphoplasmacytic lymphoma, lymph node marginal zone B-cell lymphoma, splenic marginal zone lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, lymphomatoid granulomatosis, angioimmunoblastic lymphadenopathy, X-linked lymphoproliferative syndrome, post-transplant lymphoproliferative disease, or Hodgkin's lymphoma.
Citation Information
Patent Citations
Benzanilide derivative
JP2011195484A
ebna1 inhibitors and methods of their use
JP2016540045A
EBNA1 inhibitor and method for using the same
JP2018520096A
Small molecule inhibitors targeting EB virus nuclear antigen protein, preparation method and use thereof
JP2023528919A
N-(4-pyrazolyl)amide derivatives, chemicals for agricultural and horticultural use, and usage of the same
WO2002024656A1
